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Abstract 
 
Cancer is one of the major causes of death worldwide. There are many types of 
chemotherapeutic drugs and cisplatin, the first metal-based anticancer agent, is one of 
the most widely used. Its success to treat several tumours has triggered the investigation 
of other metal-based agents with cytotoxic activity in cancer research. Ruthenium 
organometallic complexes have been in the last decade one of the most promising 
findings due to their inherent anticancer activity and to the possibility of presenting a 
different cytotoxic profile than that of platinum-based drugs. In fact, some Ru
III
 
complexes are currently undergoing clinical trials.  
A new family of ruthenium(II) arene compounds of general formula [Ru(η6:κ1-
arene:Z)(XY)]
n+
, where arene:Z is a hemilabile tethering ligand and XY is a chelating 
bidentate ligand has recently been reported. The donor group Z offers two reversible 
functionalities: (i) binding to the Ru
II
 centre to form a closed tether-ring complex 
(inactive form), or (ii) dissociation from the Ru
II
 centre (as a pendant arm) to afford an 
open-tether complex (active species). This type of complexes can be useful tools to 
target selectively the acidic microenvironment of the tumour, exploiting the metabolism 
of the cancer cell. It is known that cancer metabolism is characterized by the preference, 
even in the presence of oxygen, for 'aerobic' glycolysis, a phenomenon known as the 
Warburg effect. As a result, accumulation of lactate influences the acidity of the 
extracellular pH (values as low as 6.2 vs 7.3 in normal cells). This difference can be 
advantageous in the design of (pro-)drugs that activate selectively at low pH. 
In this context we propose to explore tethered ruthenium(II) arene complexes, of 
general formula [Ru(η6:κ1-arene:Z)(XY)]n+, as promising scaffolds to afford reversible 
pH-dependent activatable metallodrugs. This dissertation focuses in the structural 
modifications of the building blocks that constitute the ruthenium(II) tether complexes 
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by varying (i) the hemilabile ligand (arene:Z), and (ii) the chelating ligand (XY), in 
order to finely tune the Ru–Z bond activation. 
Following an introduction to the field of metals in medicine in Chapter 1, Chapter 2 
compiles the structure-activation relationship study of ruthenium(II) tether complexes 
that helped us understand how the tether arm influences the ring-opening process. This 
provides valuable information about how both length and rigidity of the tethering arm, 
and nature of the donor atom, are important features that play a crucial role in the 
activation of the Ru–Z bond to afford the open-tether (activated) species. Compounds 
bearing 2-aminobiphenyl and phenylacetic acid as hemilabile ligand were chosen as 
promising activatable platforms for further investigation. 
In Chapter 3, we investigated in depth the scaffold [Ru{η6:κ1-
C6H5(C6H4)NH2}(XY)]
n+
 (2-aminobiphenyl as hemilabile arene:Z ligand) bearing 
different chelating XY ligands. Understanding the dynamics that control the opening of 
these tether complexes is crucial for rationally designing pro-drugs with controlled 
activation profiles prior attack of the bond to biological target attack. For this reason, 
the activation of the rutheniumnitrogen bond was explored in non-aqueous 
(dimethylsulfoxide and methanol) and aqueous solvents. Importantly, these complexes 
were able to afford open species at different pH values in water. Since the open species, 
[Ru{η6-C6H5(C6H4)NH3}(XY)Cl]
n+
, can undergo protonation of the pendant NH2 
rendering the nitrogen unable to coordinate to the Ru
II
, we studied the reversible 
protonation and deprotonation phenomena for this type of compounds to better 
understand the compounds‘ aqueous dynamics. Also, we investigated the interaction of 
our switchable system with a model nucleobase. 
In Chapter 4, we explored complexes with formula [Ru(η6-
C6H5CH2COOH)(XY)Cl]
n+
, bearing phenylacetic acid as hemilabile ligand. A detailed 
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study about the speciation in aqueous solution of a series of complexes bearing different 
XY ligands is described. We also investigated the ring-opening reaction for their 
analogue closed-tether complexes to prove that κ1O-dissociation from the ruthenium(II) 
centre can be tailored under acidic conditions by a reversible pH-mediated activation 
process. Finally, we explored the capability of these complexes to undergo intracellular 
hydrogen-transfer reactions. 
In Chapter 5, we studied how the tether chelate affects stability and activation of this 
type of ruthenium(II) arene complexes. In order to do this, we compared the reactivity 
of the RuZ bond in closed-tether versus their un-tether counterparts. In addition, we 
investigated the possibility of triggering the RuZ bond activation of closed-tether 
complexes at neutral pH upon photo-irradiation. DFT calculations were carried out to 
support the experimental results. 
Finally, in Chapter 6, we studied the possibility to activate the Ru–Z bond in the 
closed-tether complexes via a solid-state reaction in the presence of vaporous reactants 
to investigate their potential development as gas sensors. The reversibility of the system 
was further investigated by different solid state techniques, showing the great versatility 
that these complexes can offer in the organometallic field. 
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Resumen 
 
El cáncer es una de las enfermedades que más muertes producen en todo el mundo. 
Hay muchos tipos de fármacos antitumorales y el cisplatino, el primer fármaco 
antitumoral basado en un metal de transición, es uno de los más empleados. Su éxito 
para combatir diferentes tipos de cáncer ha motivado la investigación de otros 
compuestos metálicos con actividad citotóxica. Los complejos organometálicos de 
rutenio han despertado un incipiente interés en los últimos años debido a sus 
propiedades antitumorales y la posibilidad de presentar un diferente mecanismo de 
acción al de los fármacos basados en platino. De hecho, algunos complejos de Ru
III 
se 
encuentran bajo ensayos en fase clínica. 
Recientemente, se ha publicado una nueva familia de compuestos de rutenio(II) con 
fórmula general [Ru(η6:κ1-areno:Z)(XY)]n+, donde areno:Z es un ligando hemilábil y 
XY es un ligando bidentado. El grupo dador Z ofrece dos funcionalidades reversibles: 
(i) coordinación al centro de Ru
II 
para formar un complejo cerrado (forma inactiva), o 
(ii) disociación del centro metálico (como brazo colgante) para generar el 
correspondiente complejo abierto (forma activa). Este tipo de complejos puede servir 
como valiosas herramientas para atacar selectivamente el microambiente tumoral, 
explotando el metabolismo de la célula cancerígena. Se sabe que el metabolismo del 
cáncer tiene preferencia por la glicolisis ‗aerobia‘, incluso en presencia de oxígeno, 
fenómeno denominado Efecto Warburg. Como resultado, la acumulación de lactato 
influye en la acidez del pH extracelular (con valores de 6.2 vs 7.3 en células normales). 
Esta diferencia puede suponer una ventaja en el diseño de (pro-)fármacos que se activen 
selectivamente a pH bajo. 
En este contexto, nosotros proponemos explorar complejos areno de rutenio(II) 
‗tethered‘, de fórmula [Ru(η6:κ1-areno:Z)(XY)]n+, como prometedoras estructuras para 
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dar lugar a metalofármacos activables dependientes del pH. Esta Tesis se enfoca en las 
modificaciones estructurales de los grupos que conforman los complejos ‘tethered‘ 
mediante la variación de (i) el ligando hemilábil (areno:Z), y (ii) el ligando quelato 
bidentado (XY), para poder controlar de manera precisa la activación del enlace Ru–Z. 
Después de una introducción al área de los metales empleados en medicina en el 
Capítulo 1, el Capítulo 2 recoge los estudios de relación estructura-activación de 
complejos de rutenio(II) ‗tethered‘ lo que nos han ayudado a entender cómo el brazo 
colgante del ligando hemilábil afecta al proceso de apertura. Esto proporciona valiosa 
información sobre cómo la longitud y rigidez del brazo, así como la naturaleza del 
átomo dador, son importantes características que juegan un papel crucial en la 
activación del enlace Ru–Z para generar el complejo abierto (activado). Los compuestos 
con ligando hemilábil 2-aminobifenilo y ácido fenilacético fueron seleccionados como 
prometedoras estructuras para una investigación más exhaustiva. 
En el Capítulo 3 investigamos en profundidad la estructura [Ru{η6:κ1-
C6H5(C6H4)NH2}(XY)]
n+ 
(donde 2-aminobifenilo es el ligando hemilábil) con distintos 
ligandos quelatos XY. Entender la dinámica que gobierna la apertura de estos complejos 
es crucial para el diseño racional de pro-fármacos con perfiles de activación controlada 
previa a la interacción con la diana terapéutica. Por esta razón, se exploró la activación 
del enlace Ru–N en disolventes no acuosos (dimetilsulfóxido y metanol) y en 
disolventes acuosos. El hallazgo más importante fue que estos complejos fueron capaces 
de producir especies abiertas a diferentes valores de pH en agua. Ya que estas especies 
abiertas, [Ru{η6-C6H5(C6H4)NH3}(XY)Cl]
n+
, pueden dar lugar a la protonación del 
grupo NH2 colgante imposibilitando así que el nitrógeno vuelva a coordinarse al centro 
de Ru
II
,
 
estudiamos el fenómeno de protonación y desprotonación para este tipo de 
complejos y de este modo entender mejor la dinámica acuosa de los compuestos. 
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Además, también investigamos la interacción de estos sistemas con una nucleobase 
modelo. 
En el Capítulo 4 exploramos los complejos con fórmula [Ru(η6-
C6H5CH2COOH)(XY)Cl]
n+
, que contienen ácido fenilacético como ligando hemilábil, y 
se realizó un estudio detallado sobre la especiación en disolución acuosa de una serie de 
compuestos que contenían diferentes ligandos XY. También investigamos la reacción 
de apertura para sus correspondientes complejos cerrados con el objetivo de demostrar 
que la disociación κ1O del centro de rutenio(II) puede ser modulada mediante un 
proceso de activación mediado por el pH. Finalmente, exploramos la capacidad de estos 
complejos para llevar a cabo reacciones de transferencia de hidrógeno y su posible 
repercusión dentro de la célula. 
En el Capítulo 5 estudiamos como el quelato ‗tether‘ afecta a la estabilidad y la 
activación de este tipo de complejos areno de rutenio(II). Para ello, comparamos la 
reactividad del enlace Ru–Z en complejos ‗tethered‘ y sus análogos sin el brazo 
colgante (‗un-tethered‘). Además, investigamos la posibilidad de activar el enlace Ru–Z 
de los compuestos cerrados bajo foto-irradiación a pH neutro. Cálculos DFT fueron 
realizados para apoyar los resultados experimentales. 
Finalmente, en el Capítulo 6 estudiamos la posibilidad de activar el enlace Ru–Z de 
los complejos cerrados mediante una reacción en estado sólido en presencia de reactivos 
en fase vapor para investigar su uso potencial como detectores de gases. La 
reversibilidad del sistema fue explorada a través de técnicas de estado sólido, mostrando 
la gran versatilidad que estos complejos pueden ofrecer en el campo de la química 
organometálica. 
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Notes to the Reader 
 
Structure of the Thesis 
Although the chapters of this book could be read independently of one another, they are 
arranged in a rational sequence of six Chapters. The first Chapter, Introduction, covers 
the state-of-the-art regarding ruthenium metallodrugs, as well as elementary principles 
and basic organometallic chemistry related to this dissertation. Chapter 2 deals with a 
structure-activation relationship study in order to find a suitable scaffold to undergo 
reversible activation of the Ru–Z bond in ruthenium(II) tether complexes. Chapters 3 
and 4 present solution studies on the switchability of two particular systems. Chapters 5 
and 6 provide preliminary yet exciting results on using this type of compounds in both 
photo-irradiation experiments and solid-state reactions, respectively. 
 
Nomenclature for Complexes 
The method used for naming the complexes has followed the recommendations by the 
International Union of Pure and Applied Chemistry (IUPAC) published in 
Nomenclature of Inorganic Chemistry 2005. 
 
Numbering of Complexes 
The numbering of the complexes in this dissertation, all of which are typed in boldface 
throughout the entire manuscript adhere to the following rules. Generally, complexes 
synthesised in their closed-tether form, where the donor atom of the pendant arm is 
coordinated to the ruthenium centre, will be coded with a number, for example, 1. 
Complexes synthesised in their open form, with a chlorido ligand coordinated to the 
ruthenium centre and therefore with the pendant arm dissociated from the metallic 
centre, will be coded with a number followed by Cl, as in 1Cl. If the complex is an open 
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tether but instead of a chlorido ligand bears a dmso molecule, it will be named as the 
number followed by dmso, this is, 1dmso. For open-tether chlorido complexes where 
the pendant arm is in its corresponding protonated form, they will be denoted as the 
number followed by HCl, as in 1HCl.  
Regarding the counterions of the cationic complexes, unless otherwise indicated, 
chlorides will be the counterions in the solid state (or sodium for negatively charged 
complexes), for example, closed tether complex 1. However, if the complex was not 
isolated as the chloride salt and a different anion was used to isolate the complex in the 
solid state, such ion accompanies the number of the complex followed by an interpunct, 
it will be coded for example, 1·PF6. 
 
Abbreviations 
Throughout this dissertation the standard abbreviations and acronyms recommended by 
American Chemical Society for Medicinal Chemistry field, as reviewed in Journal of 
Medicinal Chemistry on January 2018 
(http://pubs.acs.org/paragonplus/submission/jmcmar/jmcmar_authguide.pdf) have been 
employed. Abbreviations and acronyms which are not present in that Journal are 
conveniently indicated over the reading. 
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1.1 Metals in Medicine 
 
Metal ions play important roles in biological processes. In humans, disorders of the 
metabolism of essential metal ions can have detrimental effects; well-known examples 
include anaemia caused by low iron levels, growth retardation arising from insufficient 
dietary zinc, and progressive neurological disorders owing to copper overload.
1
 
The use of metals traces dates back to the ancient civilizations of Mesopotamia, 
Egypt, India, and China, where elements such as arsenic, gold, and iron were used in 
pharmaceutical potions.
2
 One of the first therapeutic metallodrugs was Salvarsan, an 
arsenic-based antimicrobial agent marketed in 1910. With the addition of mercury and 
bismuth, Salvarsan remained the standard remedy for syphilis until it was replaced by 
penicillin after World War II.
3
 More recent examples of metals in medicine include the 
use of platinum drugs like cisplatin (which is now widely used in cancer treatment), 
lithium salts for neurological disorders, gold drugs for treating rheumatoid arthritis, and 
vanadium compounds with antidiabetic effects.
2
  
All of these examples provide evidence of the potential of metal-based drugs in 
modern medicine. A key concept is the possibility of structurally tuning the 
metallodrugs to modulate their properties. The structure can be altered by changing the 
ligands that surround the metal, or by changing the coordination number/oxidation state 
of the metal. In this way, we can begin to overcome the toxicity, and control the 
reactivity and selectivity of the metal complex towards specific targets and diseases.
4
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1.2 Metal-based Anticancer Drugs 
 
Cancer is a major cause of mortality, with 14.1 million new cases and 8.2 million 
cancer-related deaths in 2012, affecting populations in all countries and all regions. The 
five most common types of diagnosed cancers are lung, breast, colorectum, prostate, 
and stomach (Figure 1.1); together, cancers of these five sites constitute half of the 
overall global cancer problem.
5
  
 
Figure 1.1. Estimated world cancer incidence proportions, in both sexes combined, in 2012. 
Adapted from ref 5. 
 
Cancer chemotherapy continues to play an increasingly important role in the 
management of malignancies, either directly or as an adjuvant to surgery and/or 
radiotherapy. Certain transition metal compounds have been demonstrated to effectively 
act as anticancer agents. In particular, the inorganic complex cisplatin, cis-
[Pt(NH3)2Cl2], is currently one of the most widely used chemotherapeutic drug, being 
active in the treatment of many cancers.
6
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The discovery of cisplatin by Barnett Rosenberg in the 1960s was a milestone in the 
history of metal-based compounds used in the treatment of cancer. To date, cisplatin 
and its analogues (Figure 1.2) are some of the most effective chemotherapeutic agents in 
clinical use, often as the first line of treatment in testicular and ovarian cancers.
7
  
 
Figure 1.2. Chemical structures of clinically used platinum anticancer drugs. 
 
Investigations into the activity of cisplatin at the biomolecular level indicate that 
genomic DNA is the primary target.
8
 The activity of this drug and of its derivatives is 
mediated by the formation of DNA lesions that interfere with transcription, resulting in 
cellular apoptosis.
9
 The binding of cisplatin to the DNA is dependent on the hydrolysis 
(substitution of a leaving group by a water molecule) of its labile chlorido ligands. In 
the bloodstream, high chloride ion concentration (100 mM) suppresses this process,
10
 
however once inside the cell, the lower chloride ion concentration (cytosol, 25 mM; 
nucleus, 4 mM) assists hydrolysis. This gives rise to the formation of the complex 
[Pt(NH3)2Cl(H2O)]
+
. The most nucleophilic and accessible site of DNA is the N7 atom 
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of guanine residues, and these are preferentially platinated.
11
 The remaining chloride 
ligand is substituted for a second water molecule and platinum interacts with an 
adjacent guanine base, forming a cross-link on the DNA.
12
 This chelation of nuclear 
DNA triggers a specific distortion of the duplex,
13
 recognised by the so called High-
Mobility Group (HMG) proteins which are believed to strongly bind to platinated 
DNA,
9, 14
 and other some damage-recognition proteins.
15
 Finally, the cell undergoes 
apoptosis following unsuccessful DNA repair (Figure 1.3).
16
  
  
Figure 1.3. The general mechanism of action of cisplatin involves four key steps: (i) cellular 
uptake, (ii) aquation/activation, (iii) DNA binding, and (iv) cellular processing of DNA lesions 
leading to cell death. 
 
Regardless of the achievements of current platinum drugs, there are some major 
drawbacks: they are efficient only for a limited range of cancers and additionally some 
tumours initially sensitive to cisplatin acquire resistance. Moreover, they often cause 
severe side-effects, such as nausea, bone marrow suppression and kidney toxicity.
17, 18
 
One of the goals in the field of anticancer metallodrugs is the development of non-
platinum metal anticancer drugs that present activity against tumours that are resistant to 
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platinum drugs. A secondary goal is that activity should not be accompanied by severe 
toxicity, that is, that the compounds have a good tolerability and a large therapeutic 
window.
19
 Complexes of transition metals other than platinum may, in principle, exhibit 
anticancer activity and toxic side-effects significantly different from that of platinum 
drugs for a number reasons: they are expected to have different chemical behaviour, 
hydrolysis rates, and mechanism of action.  
Compounds of almost all metals of the periodic table have been explored for in vitro 
cytotoxic activity against cancer cell lines, the most widely used screening.
20
 Ruthenium 
stands out as a particularly attractive alternative to platinum, and occupies a prevalent 
position among the several metal complexes that have been investigated for anticancer 
activity. 
Jakupec et al.
21
 have described the benefits of advantages of exploiting ruthenium in 
the development of metal-based antitumour drugs: (i) a rich and well-developed 
preparative coordination chemistry of this transition metal, providing consistent routes 
to new complexes; (ii) a rate of ligands exchange often comparable to that of platinum 
or which can be tuned by coordination of appropriate ligands; (iii) octahedral 
coordination geometry in contrast to the square planar geometry of platinum(II) 
complexes, implying a reactivity different from cisplatin; (iv) accessibility of oxidation 
states 2+, 3+, and 4+ under physiological condition; (v) the ability to tune the electron 
transfer rates and redox potentials; and (vi) the capability of ruthenium to mimic iron in 
binding to biomolecules such as albumin and transferrin, which makes ruthenium-based 
agents markedly less toxic than platinum drugs.  
These favourable properties have led to two ruthenium compounds that are currently 
undergoing clinical trials – the anti-primary-tumour imidazolium trans-
[tetrachloridobis(1H-indazole)ruthenate
III
] (KP1019) and the anti-metastasis 
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imidazolium trans-[tetrachloride(1H-imidazole)(S-dimethylsulfoxide)ruthenate
III
] 
(NAMI-A) –, opening new perspectives in cancer treatment (Figure 1.4). The most 
recent representative of this class of compounds is NKP-1339, the corresponding more 
water soluble sodium salt of KP1019.
22
 
 
Figure 1.4. The three clinically investigated ruthenium-based anticancer NAMI-A, KP1019, 
and NKP-1339. 
 
Similar to the clinically used platinum compounds, these Ru
III
 complexes are 
administered intravenously, and bind rapidly to serum proteins. The protein adduct 
formation protects the complexes against fast hydrolysis and degradation reactions 
under physiological conditions. It is hypothesised that they act as a prodrug and are 
reduced under the hypoxic conditions of the tumour tissue to the reactive Ru
II
 species.
23
 
This has led to increased interest in pseudo-octahedral organometallic Ru
II
 arene 
complexes in which the arene stabilizes ruthenium in the 2+ oxidation state. 
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1.3 Cytotoxic Ruthenium(II) Arene Complexes 
 
Because of the implication of Ru
II
 in the cytotoxic activity of the ruthenium(III) 
complexes described in the previous section, there is an increased effort in the search of 
of Ru
II
 complexes with anticancer activity. In recent years, new classes of 
organometallic Ru
II
-arene complexes, developed among others by the groups of Sadler 
and Dyson, have been found to have promising anticancer properties.
24, 25
 
Representative examples are [Ru(η6-biphenyl)(en)Cl]PF6 and [Ru(η
6
-p-
cymene)(pta)Cl2], with en = ethylenediamine and pta = 1,3,5-triaza-7-
phosphaadamantane (Figure 1.5). The piano-stool compounds of formula 
[Ru(arene)(XY)Cl]
+
, e.g. where arene = biphenyl, XY = ethylenediamine, show 
promising activity both in vitro and in vivo 
24
 and are thought to have a mode of action 
that is analogous to that of cisplatin, where DNA is the main target. The formation of 
monofunctional adducts (preferentially at guanine sites) and the non-covalent 
interactions (i.e. extended arene intercalation and en H-bonding) are believed to be 
fundamental for DNA recognition and, as a consequence, anticancer activity.
26
 
However, [Ru(η6-p-cymene)(pta)Cl2] complexes have low cytotoxic potency towards 
cancer cell lines but are potent antimetastatic  agents. Actually, the major intracellular 
targets of these compounds appear to be proteins, although DNA binding has been 
observed.
27
 
 
Figure 1.5. Molecular structures corresponding to the cytotoxic complexes [Ru(η6-
biphenyl)(en)Cl]
+
 and [Ru(η6-p-cymene)(pta)Cl2]. 
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1.3.1 Structural Features of RuII Arene Complexes 
The general structure of the half-sandwich ruthenium(II) arene complexes developed 
by Sadler is shown in Figure 1.6. All complexes contain a η6-arene occupying three 
coordination sites of the pseudo-octahedral Ru
II 
coordination sphere, a chelating ligand 
(XY) occupying two positions and a monodentate ligand (Z) occupying the sixth site. 
This ―piano-stool‖-type scaffold offers much scope for design, with potential for 
modifications in the structure, and overall charge of the complex (n+).  
 
Figure 1.6. General structure of the half-sandwich or piano-stool ruthenium(II) arene 
complexes. 
 
The arene ligand confers stability to the 2+ oxidation state, binding as a η6-electron 
donor and a π-acceptor. The presence of a chelating ligand, XY, offers additional 
stability to the entire structure and the ability of tuning the electronic properties of the 
metal centre. The monodentate ligand Z gives the molecule an activation site: if labile, 
such as halide, it can provide a vacant coordination site for interaction with 
biomolecules. Such lability can be finely tuned by the variation of both the arene and 
the XY chelating ligand. These features provide handles for the control of both the 
thermodynamics and kinetics of this system as well as its overall structural architecture. 
They also make possible to tailor the chemical reactivity of the complexes, potentially 
allowing control of important pharmacological properties including cell uptake, 
distribution, and toxic side effects.  
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1.3.2 Activation of the Ru–Z Bond 
1.3.2.1 Ru–Z Cleavage by Hydrolysis 
Metal-ligand bonds (M–L coordination bonds) are much weaker, typically 50–150 kJ 
mol
-1
, compared with covalent bonding (the energy of a single C–C bond is 300–400 kJ 
mol
-1
).
28
 As for cisplatin, activation through hydrolysis of the Ru–Z bond may be 
important for the mechanism of action of these Ru
II
 arene complexes, making these 
complexes susceptible to be exploited in medicinal chemistry in a similar way to 
cisplatin.  
 
Figure 1.7. Hydrolysis and subsequent acid/base equilibria of ruthenium(II) half-sandwich 
complexes of general formula [Ru(η6-arene)(XY)Cl]+. 
 
The mechanism of cytotoxic action of Ru
II
 arene complexes is generally thought to 
involve hydrolysis of the Ru–Z bond, thus generating an active Ru–OH2 metabolite 
(Figure 1.7). Aquation is largely suppressed at extracellular chloride concentration ([Cl
–
] about 100 mM) but becomes possible inside the cells, where [Cl
–
] is much lower (4–20 
mM). The aqua species will exist over a range of pH, but above the pKa value (the pH at 
which 50% of the species exists as Ru–OH2 and Ru–OH through deprotonation of the 
H2O ligand) the hydroxo Ru–OH species will predominate. The hydroxido complex is 
usually considered to be a less reactive species due to low lability of the Ru–OH bond. 
The pKa values of the [Ru(η
6
-arene)(en)(OH2)]
2+
 aqua species are typically between 7 
and 8, and thus at physiological pH the Ru–OH2 species prevails over the less reactive 
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Ru–OH species. The rate of hydrolysis is also important; if the complex hydrolyses too 
fast they may not reach the target site.  
The speciation of the ruthenium complexes under physiological conditions is 
therefore rather important. For example, for complex [Ru(η6-biphenyl)(en)Cl]+,29 the 
results indicate that in blood plasma, where the chloride concentration is high, the 
complexes exist primarily in their chlorido form (> 89%). In contrast, when the chloride 
concentration is much lower, as in the cell cytoplasm (about 23 mM) and cell nucleus (4 
mM), the amount of the more reactive aqua species increases to ca. 30% and 70%, 
respectively (Figure 1.8).
29
 As a result, the extracellular suppression of aquation 
followed by activation upon entering the cell provides a selective mechanism of 
activation. 
 
Figure 1.8. Speciation of [Ru(η6-biphenyl)(en)Cl]+ in blood plasma, cytoplasm and nucleus at 
equilibrium. 
 
The thermodynamics and kinetics of such activation, as well as the acidity of the 
water molecule in the aqua adduct, can be finely tuned by appropriate choice of the 
different building blocks in the general structure [Ru(η6-arene)(XY)Z]+  and will be 
further discussed in Section 1.3.4. 
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1.3.2.2 Ru–Z Cleavage through Irradiation 
Since cleavage of the Ru–Z bond appears to be an important step in the mechanism of 
action of Ru
II
 arene complexes, controlling the activation of these coordination sites can 
provide a key strategy to increase the potential of [Ru(η6-arene)(XY)Z]n+ complexes as 
anticancer agents. Photochemical activation is an attractive approach for achieving 
selectively the cleavage by the absorption of light, promoting its release and offering the 
possibility of controlling the location and timing activity of the therapeutic metal 
complex. This requires breaking of the coordination bond by the use of high-energy 
UV-visible light photons. In addition, light is already used to treat certain cancers using 
the Food and Drug Administration-approved technique of photodynamic therapy 
(PDT).
30
  
Some examples of half-sandwich Ru
II
 arene complexes, [Ru(η6-p-cym)(N,N‘)(Z)]2+ 
(where N,N‘ = bidentate chelated ligand and Z = pyridine o pyridine derivate) have 
been proved to be activated by UV-visible light to photo-dissociate selectively the 
monodentate ligand (Z) in aqueous solution and in the presence of a nucleobase (9-
ethylguanine or 9-ethyladenine).
31
 Irradiation generates the reactive aqua species, able 
to bind to the DNA base, as depicted in Figure 1.9. Such behaviour represents a 
promising way to control the hydrolysis reaction and binding of these Ru
II
 complexes to 
biomolecules such as DNA, controlling therefore the cytotoxic action of the potential 
anticancer Ru
II
 pro-drug. 
 
Figure 1.9. Photoactivation of Ru
II
 arene complexes bearing pyridine or pyridine derivate as 
monodentate ligand Z. 
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1.3.3 Mechanism of Action 
1.3.3.1 Interaction with DNA 
The aqua species is then thought to bind to nuclear DNA with a high affinity to the 
N7 position of guanine bases. Both [Ru(η6-arene)(en)]–nucleobase and nucleoside 
adducts have been isolated and characterized by X-ray crystallography where arene = 
bip (biphenyl), tha (5,8,9,10-tetrahydroanthracene), dha (9,10-dihydroanthracene), and 
en = ethylenediamine.
32
 According to solution and solid-state evidence, the main Ru–
N7 (guanine) coordination bond is assisted by stereospecific hydrogen bonding between 
the C6=O of guanine and the NH of ethylenediamine, and π-π stacking between the 
aromatic ligand and the nucleobase (Figure 1.10). Also, it has been observed that in 
cell-free media these adducts distort the DNA duplex.
33
 
 
 
Figure 1.10. X-ray crystallographic structure of [Ru(η6-dha)(en)(9-EtG)]+ (dha = 9,10-
dihydroanthracene , en = ethylenediamine, and 9-EtG = 9-ethylguanine); (A) stereospecific 
hydrogen bonding interaction of the C6=O carbonyl of 9-EtG with an NHen, (B) π-π arene 
nucleobase stacking interaction. 
 
Interactions of these complexes of general formula [Ru(η6-arene)(en)Cl]+ with several 
biologically relevant molecules and potential targets (e.g. the amino acids histidine, 
cysteine and methionine, the cytochrome c, and the tripeptide glutathione) have also 
been explored.
34
 Overall, research suggests that DNA is the preferred target. 
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1.3.3.2 Transfer Hydrogenation Catalysis 
Organometallic complexes are well known as catalysts for organic chemical reactions, 
for example, olefin metathesis by Grubbs‘ ruthenium carbene complexes,35, 36 and 
asymmetric hydrogenation of ketones by Noyori‘s ruthenium arene complexes.37, 38  
Ruthenium(II) arene complexes have shown to catalyse regioselectively the reduction 
of NAD
+
 to NADH in the presence of formate as a hydride source under physiologically 
relevant conditions.
39
 In vivo, both NAD
+
 and NADH play important roles as cofactors 
in numerous biocatalyzed processes, and the ratio NAD
+
/NADH must be tightly 
controlled to avoid cell death by oxidative stress.
40
 Because eukaryotic cells seem to 
tolerate high levels of formate,
39
 this catalytic pathway can provide a new mechanism of 
action to increase the cytotoxicity of these Ru
II
 arene metallodrugs.  
Recently, the antitumor activity of Ru
II
 arene complexes has been evaluated towards 
human ovarian cancer cells in the presence of low non-toxic doses of formate,
41
 where 
the cytotoxic activity showed a 50-fold increase. The mechanism of action for this effect 
is thought to involve the generation of reductive stress instead of apoptosis. The 
activation of the complex follows the typical substitution of the monodentate ligand by 
a water molecule which then is replaced by formate to ultimately afford the 
corresponding hydride complex. The Ru–H complex can reduce NAD+ to NADH as 
shown in the proposed mechanism by Cavinet et al. as depicted in Scheme 1.1.
42
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Scheme 1.1 
 
1.3.4 Structure-Activity Relationship. Effect of the 
Different Building Blocks 
From the confluence of the chemical, biochemical and biological studies on this 
organometallic family of Ru
II
-arene compounds, valuable pharmacological properties 
have emerged. The properties may be summarized as: (i) the ruthenium(II) centre is a 
sustainable metal ion for biological applications when is coordinated to an arene ligand; 
the stability of the ruthenium arene bond provides an excellent scaffold for 
chemotherapeutic applications; (ii) bidentate chelating ligands can be used to modulate 
the pharmacological properties of Ru
II
 arene complexes; and (iii) hydrolysis of the Ru–
Z bond allows direct coordination to biomolecular targets, rate of which can be 
controlled by using different monodentate ligands and by variation of the other building 
blocks in the structure. The latter will be discussed as follows. 
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1.3.4.1 The Arene 
The arene stabilizes ruthenium in the 2+ oxidation state, but it also provides a 
hydrophobic face to the complex, which can assist passage across cell membranes and 
play an important role in biological recognition processes.
43
 The biological activity of 
Ru
II
 arene complexes, [Ru(η6-arene)(en)Cl]+ bearing ethylenediamine as the XY-
chelated ligand, has been shown to be highly dependent on the nature of the bound 
arene, with increasing hydrophobicity correlating lower IC50 (drug concentration that 
inhibit growth of cells by 50% compared to control).
24
 Figure 1.11A shows the different 
IC50 values obtained by varying the arene group. The increase in activity with increase 
in hydrophobicity is primarily thought to be due to the ability of the extended arenes to 
intercalate into DNA, thus causing further distortion of the DNA structure.
44-46
 
 
1.3.4.2 The XY Chelating Ligand 
The reactivity of [Ru(η6-arene)(XY)Cl]+ complexes is highly dependent on the nature 
of the XY chelating ligand. Variations can be introduced by N,N-, N,O- or O,O-chelates 
with significant effects depending on the chosen N- and O-group (Figure 1.11B).  
Modification of the chelating ligand results in complexes with different cytotoxicities. 
Aliphatic diamines usually showed good activity when they contain a primary amine, 
believed to establish stereospecific hydrogen bonding interactions with guanine bases 
(C6O-HN H-bonding).
47
 Bipyridine and phenantroline derivatives are inactive, 
indicating the importance of NH groups. Replacement of the N,N-chelating ligand 
ethylenediamine by N,O-chelating ligands of some amino acids (amino acidates) 
showed a high decrease in cytotoxicity.
48
 Reactivity studies indicated that fast 
hydrolysis rates might be responsible for the lack of activity of these derivatives. 
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Figure 1.11. General trends that show the influence of (A) the arene, (B) the chelating ligand 
and (C) the leaving group on the cytotoxicity of Ru
II
 arene complexes. Adapted from ref 49. 
 
Finally, complexes with O,O-chelating ligands as acac (acetylacetonate) and its 
derivates showed good to moderate activity, despite the lack of hydrogen bond donors.
47
 
Some of these trends can be explained by the general reactivity in aqueous solution of 
Ru
II
 arene complexes, which will be discussed in more detail below.  
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1.3.4.3 The Z Leaving Group 
The series of [Ru(η6-hmb)(en)Z]n+ complexes, varying the monodentate ligand Z 
shows a correlation between the rate of hydrolysis and the cytotoxicity of the complex 
towards cancer cells, with high activity for complexes that aquate readily (halides) and 
inactivity for complexes that do not aquate (pyridine) as shown in Figure 1.11C.
50
 An 
interesting exception to this trend is when the leaving group is thiophenolate. This 
complex is active towards A2780 human ovarian cancer cells (IC50 23 M), despite 
being relatively inert to hydrolysis. The mechanism of action may be different and it has 
been reported to involve oxidation of the thiolate, followed by hydrolysis of the 
sulfenate group.
51
 
An important next step is then to rationalize the relationships between structure and 
activity by correlating biological activity to chemical reactivity. Hence, much attention 
has been given to the study of the reactivity of this family of complexes and their 
behaviour in aqueous solution. 
 
1.3.4.4 Tunning the Aqueous Solution Reactivity 
The rate and extent of hydrolysis of the Ru–Z bond are highly dependent on the 
nature of Z, more labile leaving groups affording faster hydrolysis.
50
 Good correlations 
between hydrolysis rates, hydrolysis equilibrium and cytotoxicity have been observed 
for the ruthenium complexes of general formula [Ru(η6-hmb)(en)Z]+, where hmb is 
hexamethylbenzene (Figure 1.12). In general, a faster hydrolysis rate and a high 
percentage of aqua species at equilibrium correlated with good cytotoxicity towards the 
A2780 human ovarian cancer cell line. For the halidos, the aquation rate was found to 
decrease in the order Cl  Br > I. Replacement of the chlorido ligand with the 
pseudohalide N3 slowed down the hydrolysis rate even by 40-fold. Substituting halides 
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by leaving groups such as pyridines or pyridine derivates caused a further decrease in 
the hydrolysis process and even block it almost completely at biologically-relevant time 
scales. Such complexes were not active against cancer cells.
50
 
 
Figure 1.12. Correlation of  hydrolysis with cytotoxicity. Equilibrium percentage of total Ru
II
 as 
[Ru(η6-hmb(en)(H2O)]
2+
 (% [Ru(H2O)]e), and A2780 human ovarian cancer cell IC50 values for 
[Ru(η6-hmb(en)(Z)]n+ complexes  with several leaving groups Z. Adapted from ref 50. 
 
The chelating ligand also influences the hydrolysis rate and equilibrium constant. In 
general, the effect on substitution reactions depends on the nature of the chelate, 
suggesting that electronic and steric effects are responsible for this behaviour. 
Replacement of the neutral N,N- en by the anionic O,O- acac as the chelating ligand 
increases the rate and extent of hydrolysis.
52
 However, the presence of π-acceptor 
ligands as bipyrimidines derivates slows down the hydrolysis reactions.
53
 The nature of 
the arene also affects both the rate and extent of hydrolysis. The hydrolysis reactions of 
three [Ru(η6-arene)(en)Cl)]+ complexes (arene = bip, dha, and tha) showed that the rates 
of aquation increased in the order tha  dha > bip.29 
As important as the rate and extent of hydrolysis for drug activation is the pKa of the 
coordinated water molecule of the activated aqua complex. As discussed in Section 
1.3.2.1, the pKa value determines whether the active species containing the more labile 
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Ru–OH2 bond or the less reactive deprotonated form Ru–OH prevails in solution at a 
given pH.
54
  
 
Table 1.1. pKa data for Ru
II
 organometallic complexes with different arenes and chelating 
ligands. 
 
 
 
Arene Chelating Ligand (XY) pKa Ref. 
p-cym azpyz-NMe2 4.60  47 
p-cym bpm 6.96  53 
p-cym phen 7.32  53 
Bip en 7.71  29 
Dha en 7.89  29 
Bz en 7.90  55 
Tha en 8.01  29 
p-cym en 8.25  54 
p-cym trop 9.12  56 
p-cym maltol 9.23  57 
p-cym acac 9.41  52 
 
 
 
 
 
The pKa values of the coordinated water molecule in [Ru(η
6
-arene)(en)(OH2)]
+
 was 
found to be 7.71, 7.89 and 8.01 when the arene was an extended π-system bip, dha, and 
tha, respectively.
29
 This relatively low acidity of the water ligand is important, since 
under physiological conditions large amounts of the most reactive aqua complexes (Ru–
OH2) are predicted to exist. Changing the XY-chelated ligand to monoanionic oxygen 
p-cym, p-cymene; bip, biphenyl; dha, 9,10-dihydroanthracene; bz, benzene; tha, 
5,8,9,10-tetrahydroanthracene; azpyz-NMe2,  phenylazopyrazole derivative; bpm, 
2,2‘-bipyrimidine; phen, phenantroline; en, ethylenediamine; trop, tropolone; acac, 
acetylacetonate. 
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O,O-chelates such as tropolone or acetylacetonate results in a further pKa to 9.12 for 
[Ru(η6-p-cym)(trop)(OH2)]
+ 56
 and 9.41 for [Ru(η6-p-cym)(acac)(OH2)]
+
,
52
 most likely 
as a consequence of electronic effects exerted by the chelating ligand on the metal 
centre. In contrast, the pKa of the aqua adduct in [Ru(η
6
-p-cym)(azpyz-NMe2)(OH2)]
+
 
(azpyz-NMe2 = 4-(1H-pyrazol-3-ylazo)-N,N-dimethylaniline) is 4.60,
47
 indicating the 
low electron density at ruthenium centre and consistent with the π-acidic nature of the 
ligand. Indeed, the complex has allow affinity for DNA bases as it would predominately 
exists in the more inert hydroxido form at physiological pH. 
These results clearly show that the hydrolysis reaction (and with that drug activation) 
and the pKa of the aqua adduct, can be finely tuned by the choice of the appropriate 
arene, chelating and monodentate ligands. This opens up the possibility of designing 
drugs with tailor-made properties which can be exploited in cancer therapy. 
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1.4 Targeting the Cancer Cell Metabolism 
 
Cancer is the name given to a collection of related diseases characterised by abnormal 
cell growth through which cells may acquire the potential to disperse (metastasise) from 
the site of origin (primary tumour) to other sites in the body (secondary tumour).
58
 The 
understanding of cancer has changed dramatically over the past three decades, due in 
large part to the revolution in molecular biology that has altered the face of all 
biomedical research. That research has revealed a number of molecular, biochemical, 
and cellular traits – acquired capabilities– shared by most and perhaps all types of 
human cancer. These rules that govern the transformation of normal human cells into 
malignant cancers are classified in the so-called Hallmarks of Cancer.
59
 
 
1.4.1 Hallmarks of Cancer 
The hallmarks of cancer involve a number of biological acquired capabilities during 
the multistep development of human tumours, described by Hanahan and Weinberg, 
which allows cancer cells to survive, proliferate, and disseminate. They were originally 
classified as follows: (1) sustaining proliferative signalling, (2) evading growth 
suppressors, (3) activating invasion and metastasis, (4) enabling replicative immortality, 
(5) inducing angiogenesis, and (6) resisting cell death.
59
 
 The hallmarks constitute an organizing principle for rationalizing the complexities of 
neoplastic disease. Moreover, in last decades an increasing body of research has 
suggested that four additional hallmarks of cancer are involved in the pathogenesis of 
some cancers:
60
 (7) deregulating cellular energetics,  (8) avoiding immune destruction, 
(9) genome instability and mutation, and (10) tumour-promoting inflammation. 
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Figure 1.13. Hallmarks of cancer. This illustration shows the ten acquired capabilities 
of cancer. Reproduced from ref 59. 
 
This section will be focused on the deregulation of the cellular energy of the tumour 
cell, because is a plausible niche where ruthenium(II) arene complexes might present 
unique advantages in chemotherapy research. 
 
1.4.2 Deregulating Cellular Energy. The Warburg Effect 
The chronic and often uncontrolled cell proliferation that represents the essence of 
neoplastic disease involves not only deregulated control of cell proliferation but also 
corresponding adjustments of energy metabolism in order to fuel cell growth and 
division.
60
 
The alterations of metabolism and energetics, within which glucose and adenosine 
triphosphate (ATP) are prominent players, have been recognized in recent years as an 
emerging hallmark of cancer.
60
 Actually, the importance of metabolic alterations in 
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cancer cells was recognized long ago. In the 1920s, Otto Warburg, a German 
biochemist, demonstrated that unlike normal tissues, cancer cells predominantly 
undergo fermentation instead of oxidative phosphorylation even when oxygen is 
abundant.
61-63
 This phenomenon of so-called aerobic glycolysis became known as the 
Warburg effect.
64
 In the presence of oxygen, most normal tissues metabolize glucose to 
pyruvate through glycolysis, and then completely oxidize a large fraction of the 
generated pyruvate to carbon dioxide in the mitochondria through oxidative 
phosphorylation. Under anaerobic conditions, normal cells redirect glycolytic pyruvate 
away from mitochondrial oxidation and instead largely reduce it to lactate in the 
cytosol.
65
 The fundamental paradigm stemming from Warburg‘s studies was that in 
contrast to normal cells, rapidly proliferating tumours metabolized glucose to lactate 
even under aerobic conditions despite this process being far less efficient (18-fold) in 
terms of net ATP production per molecule of glucose (Figure 1.14).
65
 Because of the 
upregulated metabolism in cancer cells, it is necessary a compromise to balance the 
need of energy and anabolites to create biomass. Oxidative phosphorylation is not ideal 
for this purpose because produces a large amount of energy as ATP but inefficient 
carbon sources.
65
 However, through aerobic glycolysis enough lactate is generated to 
supply nutrients to the cell growth and division of the proliferating cells. Additionally, 
the energy requirements are also supported due to the high glucose levels found in the 
tumour cells.
66
 This phenomenon has since been observed across several tumour types 
and often occurs in parallel with a marked increase in glucose uptake and consumption, 
as visualized, and clinically exploited, through the use of 18F-deoxyglucose-positron 
emission tomography.
67
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Figure 1.14. Schematic representation of the different metabolism of normal versus cancer cells 
and its ultimate effect in the final extracellular pH. 
 
The high conversion rate of pyruvate to lactate via the aerobic glycolysis (Warburg 
effect), and its accumulation in tumour cells, has been observed to be critical in the 
development and progression of cancer.
68
 Actually, the accumulation of lactate in 
cancer has been demonstrated to possess clinical relevance as a prognostic marker.
69
 
Following production, lactic acid is transported out of the cancer cell and across the 
plasma membrane by carboxylate transporter (MCT) family proteins.
68
  The MCTs are 
essential components of cellular metabolism and provide an important contribution to 
the regulation of tumour intracellular pH (pHint) by coupling H
+
 export with 
monocarboxylates such as lactate. This lactate production/release is commonly 
considered to be the primary acidification mechanism of the metabolic 
microenvironment providing additional extracellular acidification (pHext).
70-73
 For this 
reason, tumour cells present slightly acidic pHext values (6.2–6.9 vs 7.3–7.4 in normal 
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cells) while producing slight alkaline pHint values (7.1–7.7 vs 6.9–7.1 in normal cells).
74
 
This creates a reversed pH gradient across the cell membrane that increases as the 
tumour progresses. The development and maintenance of this gradient is directly due to 
the ability of the tumour cells to secrete protons (H
+
) and acidify their extracellular 
environment.
75
 Cancer cells have an acid-base balance that is completely different than 
that observed in normal tissues and that increases with increasing neoplastic state: an 
alkaline intracellular pH (pHint) linked to a ―malignant‖ extracellular acid 
microenvironment (pHext).  
Exploting the peculiar cancer H
+
 dynamics (both pHext and pHint) coupled with 
intracellular metabolic disruption could provide a new strategy for anticancer 
therapeutics,
76
 for example those that activate selectively at low pH. 
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1.5 Ruthenium(II) Tether Complexes 
 
1.5.1 General Objective of this Thesis 
Taking into account the more acidic extracellular pH predominating in cancer cells I 
will explore ruthenium(II) arene complexes that would undergo activation under low 
pH. 
The general structure described above for typical half-sandwich complexes might 
provide complexes whose reactivity is pH-dependent by using a pH-activatable 
monodentate ligand, i.e., by protonation of a suitable Z following cleavage of the Ru–Z 
bond (Figure 1.15).  
 
Figure 1.15. Activation of a typical Ru
II
 arene complex. This process is non-reversible because 
the Z ligand is released and a solvent molecule, L, (or biomolecule) occupies the vacant site.  
 
However, tethering the monodentate ligand (Z) to the Ru
II–arene structure may 
provide an attractive strategy to create not only pH-dependent complexes but also 
switchable compounds which ―turn-on‖ in a reversible manner. These ―tether‖ 
complexes contain the π-coordinated neutral arene group from which the σ-coordinated 
ligand (Z) is tethered. The donor group offers two reversible functionalities: (i) binding 
to the Ru
II
 centre to form a tether-ring-closed (inactivated) complex, or (ii) dissociation 
of the donor group from the Ru
II
 centre (as a dangling arm) to afford an open-tether 
complex with a pendant free Z group (Figure 1.16).
77
 Protonation of the labile group Z 
would impair reversible metal coordination (active complex), while a decrease in proton 
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concentration enables coordination to the metal centre. These features make complex 
activation pH-dependent and reversible. 
 
Figure 1.16. Schematic representation of the pH activation of tether complexes. First, the closed 
complex can undergoes the ring-opening process by the dissociation of the donor atom Z from 
the Ru
II
 centre. If pH drops, the donor atom is susceptible to be protonated impairing the 
reversible coordination to the metal centre. However, if the pH increases, deprotonation of Z 
can reversibly trigger the ring closure reaction. 
 
1.5.2 State-of-the-Art of RuII-Tether Complexes 
1.5.2.1 Synthesis 
Ruthenium(II) η6-arene complexes with tethered carboxylic,78 amine79, 80, alcohol,81, 82 
phosphorous
83, 84
 or carbene
85
 group functions have been reported. Side chains 
containing a coordinating moiety such as these donor groups result in hemilabile tether 
η6:κ1-arene ligands. 
Such ligand provides a group that binds strongly to the metal centre (through the η6-
arene), and a relatively weak donor which may protect a vacant site on the metal centre 
until it is displaced by an incoming ligand.
86
 This displacement can be a reversible 
process as shown in Figure 1.17. 
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Figure 1.17. General properties of hemilabile tethering ligands coordinated to transition metals. 
 
The preparative procedures for tether arene complexes can be organised in three 
different classes, which are represented in Figure 1.18 and described below: 
1) A labile arene is displaced by a second arene, which is attached by a tether arm to 
the already coordinated donor atom.  
2) A η6-coordinated functionalized arene is connected by a tether arm to a donor 
group. The tether is formed by displacement of the monodentate ligand (L) and 
coordination of the Z donor atom to the metal centre. 
3) Intramolecular condensation reaction between a substituent on the η6-arene (Y) 
and a functional group on the monodentate ligand (X). 
 
Figure 1.18. Schematic representation of the different experimental procedures for the synthesis 
of Ru
II
 tether complexes. 
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Synthetic path 1 
This is the most widely used synthetic method for obtaining Ru
II
 tether complexes. 
Smith and Wright reported the first η6-arene tether complexes using this methodology in 
the second half of the 1990s. As shown in Figure 1.19A, the complex [Ru{η6:κ1-
C6H5(CH2)3PPh2}Cl2] was obtained by thermolysis of [Ru(
6
-p-cym){κ1-
PPh2(CH2)3Ph}Cl2] at high temperature.
87
 In the same year, Therrien et al. hoped that 
the chelating effect may force the arene to displace the coordinated p-cymene in [Ru(6-
p-cymene){κ1-P-o-C6H4(CH2OH)(CH2CH2PPh2)}Cl2]. Having failed, they sought to 
synthesize a more labile ruthenium arene dimer as the precursor for the arene 
exchanging reaction. Since electron-poor arenes gave the lowest yields in displacement 
reactions with [Ru(6-p-cymene)Cl2]2, they reasoned that [Ru(
6
-etb)Cl2]2 (etb = ethyl 
benzoate) would may be a good starting material for the synthesis of [Ru{6:κ1-
C6H4(CH2OH)(CH2CH2PPh2)}]Cl2]. Birch reduction of ethyl benzoate yielded ethyl-
1,4-cyclohexadiene-3-carboxylate.
88-90
 Reaction of the cyclohexadiene with RuCl3 in 
ethanol afforded [Ru(6-etb)Cl2]2 in high yield. This dimer was a promising starting 
material for arene-exchange reactions. Treatment of dimer [Ru(η6-etb)Cl2]2 with the 
phosphine alcohol {o-C6H4(CH2OH)(CH2CH2PPh2)} afforded [Ru(η
6
-etb){κ1-P-o-
C6H4(CH2OH)(CH2CH2PPh2)}Cl2]. The intramolecular arene exchange was effectively 
carried out in a sealed tube leading to the corresponding tether complex (Figure 
1.19B).
91
 Nowadays, in addition to ethyl benzoate dimers, methyl benzoates complexes 
are used as general precursors since they undergo the tether reaction much faster than p-
cymene counterparts because the former fragment is a much better leaving group as it 
was observed by Navarro et al.
84
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Figure 1.19. Synthetic method of Ru
II
 tether complexes by arene displacement through 
intramolecular exchange. (A) [Ru(η6:κ1-C6H5(CH2)3PPh2)Cl2], (B) [Ru(
6:κ1-o-
C6H4(CH2OH)(CH2CH2PPh2))]Cl2]. 
 
Synthetic path 2 
Ruthenium(II) tether complexes with oxygen as the donor atom have been 
synthesized from the starting dimer [Ru{η6-C6H5(CH2)3OH}Cl2]2, prepared through the 
reaction between the corresponding cyclohexadiene derivative C6H7(CH2)3OH 
(obtained by the Birch reduction of C6H5(CH2)3OH) and RuCl3. Subsequent reaction 
with bipyridine afforded the complex [Ru{η6-C6H5(CH2)3OH}(bip)Cl]BF4, which on 
treatment with AgBF4 loses the chlorido ligand generating the alcohol tether 
[Ru{η6:κ1O-C6H5(CH2)3OH}(bip)](BF4)2.
81
  
Similarly, complex [Ru{η6-C6H5(CH2)3NH3}(PPh3)Cl2]Cl was susceptible to afford 
its corresponding closed tether counterpart [Ru{η6:κ1N-C6H5(CH2)3NH2}(PPh3)Cl]BF4 
upon treatment with sodium hydroxide (to deprotonate the ammonium group and 
subsequently free the nitrogen for metal binding) and NaBF4.
81
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Figure 1.20. Synthesis of Ru
II
 tether complexes via coordination of the donor atom from the 
arene to the ruthenium centre.  
 
Synthetic path 3 
Several examples are known of ruthenium(II) tether complexes having either sulphur 
or phosphorous as the donor atom in which the tether results from an intramolecular 
condensation between a substituent on the arene and a functional group on the 
monodentate ligand. A typical example is shown in Figure 1.21. The treatment of the 
vinyldiphenylphosphine complex with KO
t
Bu in refluxing acetonitrile gave the 
corresponding tethered complex [Ru{η6:κ1-p-Me2CH-C6H4(CH2)3PPh2}Cl2] where only 
the methyl group on the p-cymene arene has been deprotonated.
92
 This procedure 
provides an alternative approach to the synthesis of new tethered complexes.  
 
Figure 1.21. Synthesis of Ru
II 
tethered complexes via intramolecular condensation. 
  
1.5.2.2 Applications 
The introduction of a hemilabile group on the metal centre not only allows for the 
modulation of steric and electronic properties of the resulting complexes but also 
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confers other interesting features for their use as metallodrugs. As an example, it has 
been reported that bischelated P,N aminophosphene Pt
II
 complexes binds to the model 
DNA base 5’-dTMP through a chelate ring-opening mechanism,93 showing that the 
activation could be controlled by the substituents on the N atom, the size of the chelate 
ring, the pH, and the concentration of an external reagent such as the Cl
–
 ion.
94
 
Moreover, in a recent report, Molas et al. have described platinum(II) square planar 
complexes with intricate solvent-mediated interconversion of open and closed chelates 
with varying cytotoxic action against different cancer cell lines.
95
 Hemilabile 
coordination complexes have also encountered success with applications in catalysis 
and small molecule sensing.
96, 97
 
The length of a tether and its composition (heteroatom, branching, or multiple bonds) 
are anticipated to affect the tether ring properties, including the rate of tether ring 
formation, ring strain, and orientation of the tethering functional group. Thus, a 
molecular switch can be design to work by selective ring-opening of the tether under 
certain conditions. Control over the opening and closure of the tether ring as a function 
of pH might provide a Ru-arene complex which is specifically activated in cancer cells. 
Last but not least, tether complexes are commonly used for asymmetric transfer 
hydrogenation and asymmetric hydrogenation of ketones and imines, in which the 
suitable carbon chain length of the tether arm has an important role. Thus, this type of 
complexes can undergo the transfer hydrogenation of the biological cofactor NAD
+
 to 
NADH providing a new mechanism of activation to trigger the cytotoxicity of Ru
II
 
tether complexes. 
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2.1 Introduction 
 
The first part of this Chapter is devoted to an introduction towards the rational design 
of the hemilabile ligand, which plays a crucial role triggering the activation of Ru
II
 
tethered complexes. Different structural modifications on this ligand were proposed in 
an attempt to control the Ru–Z bond activation. In the second part of the Chapter, the 
synthesis and structural characterization of Ru
II 
tethered complexes after complexation 
with different hemilabile and/or XY chelating ligands is presented and discussed. 
Moreover, acidic activation of a series of complexes was investigated by means of 
1
H 
NMR to develop a structure-activation relationship of a variety Ru
II
-tether scaffolds 
retaining ethylenediamine as the XY chelate on the metal. 
 
2.1.2 The Hemilabile Arene:Z Ligand 
The term ―hemilabile ligand‖ was first introduced in synthetic chemistry in 1979 by 
Jeffrey and Rauchfuss.
1
 Since then, a broad range of coordinating groups of different 
reactivity has been synthesized and complexed to various metal centres, and several 
reviews have highlighted the versatile coordination chemistry with various types of 
scaffolds.
2, 3
 This hemilabile ligand, that contains both substitutionally inert and labile 
groups, forms a chelate with the metal centre (Figure 2.1).  
The reason behind studying hemilabile ligands relates to their ability to provide open 
coordination sites at the metal through a weak and reversible bonding interaction of 
specific donor groups. In fact, the small energy differences (often in the order of 50 kJ 
mol
-1
) involved in the dynamic reversible process of bond breaking and bond making 
forms the basis of hemilabity conferring to these systems interesting properties.
2
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Figure 2.1. Representation of a hemilabile ligand in a Ru
II 
complex. The arene group binds 
strongly to the metal centre while the Z atom is labile, offering the possibility of dissociation of 
the metal in a reversible way. The hemilability of the Ru–Z bond can be tuned by varying the 
spacer length, the spacer rigidity, and the donor binding strength. Sustituents of different nature 
on the arene as well as the remaining ligands will also swift the lability of the Ru–Z bond (vide 
infra). 
 
Although such aspects will not be discussed here, it is interesting to note that some 
metalloenzymes operate through a mechanism of activation similar to hemilability; for 
example, the opening of a zinc-cysteine bond allowing coordination of a water molecule 
occurs when going from an inactive to an active form of the metalloenzyme.
4, 5
  
The modification of both steric and electronic effects of the tether arm (spacer) 
provides an important modulation approach for a rational design of hemilabile ligands. 
Since we are developing these complexes for aqueous-based reactivity, we have focused 
on the modulation of the pKa of the labile donor group Z (ZH
+
/Z), to provide complexes 
whose hemilabile chelate allows protonation and depronation upon dissociation from 
the metal depending on the surrounding pH. This requirement is key to produce 
complexes susceptible to undergo activation of a coordination site in order to further 
interact with a biomolecule (or solvent molecule) taking into account the biological 
context of the cancer cell, this is, the slight acidic extracellular pH. 
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2.1.3 Acid-Base Properties of Z in the Hemilabile Ligand 
2.1.3.1 The Acid-Base Equilibrium. The pKa 
The main feature of the hemilabile ligand is the presence of the two distinguished 
groups, one of them weakly bound (Z) to the metal centre offering the possibility to de-
coordinate from the metal atom. This dissociation can be followed (and perhaps 
controlled) by a protonation/deprotonation process in the labile group, this is, an acid-
base reaction. The possibility of controlling Ru–Z activation by the acidity of Z has 
brought us to investigate which would be good candidates for our switchable system. 
Three functional groups appear most appropriate for our system (because of other 
functional groups are too weak to behave as acids or bases in aqueous solution): amines 
(pKa  11), phenols (pKa  10) and carboxylic acids (pKa  5).  
 
Figure 2.2. Acid-base reaction between ammonia and hydrogen chloride. 
 
As the typical example of Brønsted-Lowry acid-base reactions shown in Figure 2.2, 
hydrogen chloride (HCl), the acid, donates a proton to ammonia (:NH3), the base. The 
chloride ion is the conjugate base and ammonium ion is the conjugate acid.  
Acids differ in their ability to donate H
+
. Stronger acids, such as HCl, react almost 
completely with water, whereas weaker acids, such as acetic acid (CH3CO2H), react 
only slightly. The strength of an acid HA dissolved in water is measured by its acidity 
constant (Ka) for the acid-dissociation equilibrium (equation 2.1).
6
  
 
Equation 2.1 
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A large value of Ka means the acid is a strong acid, and a small value of Ka means the 
acid is a weak acid. A convenient way to express the strength of an acid is by its pKa 
defined in equation 2.2.
6
 A stronger acid (larger Ka) has a smaller pKa, and a weaker 
acid (smaller Ka) has a larger pKa.  
 
Equation 2.2 
 
Table 2.1 lists the pKa values of some common acids in order of their strength. As 
shown in the table the stronger the acid, the weaker its conjugate base. The stronger the 
base, the weaker its conjugate acid.  
 
Table 2.1. Relative strengths of some common acids and their conjugate bases.
7
 
 
 
 
2.1.3.2 Amines 
Amines are driven to equilibrium in aqueous solution, where water acts as an acid and 
transfers a proton to the amine. The basic strength of an amine can be measured by the 
basicity constant Kb (Equation 2.3). The larger the value of Kb, the smaller the value of 
pKb. Thus, the more favorable the proton-transfer equilibrium, the stronger the base. 
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Equation 2.3 
 
In practice, Kb values are not often used. Instead, the most convenient way to measure 
the basicity of an amine (RNH2) is to look at the acidity of the corresponding 
ammonium ion (RNH3
+
) as represented in Equation 2.4. The more acidic the ammonium 
ion, the less tightly the proton is held and the weaker the corresponding base. That is, a 
weaker base has an ammonium ion with a smaller pKa and a stronger base has an 
ammonium ion with a larger pKa. 
 
Equation 2.4. 
 
Table 2.2 lists pKa values of the ammonium ions of a variety of amines and indicates 
that there is a substantial range of amine basicities. It is shown that arylamines are 
considerably less basic that alkylamines.
7
 
Table 2.2. Basicity of some common amines. 
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2.1.3.3 Alcohols and Carboxylic Acids 
The acidity of alcohols vary widely, from alcohols that are about as acidic as water to 
some that are orders of magnitud less acidic, as displayed in Table 2.3. Phenols are 
about 10
6
 times more acidic than alcohols because the phenoxide anion is resonance-
stabilized. Both alcohols and phenols  may dissociate in aqueous solution by donating a 
proton to water, generating H3O
+
 and an alkoxide ion, RO
–
, and  phenoxide ion, ArO
–
, 
respectively. 
With pKa values of ca. 5, carboxylic acids are much stronger acids than water and 
alcohols. Like other Brønsted-Lowry acids, carboxylic acids dissociate in aqueous 
solutions to give H3O
+
 and the corresponding carboxylate anions, RCO2
–
. The extent of 
dissociation is given again by the acidity constant, Ka. Table 2.3 represents the acidity 
of some carboxylic acids in comparison with alcohols.
7
 
 
Table 2.3. Acidity of some alcohols and carboxylic acids. 
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2.1.4 Scope of This Chapter 
We have selected a number of hemilabile ligands to bind ruthenium(II) to explore the 
effect of the formerly discussed considerations for Ru–Z bond activation, namely, 
length and rigidity of the spacer, nature of the donor atom that closes the tether, and the 
acidity of its protonated form. In order to fully investigate such an effect and its 
tuneability we have studied variation of another crucial building block in this structure, 
i.e. the XY ligand. This serves as starting point for the exploration of the effect of the 
XY in the Ru–Z bond activation and will be expanded later in this Thesis. 
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2.2 Results and Discussion 
 
2.2.2 Selection of Hemilabile Ligands 
A series of hemilabile ligands (Table 2.4) were chosen considering several structural 
features. First, donor atoms (Z) were preferred to be nitrogen and oxygen according to 
their reported affinity for Ru
II
. Second, ligands with a wide range of pKa (3.8–15.2) 
were selected to investigate the influence of the acidity of ZH
+
 in the ring opening 
mechanism. For nitrogen-based ligands the pKa corresponds to the cation ZH
+
 (e.g. 
RNH3
+
 and pyH
+
), while for alcohols and carboxylic acids the pKa correspond to the 
ROH and RCOOH species, respectively. Finally, different length size and rigidity of the 
tether arm were considered to study their relationship with the lability of the Ru–Z 
bond. The Ru
II
 tether complexes synthesized with these hemilabile ligands were 
classified in three groups attending to the type of functional group (Z) coordinated to 
the metallic centre, i.e. amines, alcohols and carboxylic acids. 
 
Table 2.4. Proposed hemilabile ligands to be studied in this Thesis ordered by increasing pKa. 
The indicated pKa for the amines corresponds to the pKa of their conjugated acid. 
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2.2.3 Tethering Amines 
2.2.3.1 Synthesis and Characterization 
Fourteen Ru
II
 tethered complexes of the type [Ru(η6:κ1-arene:N)(XY)]0/+2 (Figure 2.4 
and Table 2.5), where the hemilabile ligand or arene:N is 1-methyl-3-
phenylpropylamine (1–3), 3-phenyl-1-propylamine (4–6), 2-phenylethylamine (7), 1,2-
diphenylethylamine (8), 2-benzylpyridine (9–12) or 2-aminobiphenyl (13–14), and XY 
is the chelating ligand ethylenediamine (en), 1,3-diaminopropane (dap), N,N-
diethylethylenediamine (deen), 1,10-phenantroline (phen), o-phenylendiamine (o-pda) 
or oxalate (oxo) were synthesized in good yields by reaction of different chelating 
ligands with the appropriate dichlorido complex [Ru(η6-arene:N)Cl2]. This precursor 
dichlorido complex was synthesized according to the route employed by Melchart et 
al.,
8
 and indicated in Scheme 2.1, which involves the thermal displacement of ethyl 
benzoate (etb) from [Ru(η6-etb)Cl2]2 by the convenient nitrogen-donor derivative 
(synthetic path 1, Chapter 1). Subsequent reaction with the corresponding XY chelating 
ligand afforded closed complexes 1–14. Detailed synthetic procedures are explained in 
the Experimental Section at the end of this Chapter. Complexes were characterized by 
elemental analysis, 
1
H NMR spectroscopy and/or ESI-MS spectroscopy. The molecular 
structures of 5–7, 9, 12 and 13 were determined by single crystal X-ray diffraction (vide 
infra).  
 
Scheme 2.1 
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Figure 2.4. General structure for closed tethered complexes of formula [Ru(η6:κ1-
arene:N)(XY)]
0/+2
. 
 
Table 2.5. Hemilabile ligands and XY-chelating ligands used in this Chapter for the synthesis 
of tethered complexes 1–14. 
 
 
 
The 
1
H NMR spectra of the tethered complexes in D2O at 298 K proved η
6
-
coordination of the corresponding arene ligand to the metal. Coordination of the amine 
to the metal centre was verified by a typical NMR pattern of the η6-bound arene 
resonances in the aromatic region. Three characteristic peaks (triplet:doublet:triplet in a 
Complex
Hemilabile 
Ligand
XY Chelating 
Ligand
Complex
Hemilabile 
Ligand
XY Chelating 
Ligand
1 8
2 9
3 10
4 11
5 12
6 13
7 14
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ratio 2:2:1) were assigned to these η6-coordinated arene ring protons. These 
characteristic signals for the η6-bound arene in the complexes were upfield-shifted (ca. 
1.8 ppm) in all cases with regard to those of the free ligands. Moreover, the large 
distance between the most deshielded and most shielded η6-bound arene signals (ca. 0.8 
ppm) evidenced coordination of Z to the metal centre. Crystallographic structures 
confirmed unequivocally the structure of these complexes. 
 
2.2.3.2 X-Ray Crystallography 
Suitable crystals for X-ray diffraction studies were obtained from slow diffusion of 
diethyl ether into methanol solutions or slow evaporation of water solutions. The crystal 
structures of complexes [Ru{η6:κ1-C6H5(CH2)3NH2}(dap)]Cl2 (5), [Ru{η
6:κ1-
C6H5(CH2)3NH2}(deen)]Cl2 (6), [Ru{η
6:κ1-C6H5(CH2)2NH2}(en)]Cl2 (7), [Ru{η
6:κ1-
C6H5CH2(C5H4N)}(en)]Cl2 (9), [Ru{η
6:κ1-C6H5(CH2)C5H4N}(oxo)] (12) and 
[Ru{η6:κ1-C6H5(C6H4)NH2}(en)]Cl2 (13) were determined by X-ray diffraction. Their 
molecular structures and numbering schemes are shown in Figure 2.5. The 
crystallographic structure of complex [Ru{η6:κ1-C6H5(C6H4)NH2}(oxo)] (14) has been 
published previously and its crystallographic data have been used here for comparative 
reasons.
9
 Selected bond lengths and angles are given in Table 2.6, and the 
crystallographic data are listed in Appendix II.  
Chapter 2 
53 
 
Figure 2.5. X-ray structures and atom numbering schemes for complexes (A) [Ru{η6:κ1-
C6H5(CH2)3NH2}(dap)]Cl2 (5), (B) [Ru{η
6:κ1-C6H5(CH2)3NH2}(deen)]Cl2 (6), (C) [Ru{η
6:κ1-
C6H5(CH2)2NH2}(en)]Cl2 (7), (D) [Ru{η
6:κ1-C6H5CH2(C5H4N)}(en)]Cl2 (9), (E) [Ru{η
6:κ1-
C6H5CH2(C5H4N)}(oxo)] (12) and (F) [Ru{η
6:κ1-C6H5(C6H4)NH2}(en)]Cl2 (13). The hydrogen 
atoms and counterions have been omitted for clarity (except on the nitrogen of the tether arm). 
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Table 2.6. Selected bond lenghts (Å) and angles (deg) for complexes 5–6, 7, 9 and 12–14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The structures are similar, and all the complexes adopt the ―piano stool‖ type of 
geometry common to several other ruthenium(II) arene compounds.
10, 11
 The arene 
ligands display the usual π-bonded η6-coordination mode, whereas the XY chelating 
ligand assumes a bidentate-chelate coordination mode, occupying two coordination 
positions. The last place in the coordination sphere is occupied by the nitrogen atom 
pendant from the tethered arene. This resulted in an additional chelate (5-membered) in 
the structure. Complexes 5, 6, 7 and 9 crystallized with four independent molecules in 
the unit cell, while complex 13 crystallized with six molecules. The structure of 12 
showed dimer formation between equivalent molecules. The Cl
–
 counterions in the 
crystal structures of 5–7 and 13 were extensively involved in H-bonding to the Ntether 
hydrogen atoms (N–H···Cl distances of 2.310–2.854 Å) and to the hydrogens atoms on 
the nitrogen of the chelating ligands (N–H···Cl distances in the range 2.325–2.575 Å). 
Only the crystal structure of complex 12 showed intermolecular π-π interaction between 
the pyridines of adjacent molecules with a distance between pyridine centroids of 3.544 
Å.  
 
Bond / angle 5 6 7 9 12 13 14
14
 
Ru-C6 2.202(2) 2.188(7) 2.125(2) 2.117(5) 2.165(5) 2.115(13) 2.104(2) 
Ru-C5 2.186(2) 2.178(7) 2.175(2) 2.182(5) 2.157(5) 2.184(13) 2.160(2) 
Ru-C4 2.181(2) 2.194(7) 2.186(2) 2.176(4) 2.168(5) 2.207(14) 2.174(3) 
Ru-C3 2.197(2) 2.187(7) 2.203(2) 2.195(5) 2.197(5) 2.221(15) 2.214(2) 
Ru-C2 2.192(2) 2.194(7) 2.183(2) 2.175(5) 2.163(5) 2.198(13) 2.192(2) 
Ru-C1 2.197(2) 2.194(7) 2.176(2) 2.163(5) 2.111(4) 2.191(13) 2.159(2) 
Ru-centroid 1.679 1.679 1.651 1.652 1.637 1.659 1.635 
Ru-X 2.1433(18) 2.136(5) 2.1238(17) 2.143(3) 2.092(3) 2.144(11) 2.081(1) 
Ru-Y 2.1470(19) 2.122(5) 2.1258(19) 2.116(3) 2.096(3) 2.148(11) 2.076(1) 
Ru-N1 2.1372(18) 2.138(7) 2.1269(17) 2.121(4) 2.136(4) 2.161(11) 2.131(2) 
X-Ru-Y 80.32(7) 85.5(2) 79.49(7) 78.83(13) 77.81(11) 80.4(4) 78.42(6) 
X-Ru-N1 87.56(7) 85.2(2) 86.61(8) 91.65(13) 90.23(13) 88.2(4) 86.19(6) 
Y-Ru-N1 84.19(7) 87.1(3) 89.51(7) 90.19(14) 89.29(13) 88.0(4) 86.63(7) 
Ru-C6-C7 126.41 126.41 114.49 114.44 115.37 112.82 112.19 
C7-offset 0.147 (+) 0.112 (+) 0.446 (+) 0.436 (+) 0.423 (+) 0.488 (+) 0.481 (+) 
[a] Offset of C7 with respect to the plane formed by the bound arene (carbons C1–C6); (+) toward ruthenium 
[a]  
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The Ru–Carene bond lengths were in the range of 2.104(2)–2.221(15) Å. The Ru–
centroid distances for the different complexes fell into a narrow interval (1.635–1.679 
Å) and were comparable with similar tethered complexes (e.g. [Ru{η6:κ1-
C6H5(CH2)3NH2}Cl2],
12
 [Ru{η6:κ1-C6H5(CH2)2NH2}Cl2]
8
 and [Ru{η6:κ1-
C6H5(C6H6N)}Cl2],
13
 for comparison with complex 5, 7 and 9, respectively). Longer 
distances between the bound arene and the ruthenium centre have been observed when 
the Ntether is replaced by a phosphine group (ranging from 1.682 to 1.794 for 
literature).
14, 15
 The Ru–X/Y distances were ranged between 2.076(1)–2.148(11) Å, and 
the Ru–N1 distances with values between 2.121(4)–2.161(11) Å.  
No significant structural differences were observed between the complexes, however, 
some variations were appreciated regarding to the Ru-C6-C7 angle (112.19–126.41º). 
This angle, where C6 is the arene carbon connected to the tether and C7 is the first 
carbon atom on the tether arm, is an important geometrical parameter which correlates 
with the strain imposed on the tether ring. It is interesting to note that the non-strained 
Ru-C6-C7 angle is ca. 130º. However, for these tethered complexes this value was 
smaller. The observed trend followed as: 5, 6 >> 7, 9, 12 > 13, 14, with complex 14
9
 
bearing the most strained tether chelate. Additional tether-ring strain was defined by the 
offset of C7 with regard to the plane that contains the η6-bound arene (from 0.112 Å 
towards ruthenium for 6 and 0.488 Å for 13). 
Complexes 5 and 6 exhibited the largest Ru-C6-C7 angle (126.41º). These results are 
in accordance with the published analogue complex [Ru{η6:κ1-C6H5(CH2)3NH2}Cl2]
8
 
with an angle of 127.17º, near to the non-strained angle 130º. This suggests that the 
three-atom spacer in the tether of 5 and 6 present a lower strain when compared to the 
rest two-atom spacers in complexes 7, 9, 12, 13 and 14. Complexes containing 2-
aminobiphenyl (13 and 14) presented, however, the highest constrain in the molecule 
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(ca. 112º). Finally, when we compared complex 13 with its open-tether analogue 
[Ru{η6-C6H5(C6H4)NH2}(en)Cl]Cl,
16
 the tether chelate strain disappeared due to the 
free rotation of the tether arm, and the latter complex presents a Ru-C6-C7 angle of 
133.17º. 
 
2.2.4 Alcohols and Carboxylic Acid as Hemilabile 
Ligands 
2.2.4.1 Synthesis and Characterization 
Six ruthenium(II) complexes of general formula [Ru(η6-arene)(XY)Cl]0/+1 (Figure 2.6 
and Table 2.7) were synthesised bearing as hemilabile ligand 2-phenylethyl alcohol 
(15Cl–19Cl) and phenylacetic acid (20Cl), and containing as XY-chelating ligand 
ethylenediamine (en), N,N,N’,N’-tetramethylethylendiamine (tmen), N,N-dimethyl-4-(2-
pyridylazo)aniline (azpy-NMe2), 2,2‘-bipyridine (bip) and sodium oxalate (oxo). These 
open tether complexes are interesting because they could potentially afford the typical 
closed tethered complexes through the synthetic path 2 detailed in the Chapter 1. 
 
 
Figure 2.6. General structure for open tethered complexes of formula [Ru(η6-
arene)(XY)Cl]0/+1, which can potentially afford the closed tethered counterpart by synthetic 
path 2, as indicated in Chapter 1. 
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Table 2.7. Hemilabile ligands and XY-chelating ligands used in this Chapter for the synthesis 
of complexes 15Cl–20Cl. 
 
 
 
Synthesis of alcohols derivatives was carried out as follows. First, cyclohexa-2,5-
dienecarboxylic acid was prepared by Birch reduction of commercially available 
benzoic acid,
17
 followed by esterification.
18
 Treatment of RuCl3 with the diene afforded 
the dimer complex [Ru(η6-etb)(µ-Cl)Cl]2 in high yield (Scheme 2.1). This was 
converted to the corresponding 2-phenylethyl alcohol dimer [Ru{η6-C6H5(CH2)2OH}(µ-
Cl)Cl]2 when treated with a high excess of 2-phenylethyl alcohol in a closed vessel 
under pressure, rising as a novel and effective procedure for obtaining that dimer 
(Scheme 2.2). The resulting red crystals were reacted with the appropriate X,Y-
chelating ligand in methanol to afford complexes 15Cl–19Cl. 
 Complex 20Cl containing phenylacetic acid as hemilabile ligand was also 
synthesized as an open tether complex with the carboxylic group dissociated from the 
ruthenium(II) centre. In contrast to the preparation of alcohol complexes, a different 
method was used for the synthesis of complex 20Cl.  
 
Chapter 2 
58 
 
Scheme 2.2 
 
Birch reduction of commercial phenylacetic acid afforded 2,5-dihydrophenylacetic 
acid, which was reacted with RuCl3 to obtain the dimer [Ru(η
6
-C6H5CH2COOH)(µ-
Cl)Cl]2.
19
 Cleavage of the chloro bridges of the dinuclear dimer with two equivalents of 
ethylenediamine (en) in methanol afforded the monomeric complex 20Cl (Scheme 2.3). 
 Several attempts to obtain complexes bearing 2-phenylphenol as hemilabile ligand 
were unsuccessful since decomposition or starting material was invariably found. The 
lack of success was found upon varying the solvent, the temperature and/or the reaction 
time.  
 
Scheme 2.3 
 
All complexes were characterized by CHN elemental analysis, 
1
H NMR spectroscopy 
and single crystal X-ray diffraction analysis for complexes 15Cl–18Cl and 20Cl. 
Complexes 15Cl and 20Cl were also confirmed by ESI-MS. The mass spectra recorded 
in positive ion mode featured peaks at m/z values in close agreement with the expected 
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values for [M–Cl–H]+ ions, after cleavage of the labile chlorido ligand from the metal 
complex during the ionization process.  
The 
1H NMR spectra show five CH resonances in the coordinated η6-arene region for 
all complexes 15Cl–20Cl, in addition to the peaks in the aliphatic spectral region. The 
presence of three signals attributed to the coupling between para, meta and ortho 
positions gives two triplets and one doublet of relative intensities 2:1:2, respectively. 
The distance between the most deshielded and shielded η6-bound arene signals are ca. 
0.1 ppm, in contrast to values observed for complexes 1–14 (ca. 0.8 ppm). This suggests 
a bigger nuclear equivalence of the arene protons due to the free rotation of the η6-
bound arene in contrast to no rotation in the buckled closed tethered structure. Figure 
2.7 illustrates the above mentioned differences in the 
1
H NMR between closed and open 
tether complexes.  
 
Figure 2.7. 
1
H NMR spectrum (D2O) showing the η
6
-arene region of the open complex 
[Ru{(η6-C6H5(CH2)2OH}(en)Cl]
+1 
(15Cl) and its related closed tether complex [Ru{η6:κ1-
C6H5(CH2)2NH2}(en)]
+2 
(7). Pendant arm (de)coordination from the metal centre can be related 
to the splitting of the coordinated η6-arene proton signals. 
 
In accordance with literature reports,
20
 the treatment of open tether complexes 15Cl–
20Cl with silver salts should afford the closed tethered derivatives [Ru{η6:κ1-
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arene:O}(XY)]
+2
, which results from the elimination of the chlorido ligand and 
subsequent coordination of the pendant arm to the ruthenium(II) centre. However, only 
compound 20Cl afforded the corresponding closed tethered complex 20, of formula 
[Ru{η6:κ1-C6H5(CH2)COO}(en)]
+
,
 
via a method explained in detail in Chapter 4. The 
impossibility of the –CH2CH2OH side arm of compounds 15Cl–19Cl to form a tethered 
chelate (closed species) was somehow unexpected since related derivatives readily 
generated tethered η6:κ1arene-O complexes under similar reaction conditions.21, 22 
Explorative work by our research group has shown that in the case of 15Cl–19Cl 
derivatives, where the alcohol oxygen is only weakly nucleophilic, a larger side tether 
arm (more than two-carbon spacer) is necessary for coordination to the metal and to 
afford a sufficiently stable closed tether η6:κ1arene-O complex to be isolated.23 
 
2.2.4.2 X-Ray Crystallography 
Crystals of complexes 15Cl–18Cl and 20Cl suitable for X-ray analysis were obtained 
from methanol solutions layered with diethyl ether. Once again, the ORTEP views 
showed the classical pseudo-octahedral ―three-legged piano-stool‖ geometry around the 
metal centre, with Ru
II
 π-bonded to the arene ligand (1.666–1.711 Å), σ-bonded to a 
chloride (2.390(2)–2.4172(15) Å) and a chelating ligand (2.057(7)–2.209(11) Å) which 
constituted the three ―legs‖ of the piano stool. The structures along with their atom 
numbering schemes are shown in Figure 2.8. Selected bond lengths and angles are listed 
in Table 2.8. 
Chapter 2 
61 
 
Figure 2.8. X-ray structures and atom numbering schemes for complexes (A) [Ru{η6-
C6H5(CH2)2OH}(en)Cl]Cl (15Cl),  (B) [Ru{η
6
-C6H5(CH2)2OH}(tmen)Cl]Cl (16Cl), (C) [Ru{η
6
-
C6H5(CH2)2OH}(azpy-NMe2)Cl]Cl (17CL), (D) [Ru{η
6
-C6H5(CH2)2OH}(bip)Cl]Cl (18Cl) and 
(E) [Ru{η6-C6H5(CH2COOH}(en)Cl]Cl (20Cl). The hydrogen atoms and counterions have been 
omitted for clarity (except on the oxygen pendant from the tether arm). 
 
Table 2.8. Selected bond lenghts (Å) and angles (deg) for complexes 15Cl–18Cl and 20Cl. 
 
 
 
 
 
 
 
 
 
 
 
 
Bond / angle 15Cl 16Cl 17Cl 18Cl 20Cl 
Ru-C6 2.220(5) 2.234(12) 2.250(8) 2.252(18) 2.1819(19) 
Ru-C5 2.207(4) 2.155(14) 2.226(9) 2.181(17) 2.182(2) 
Ru-C4 2.154(4) 2.164(10) 2.185(10) 2.182(18) 2.202(2) 
Ru-C3 2.171(6) 2.188(11) 2.214(10) 2.184(19) 2.180(2) 
Ru-C2 2.154(4) 2.177(16) 2.173(9) 2.17(2) 2.186(2) 
Ru-C1 2.207(4) 2.210(14) 2.203(10) 2.219(17) 2.158(2) 
Ru-centroid 1.667 1.701 1.711 1.710 1.666 
Ru-X 2.117(3) 2.209(11) 2.070(7) 2.102(13) 2.1255(17) 
Ru-Y 2.117(3) 2.177(11) 2.057(7) 2.091(13) 2.1229(16) 
Ru-Cl 2.4172(15) 2.415(3) 2.390(2) 2.411(4) 2.4114(5) 
X-Ru-Y 79.40(19) 79.3(5) 75.0(3) 77.6(5) 78.84(7) 
X-Ru-Cl 84.47(10) 88.1(3) 85.44(19) 84.3(3) 83.95(5) 
Y-Ru-Cl 84.47(10) 85.5(3) 86.1(2) 84.6(4) 85.10(5) 
Ru-C6-C7 130.33 126.50 127.06 128.39 127.71 
C7-offset 0.034 (+) 0.008 (+) 0.071 (+) 0.065 (+) 0.069 (+) 
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Complexes 15Cl and 20Cl crystallized with four independent molecules in the unit 
cell, while complex 16Cl crystallized with two molecules, and 17Cl and 19Cl with 
eight molecules in the unit cell. The Cl
–
 counterions in the crystal structures of 15Cl and 
20Cl were extensively involved in H-bonding to the Otether hydrogen atoms (O–H···Cl 
distance of 2.029–2.202 Å) and to the hydrogen atoms on the nitrogen of the chelating 
ligands (N–H···Cl distances in the range 2.389–2.590 Å). As expected for open-tether 
complexes, the Ru-C6-C7 angles fall within the range 126.5–130.3º. Structures of 16Cl 
and 19Cl showed H-bonding interactions between Cl
–
 counterions and the Otether 
hydrogen atoms (O–H···Cl distance in the range 2.164–2.467 Å). Only the crystal 
structure of complex 18Cl showed evidence for intermolecular π-π interactions between 
the pyridine rings of adjacent molecules with a distance between centroids of 3.581 Å. 
 
2.2.5 Structure-Activation Relationship 
In this part of the Chapter we illustrate the activation (opening) of the Ru–Z bond of 
closed tethered complexes under acidic conditions (Figure 1.15). To establish a 
structure-activation relationship regarding the effect of the arene:Z hemilabile ligand, 
we selected closed-tethered complexes bearing ethylenediamine (en) as XY chelating 
ligand.  
Complexes of formula [Ru(η6:κ1-arene:Z)(en)]n+, i.e.; 1, 4, 7, 8, 9, 13 and 20, were 
dissolved in D2O at pH 7.0 at 298 K. Then, the pH of the solutions was adjusted to ca. 
0. Their 
1
H NMR spectra were recorded at 298 K immediately after the pH adjustment 
(ca. 15 min) and after 24 h. Figure 2.9 shows the different extents of activation. The 
amount of activated open-tether complexes was determined by integration of the η6-
bound arene ring signals. The 
1
H NMR spectra for complexes 1 and 4 did not show any 
new signals overtime after 24 h. At t = 15 min only complexes 9, 13 and 20 showed 
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activation by the presence of new set of 
1
H NMR signals corresponding to the open 
protonated species (9HCl, 13HCl and 20HCl), of general formula [Ru(η6-
arene:ZH)(en)Cl]
n+
, whose characterization will be described in detail in Chapters 3 and 
4. Percentages of the open protonated species were 10, 79 and 100% for complexes 
9HCl, 13HCl and 20HCl, respectively. Over 24 h, all tethered complexes containing 
two-carbon tether in the pendant arm underwent activation of the Ru–Z bond at 
different extents. At this point, when equilibrium is reached, intensity of peaks assigned 
to 9HCl and 13HCl increased up to 100%, while peaks of very little intensity attributed 
to 7HCl and 8HCl were also observed (3 and 2%, respectively). Since pH 0 < pKa for 
all complexes, the pendant arm of the tether must be protonated (ZH
+
). Despite the 
important role of Z protonation in bloking the complex in its (open) active form, the 
data clearly shows that the pKa of the hemilabile ligands is not the only factor driving in 
the opening process.  
 
Figure 2.9. Extents of open protonated species through acidic activation (pH ca. 0) of  
[Ru(η6:κ1-arene:Z)(en)]n+ complexes bearing different hemilabile ligands and fixed chelating 
ligand (en). 
 
We could highlight two features affecting the ring-opening process: i) appropriate 
ring constrain, including length and flexibility of the pendant arm, and ii) the nature of 
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the donor tether atom (functional group and pKa). All complexes with η
6
-bound arene 
bearing two-carbon atoms in the side arm (7–9, 13 and 20) showed acidic activation 
after 24 h at different extents. However, complexes 1 and 4 bearing three-carbon atoms 
in the spacer of the pendant arm showed no activation overtime. This observation can be 
explained by discussing the representatives crystal structures of [Ru{η6:κ1-
C6H5(CH2)3NH2}(dap)]Cl2 (5, three-atom tether) and [Ru{η
6:κ1-
C6H5(CH2)2NH2}(en)]Cl2 (7, two-atom tether). As mentioned in the X-ray 
Crystallography Section, the Ru-C6-C7 angle in 5 is closer to 130º (126.41º) than the 
angle observed for 7 (114.5º), showing that 5 appears to accommodate a non-strained 
tether chelate, while 7 presents a forced chelate. In this manner, more strained (short) 
tether arms favours tether-ring opening. 
Complexes 7–9 and 13 (hemilabile ligand containing amines with two-atom tethers) 
all showed acidic activation after 24 h. However, the percentage of the open activated 
forms of complexes 7 and 8 (where Z is an aliphatic amine) was only of ca. 3% while 
the total activation was observed for complexes 9 and 13 (where Z is an aromatic 
amine) over 24 h. These results reveal that aromatic amines as pendant arms show a 
substantial increase of activation compared with aliphatic amines. This could be 
explained on the basis that the unshared electron pair on nitrogen in aliphatic amines 
occupies a sp
3
-hybridized orbital. This lone pair is involved in the coordination to the 
ruthenium(II) center. However, the unshared electron pair on the nitrogen in 2-
aminobiphenyl is delocalized into the π-system of the ring and 2-benzylpyridine 
presents a sp
2
-hybridization. This feature makes aromatic amines less basic and less 
nucleophilic than aliphatic amines, regarding their coordination to ruthenium(II) 
providing complexes with weaker Ru–Z bond and thus more prone to activation. 
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A significant difference in the rate of activation is observed between complexes 9 and 
13 (at time 15 min, 10 vs 79%, respectively). This observation is consistent with a high 
ring constrain imposed by a sp
2
-hybridization on the C7 atom in complex 13 versus the 
sp
3
-hybridization in complex 9, proving the importance on the rigidity of the side arm or 
spacer in the tether opening process.  
Complex 20, bearing a carboxylate group from the η6-bound arene underwent the 
fastest activation which was complete in the first 15 min of reaction in acidic water. 
This suggests that κ1O-coordination is weaker than κ1N-coordination. This demonstrates 
the crucial role of the donor atoms nature in the activation of the Ru–Z bond. 
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2.3 Conclusions 
 
When designing a new molecule for a certain purpose always the structure and the 
stereo-electronic properties should be taken into account and modified and modulated 
accordingly. We consider that it is rather important to study in detail the structural 
aspects of hemilabile ligands and their influence on the Ru–Z bond activation in order 
to design Ru
II
 tether switchable complexes. It is crucial to have a clear overall picture of 
what the structural and stereo-electronic properties affecting the κ1Z 
dissociation/association from the ruthenium(II) centre, since dissociation (inactivation) 
will provide a site for coordinative interactions with intracellular targets. The novel 
structure-activation relationship established between the new tethered complexes 1, 4, 
7–9, 13 and 20 of formula [Ru(η6:κ1-arene:Z)(en)]n+ displayed essential information 
about the hemilabile ligand structural features and how they affect the susceptibility of 
Ru–Z activation.  
Complexes containing hemilabile ligands with nitrogen as donor atom (1, 4, 7–9 and 
13) only underwent activation if the side arm is short (two-atom tether) in different 
extents in an acidified environment. In that case, only complexes bearing aromatic 
amines as the coordinating group (9 and 13) showed total activation after 24 h. Complex 
[Ru{η6:κ1-C6H5(C6H4)NH2}(en)]Cl2 (13) bearing 2-aminobiphenyl (two-carbon atoms 
with sp
2
-hybridization) exhibited the fastest tether activation. For this reason, a detailed 
study of ruthenium(II) complexes containing 2-aminobiphenyl as hemilabile ligand will 
be presented in Chapter 3. 
Our results demonstrated that κ1O-coordination is weaker than κ1N-coordination. On 
the one hand, complexes containing 2-phenylethyl alcohols could not be isolated as 
closed tethered counterparts, and an elongation of the tether arm was necessary to 
achieve the κ1O-coordination.23 On the other hand, the total conversion of complex 20 
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towards the open protonated species was observed after 15 min following acidification. 
The interesting features observed for complex 20 led us to develop a new family of 
ruthenium(II) complexes containing 2-phenylacetic acid as hemilabile group, which will 
be presented in Chapter 4. 
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2.4 Experimental Section 
 
2.4.2 Instrumentation 
NMR Spectroscopy. 
1
H NMR spectra were acquired in 5 mm NMR tubes using a 
Bruker DPX 400 MHz spectrometer. 
1
H NMR chemical shifts were internally 
referenced to 1,4-dioxane (3.75 ppm) for aqueous solutions, (CHD2)(CD3)SO (2.50 
ppm) for DMSO-d6 and CD2HOD (3.34 ppm) for methanol-d4. Data processing was 
carried out using MestreNova, version 6.0 (Mestrelab Research, S.L.). 
 
Single Crystal X-ray Diffraction. Suitable crystals of compounds 5–7, 9, 12–13, 
15Cl–18Cl and 20Cl, were coated with mineral oil and mounted on Mitegen 
MicroMounts. The samples were measured in a Bruker D8 KAPPA APEX II 
diffractometer with CCD area-detector, equipped with graphite-monochromated Mo Kα 
radiation (λ = 0.71073 Å). The substantial redundancy in data allowed empirical 
absorption corrections (SADABS)
24
 to be applied using multiple measurements of 
symmetry-equivalent reflections. Raw intensity data frames were integrated with the 
SAINT program, which also applied corrections for Lorentz and polarization effects. 
The Bruker SHELXTL Software Package was used for space group determination, 
structure solution, and refinement.
25
 The space group determination was based on a 
check of the Laue symmetry, and systematic absences were confirmed using the 
structure solution. The structures were solved by direct methods (SHELXL-2014/7),
26, 27
 
completed with different Fourier syntheses, and refined with full-matrix least-squares 
using SHELXS minimizing ω(Fo
2
 – Fc
2
)
2
. Weighted R factors (Rw) and goodness of fit 
(S) are based on F
2
; conventional R factors (R) are based on F. All non-hydrogen atoms 
were refined with anisotropic displacement parameters. Hydrogen atom positions were 
geometrically calculated and allowed to ride on their parent carbon or nitrogen atoms 
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with fixed isotropic U. All scattering factors and anomalous dispersion factors are 
contained in the SHELXTL 6.10 program library. The data were processed by the 
modelling program Mercury version 3.9 (CSD System).  
 
Mass Spectrometry. Electrospray ionization mass spectra (ESI-MS) were obtained by 
infusing the samples into an Agilent 6120 Single Quadrupole LC/MS. The cone voltage 
was varied between 40 and 200 V depending on sensitivity. The mass spectra were 
recorded with a scan range of m/z 50–500 for positive ions. 
 
Elemental Analysis. Elemental analysis was carried out using a Leco analytical 
elemental analyzer CHNS-932. 
 
pH Measurements. The pH* values (pH meter readings in D2O solutions) of NMR 
samples in D2O were measured at 298 K directly in the NMR tube, using a FiveEasy pH 
meter equipped with a Crison micro-electrode calibrated with Crison buffer solutions at 
pH 4 and 7. The pH* values can be converted to pH values by use of the equation pH = 
0.929 pH* + 0.42, suggested by Krezel and Bal,
28
 for comparison with related values in 
the literature. 
 
2.4.3 Methods 
Acidic Activation. The ring-opening process of closed tethered complexes 1, 4, 7, 8, 9, 
13 and 20 was monitored by 
1
H NMR in aqueous solutions at 298 K. After dissolving 
complexes (6–7 mM) in D2O at pH 7.0, DCl was used to adjust the pH close to ca. 0. 
The relative percentages of closed- and open-tether species were quantified at different 
time points (15 min and 24 h) by integration of peaks in the 
1
H NMR spectra. 
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2.4.4 Synthesis 
MATERIALS 
RuCl33H2O was acquired from Precious Metals Online. Benzoic acid, 
ethylendiamine (en), 1,3-diaminopropane (dap), N,N,N′,N′-tetramethylethylenediamine 
(tmen), sodium oxalate (oxo), 2,2'-bipyridyl (bipy), 1-methyl-3-phenylpropylamine, 3-
phenylpropylamine, phenylethylamine, 1,2-diphenylethylamine, 2-benzylpydirine 
phenylacetic acid and deuterium chloride were purchased from Sigma-Aldrich. N,N′-
diethylethylenediamine (deen), N,N, dimethyl-4-(2-pyridylazo)aniline (azpi-NMe2) and 
2-phenylphenol were acquired from Cymit. Dichloroethane and magnesium were 
acquired from Acros Organics, and 2-aminobiphenyl, phenylethyl alcohol, iodine, 
molecular sieves of 3Å and silver hexafluorophosphate from Fisher. Ethanol, dry 
methanol, diethyl ether, tetrahydrofuran, sodium metal, and sodium chloride were 
purchased from Sharlau. For NMR spectroscopy, the solvents used were MeOD-d4, 
dimethyl-d6 sulfoxide, deuterium oxide and 1,4-dioxane obtained from VWR 
International.  
 
PREPARATION OF PRECURSORS 
Dichlorido complexes of general formula [Ru(η6:κ1-arene:N)Cl2] were prepared by 
previously reported procedures.
16, 19
 Typically, dimer [RuCl2(η
6
-etb)]2 and the 
corresponding hemilabile ligand were suspended in 1,2-dichloroethane. The mixture 
was stirred for 45 min at ambient temperature giving a dark red solution. THF (1 mL) 
was added, and the mixture degassed with argon for 30 min. The vessel was closed, and 
the reaction mixture heated under pressure at 393 K (5–16 h depending on the target 
product). The air stable microcrystalline material was collected by filtration, washed 
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with acetone and diethyl ether, and dried in air. Details of the amounts of reactants, 
volume of solvents, stirring times, and the aspect of the product are described below for 
the individual reactions, as well as any variation in the synthetic procedure. 
 
[Ru(η6-etb)(µ-Cl)Cl]2. Benzoate dimer. Birch reduction of benzoic acid was carried 
out following the experimental procedure described by Habtemariam et al.
1
 to afford 
cyclohexa-2,5-dienecarboxylic acid. However, the esterification step to obtain ethyl 
cyclohexa-2,5-dienecarboxylate was performed according to the experimental 
conditions published by Butters et al.
2
 Ethyl cyclohexa-2,5-dienecarboxylate (628 mg, 
4.13 mmol) and RuCl3·3H2O (216 mg, 0.83 mmol) were stired under reflux in dry 
EtOH (25 mL) overnight. The solvent was concentrated and the orange precipitate was 
filtered off, washed with cold ethanol and diethyl ether, and dried in vacuum. Yield: 264 
mg (99%). 
1
H NMR (400 MHz, CDCl3, δ): 6.47 (d, J = 6.3 Hz, Ar H, 2H), 5.97 (dd, J = 
8.2, 3.0 Hz, Ar H, 1H), 5.78 (t, J = 5.8 Hz, Ar H, 2H), 4.47 (q, J = 7.2 Hz, –CH2CH3, 
2H), 1.42 (t, J = 7.1 Hz, –CH2CH3, 3H). 
 
[Ru{η6:κ1-C6H5(C3H5Me)NH2}Cl2]. Precursor of complexes 1–3. [RuCl2(η
6
-etb)]2 
(200 mg, 0.31 mmol) and 1-methyl-3-phenylpropylamine (100 L, 0.62 mmol) were 
suspended in 1,2-dichloroethane (20 mL). The reaction mixture was heated under 
pressure at 393 K for 16 h. The red-brown, air stable microcrystalline material was 
collected by filtration, washed with acetone and diethyl ether, and dried in air. Yield: 
173 mg (87%). Elemental analysis: Cald for C10H15Cl2NRu (321.21): C, 37.39; H, 4.71; 
N, 4.36. Found: C, 37.55; H, 4.61; N, 4.61. 
1
H NMR (400 MHz, CDCl3-d1, δ): 5.88 (t, J 
= 5.6 Hz, Ar H, 1H), 5.81 (t, J = 5.6 Hz, Ar H, 1H), 5.69 (t, J = 5.6 Hz, Ar H, 1H), 5.25 
(d, J = 5.7 Hz, Ar H, 1H), 5.09 (t, J = 5.4 Hz, Ar H, 1H), 3.37–3.27 (m, 1H), 3.03 (br s, 
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NH2, 2H), 2.82–2.78 (m, 1H), 2.28–2.17 (m, 2H), 2.08–2.03 (m, 1H), 1.39 (t, J = 5.8 
Hz, –CH3, 3H). 
 
 [Ru{η6:κ1-C6H5(CH2)3NH2}Cl2] . Precursor of complexes 4–6.  [RuCl2(η
6
-etb)]2 
(250 mg, 0.388 mmol) and 3-phenyl-1-propylamine (113 mg, 0.775 mmol) were 
suspended in 1,2-dichloroethane (20 mL). The reaction mixture was heated under 
pressure at 393 K for 16 h. A red-brown, air stable microcrystalline material was 
collected by filtration, washed with acetone and diethyl ether, and dried in air. Yield: 
164 mg (69%). Elemental analysis: Cald for C9H13Cl2NRu (307.18): C, 35.19; H, 4.27; 
N, 4.56. Found: C, 35.44; H, 4.18; N, 4.44. 
1
H NMR (400 MHz, CDCl3-d1, δ): 5.87 (t, J 
= 5.7 Hz, Ar H, 2H), 5.72 (t, J = 5.6 Hz, Ar H, 1H), 5.15 (d, J = 5.7 Hz, Ar H, 2H), 3.21 
(br s, NH2, 2H), 2.96–2.91 (m, 2H), 2.49–2.46 (m, 2H), 2.22–2.16 (m, 2H). 
 
[Ru{η6:κ1-C6H5(CH2)2NH2}Cl2]. Precursor of complex 7.  [RuCl2(η
6
-etb)]2 (187 mg, 
0.289 mmol) and 2-phenylethylamine (77 L, 0.61 mmol) were suspended in 1,2-
dichloroethane (20 mL). The reaction mixture was heated under pressure at 393 K for 
18 h. The red, air stable microcrystalline material was collected by filtration, washed 
with acetone and diethyl ether, and dried in air. Yield: 107 mg (63%). Elemental 
analysis: Cald for C8H11Cl2NRu (293.15): C, 32.78; H, 3.78; N, 4.78. Found: C, 33.14; 
H, 3.70; N, 4.66. 
1
H NMR (400 MHz, CDCl3-d1, δ): 5.93 (t, J = 5.8 Hz, Ar H, 2H), 5.52 
(t, J = 5.6 Hz, Ar H, 1H), 5.21 (d, J = 5.8 Hz, Ar H, 2H), 3.91–3.88 (m, 2H), 3.62 (br s, 
NH2, 2H), 2.83 (t, J = 6.7 Hz, –CH2–, 2H). 
 
[Ru{η6:κ1-C6H5(C8H8)NH2}Cl2]. Precursor of complex 8.  [RuCl2(η
6
-etb)]2 (50 mg, 
0.078 mmol) and 1,2-diphenylethylamine (15 L, 0.078 mmol) were suspended in 1,2-
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dichloroethane (7 mL). The reaction mixture was heated under pressure at 393 K for 18 
h. The yellow material was collected by filtration, washed with diethyl ether, and dried 
in air. Yield: 21 mg (72%). Elemental analysis: Cald for C14H15Cl2NRu (369.25): C, 
45.54; H, 4.09; N, 3.79. Found: C, 45.42; H, 4.12; N, 3.47. 
1
H NMR (400 MHz, CDCl3-
d1, δ): 7.50–7.41 (m, Ar H, 5H), 6.04 (t, J = 5.5 Hz, Ar H, 1H), 5.89–5.84 (m, Ar H, 
1H), 5.54 (t, J = 5.3 Hz, Ar H, 1H), 5.43–5.42 (m, Ar H, 1H), 5.33 (d, J = 5.6 Hz, Ar H, 
1H), 5.18–5.09 (m, 1H), 3.21 (dd, J = 13.7, 5.2 Hz, –CH2–, 1H), 3.04 (t, J = 13.3 Hz, –
CH2–, 1H). ESI-MS (m/z): [M–Cl]
+
 calcd. for C14H15Cl2NRu, 334.0; found, 334.0. 
 
[Ru{η6:κ1-C6H5(C5H8O2)NH2}Cl2].  [RuCl2(η
6
-etb)]2 (100 mg, 0.155 mmol) and L-
phenylalanine ethyl ester (60 mL, 0.310 mmol) were suspended in 1,2-dichloroethane 
(20 mL). The reaction mixture was heated under pressure at 393 K for 16 h. The brown 
solid was collected by filtration, washed with diethyl ether, and dried in air. Yield: 67 
mg (59%). 
1
H NMR (400 MHz, CDCl3-d1, δ): 6.03 (t, J = 5.6 Hz, Ar H, 1H), 5.92 (t, J = 
5.6 Hz, Ar H, 1H), 5.51 (t, J = 5.6 Hz, Ar H, 1H), 5.38 (d, J = 5.6 Hz, Ar H, 1H), 5.27 
(d, J = 5.7 Hz, Ar H, 1H), 4.72–4.55 (m, 2H), 4.34–4.28 (m, 2H), 3.29 (dd, J = 14.1, 6.1 
Hz, 1H), 2.97(dd, J = 14.1, 11.3 Hz, 1H), 1.34 (t, J = 7.1 Hz, 3H). This dichlorido 
precursor did not afford the subsequent reaction with ethylenediamine. 
 
[Ru{η6:κ1-C6H5CH2(C5H4N)}Cl2]. Precursor of complexes 9–12.  [RuCl2(η
6
-etb)]2 
(117 mg, 0.182 mmol) and 2-benzylpyridine (58 L, 0.364 mmol) were suspended in 
1,2-dichloroethane (12 mL). The reaction mixture was heated under pressure at 393 K 
for 16 h. A pale green powder was collected by filtration, washed with acetone and 
diethyl ether, and dried in air. Yield: 92 mg (75%). Elemental analysis: Cald for 
C12H11Cl2NRu (341.20): C, 42.24; H, 3.25; N, 4.11. Found: C, 42.45; H, 3.26; N, 3.95. 
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1
H NMR (400 MHz, DMSO-d6, δ): 7.95 (td, J = 7.7, 1.7 Hz, Ar H, 1H), 7.76 (dd, J = 
5.8, 1.4 Hz, Ar H, 1H), 7.50 (d, J = 7.9 Hz, Ar H, 1H), 7.36 (t, J = 6.7 Hz, Ar H, 1H), 
5.99 (t, J = 5.8 Hz, Ar H, 2H), 5.79 (d, J = 5.8 Hz, Ar H, 2H), 5.56 (t, J = 5.6 Hz, Ar H, 
1H), 4.43 (s, –CH2–, 2H). 
 
[Ru{η6:κ1-C6H5(C6H4)NH2}Cl2]. Precursor of complexes 13 and 14.  [RuCl2(η
6
-
etb)]2 (200 mg, 0.31 mmol) and 2-aminobiphenyl (105 mg, 0.62 mmol) were suspended 
in 1,2-dichloroethane (25 mL). The reaction mixture was heated under pressure at 393 
K for 5 h. The red crystals were collected by filtration, washed with acetone and diethyl 
ether, and dried in air. Yield: 202 mg (95%). Elemental analysis: Cald for 
C12H11Cl2NRu (341.20): C, 42.24; H, 3.25; N, 4.11. Found: C, 42.11; H, 3.22; N, 3.97. 
1
H NMR (400 MHz, DMSO-d6, δ): 7.38 (d, J = 7.7 Hz, Ar H, 1H), 7.16 (t, J = 7.4 Hz, 
Ar H, 1H), 6.80 (d, J = 8.0 Hz, Ar H, 1H), 6.67 (t, J = 7.4 Hz, Ar H, 1H), 6.22 (d, J = 
6.0 Hz, Ar H, 2H), 6.13 (t, J = 5.5 Hz, Ar H, 1H), 5.95 (t, J = 5.9 Hz, Ar H, 2H), 5.42 
(br s, NH2, 2H).  
 
[Ru{η6-C6H5(CH2)2OH}(µ-Cl)Cl]2. Precursor for complexes 15Cl–19Cl. A 
suspension of [Ru(η6-etb)(µ-Cl)Cl]2 (50 mg, 0.078 mmol) in 2-phenylethyl alcohol (1 
mL, 8.3 mmol) and DCE (1 mL) was fluxed with argon for 15 min. The vessel was 
closed, and the reaction mixture heated under pressure at 393 K for 12 h. The red 
precipitate was filtered off, washed with cold ethanol and diethyl ether, and dried in 
vacuum. Yield: 39 mg, 85%. Elemental analysis: Cald for C16H20Cl4O2Ru2 (588.27): C, 
32.67; H, 3.45. Found: C, 33.45; H, 3.45.  
1
H NMR (400 MHz, DMSO-d6, δ): 5.98 (t, J 
= 5.9 Hz, Ar H, 2H), 5.78 (d, J = 6.1 Hz, Ar H, 2H), 5.75 (t, J = 5.7 Hz, Ar H, 1H), 3.69 
(t, J = 6.1 Hz, –CH2–, 2H), 2.57 (t, J = 6.1 Hz, –CH2–, 2H). 
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 [Ru{η6-C6H5CH2COOH}(µ-Cl)Cl]2. Precursor for complex 20Cl. Birch reduction of 
phenylacetic acid following a previously reported procedure
19
 afforded 2,5-
dihydrophenylacetic acid. The cyclic diene (400 mg, 2.9 mmol) and RuCl3·3H2O (473 
mg, 1.810 mmol) were suspended in 10 mL of 1:4 (v/v) water/acetone in a closed 
pressure tube. The reaction mixture was heated at 100 ºC for 3 h. The red precipitate 
was filtered off, washed with cold ethanol and diethyl ether, and dried in vacuum. 
Yield: 445 mg, 80%. Elemental analysis: Cald for C16H16Cl4O4Ru2 (616.24): C, 31.19; 
H, 2.62. Found: C, 31.66; H, 2.55.  
1
H NMR (400 MHz, DMSO-d6, δ): 12.79 (br s, OH, 
1H), 6.01 (t, J = 5.9 Hz, Ar H, 2H), 5.91 (d, J = 6.1 Hz, Ar H, 2H), 5.83 (t, J = 5.6 Hz, 
Ar H, 1H), 3.49 (s, CH2, 2H).  
 
PREPARATION OF CLOSED TETHERED COMPLEXES 1–14  
[Ru{η6:κ1-C6H5(C3H5Me)NH2}(en)]Cl2 (1). Ethylenediamine (15 L, 0.23 mmol) was 
added to a suspension of [Ru{η6:κ1-C6H5(C3H5Me)NH2}Cl2] (63 mg, 0.19 mmol) in dry 
methanol (3 mL). The reaction mixture was stirred at ambient temperature for 2 h. The 
solvent was removed under reduced pressure to give a solid, which was redissolved in 
the minimum volume of ethanol. Addition of diethyl ether afforded the precipitation of 
a yellow solid, which was collected by filtration, and dried in vacuum. Yield: 40 mg 
(67%). 
1
H NMR (400 MHz, D2O, δ): 6.03 (t, J = 5.8 Hz, Ar H, 1H), 5.94 (t, J = 5.8 Hz, 
Ar H, 1H), 6.61 (d, J = 6.0 Hz, Ar H, 1H), 5.54 (d, J = 5.7 Hz, Ar H, 1H), 5.46 (t, J = 
5.7 Hz, Ar H, 1H), 2.89–2.82 (m, 2H), 2.65–2.51 (m, 3H), 2.44–2.28 (m, 2H), 2.14–
2.08 (m, 1H), 1.97–1.87 (m, 1H), 1.30 (d, J = 6.5 Hz, –CH3, 3H). ESI-MS (m/z): [M–
H]
+
 calcd. for C12H23Cl2N3Ru, 310.0; found, 310.1.  
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[Ru{η6:κ1-C6H5(C3H5Me)NH2}(o-pda)]Cl2 (2). To a suspension of [Ru(η
6:κ1-
C6H5(C4H8)NH2)Cl2] (25 mg, 0.078 mmol) in methanol was added o-phenyldiamine 
(8.42 mg, 0.078 mmol). The reaction mixture was stirred for 16 h. Solvent was removed 
in the rotary evaporator to give a yellow solid, which was washed with acetone and 
dried in air. Yield: 21 mg (64%). Elemental analysis: Cald for C16H23Cl2N3Ru (429.35): 
C, 44.76; H, 5.40; N, 9.79. Found: C, 43.51; H, 5.38; N, 9.44. 
1
H NMR (400 MHz, D2O, 
δ): 7.41–7.29 (m, Ar H, 4H), 6.17 (t, J = 5.8 Hz, Ar H, 1H), 6.07 (t, J = 5.7 Hz, Ar H, 
1H), 5.71 (d, J = 6.0 Hz, Ar H, 1H), 5.63 (d, J = 5.6 Hz, Ar H, 1H), 5.52 (t, J = 5.8 Hz, 
Ar H, 1H), 2.95–2.86 (m, 2H), 2.41–2.31 (m, 1H), 2.02–1.92 (m, 1H), 1.21 (d, J = 6.5 
Hz, –CH3, 3H). ESI-MS (m/z): [M–H]
+
 calcd. for C16H23N3Ru, 358.1; found, 358.1. 
 
[Ru{η6:κ1-C6H5(C3H5Me)NH2}(phen)]Cl2 (3). 1,10-phenantroline (10 mg, 0.056 
mmol) was added to a suspension of [Ru(η6:κ1-C6H5(C3H5Me)NH2)Cl2] (18 mg, 0.056 
mmol) in methanol (1 mL). The reaction mixture was stirred for 16 h. Solvent was 
removed in the rotary evaporator to give a pale yellow solid, which was washed with 
acetone and dried in air. Yield: 16 mg (57%). Elemental analysis: Cald for 
C22H23Cl2N3Ru (501.42): C, 52.70; H, 4.62; N, 8.38. Found: C, 51.81; H, 4.69; N, 8.10. 
1
H NMR (400 MHz, D2O, δ): 9.68 (d, J = 5.3 Hz, Ar H, 1H), 9.65 (d, J = 5.2 Hz, Ar H, 
1H), 8.83 (m, Ar H, 2H), 8.19 (s, Ar H, 2H), 8.06 (m, Ar H, 2H), 6.44 (t, J = 6.0 Hz, Ar 
H, 1H), 6.28 (t, J = 6.0 Hz, Ar H, 1H), 6.14 (d, J = 6.2 Hz, Ar H, 1H), 6.03 (d, J = 6.0 
Hz, Ar H, 1H), 5.52 (t, J = 5.9 Hz, Ar H, 1H), 3.07–2.92 (m, 2H), 2.75–2.67 (m, 1H), 
2.29–2.13 (m, 2H), 1.03 (d, J = 6.6 Hz, –CH3, 3H). ESI-MS (m/z): [M–H]
+
 calcd. for 
C22H23N3Ru, 430.1; found, 430.1. 
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[Ru{η6:κ1-C6H5(CH2)3NH2}(en)]Cl2 (4). Ethylenediamine (15 L, 0.22 mmol) was 
added to a suspension of [Ru{η6:κ1-C6H5(CH2)3NH2}Cl2] (57 mg, 0.18 mmol) in dry 
methanol (2 mL). The reaction mixture was stirred at ambient temperature for 2 h. The 
solvent was removed in the rotary evaporator to give a yellow solid, which was 
redissolved in the minimum volume of ethanol. Addition of diethyl ether aided 
precipitation of a yellow solid, which was collected by filtration, and dried in vacuum. 
Yield: 40 mg (61%). 
1
H NMR (400 MHz, D2O, δ): 6.01 (t, J = 5.9 Hz, Ar H, 2H), 5.60 
(d, J = 5.9 Hz, Ar H, 2H), 5.54 (t, J = 5.7 Hz, Ar H, 1H), 2.83–2.81 (m, –CH2–, 2H), 
2.66–2.61 (m, –CH2–, 2H), 2.57 (t, J = 6.1 Hz, –CH2–, 2H), 2.51–2.45 (m, –CH2–, 2H), 
2.14–2.08 (m, –CH2–, 2H). ESI-MS (m/z): [M–H]
+
 calcd. for C11H21N3Ru, 296.1; 
found, 296.1. 
 
[Ru{η6:κ1-C6H5(CH2)3NH2}(dap)]Cl2 (5). Complex [Ru{η
6:κ1-C6H5(CH2)3NH2}Cl2] 
(10 mg, 0.03 mmol) was suspended in methanol (1 mL). 1,3-diaminopropane (3 L, 
0.03 mmol) was added and the reaction mixture was stirred for 1 h at room temperature. 
The solvent was removed, and addition of diethyl ether afforded a yellow solid which 
was dried at vacuum. Yield: 10 mg (87%). 
1
H NMR (400 MHz, DMSO-d6, δ): 5.96 (t, J 
= 5.6 Hz, Ar H, 2H), 5.63 (t, J = 5.9 Hz, Ar H, 1H), 5.39 (d, J = 5.6 Hz, Ar H, 2H), 
2.67–2.33 (m, –CH2–, 8H), 2.04–1.97 (m, –CH2–, 2H), 1.75–1.72 (m, –CH2–, 1H), 
1.60–1.50 (m, –CH2–, 1H). Crystals suitable for X-ray diffraction were obtained by 
slow evaporation of a methanol/diethyl ether solution at ambient temperature 
 
[Ru{η6:κ1-C6H5(CH2)3NH2}(deen)]Cl2 (6). Complex [Ru(η
6:κ1-C6H5(CH2)3NH2)Cl2] 
(10 mg, 0.03 mmol) was suspended in methanol (1 mL). 1,3-diaminopropane (4 L, 
0.03 mmol) was added and the reaction mixture was stirred for 1 h at room temperature. 
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The solvent was removed in the rotary evaporator, and addition of diethyl ether afforded 
a yellow solid, which was dried in vacuum. Yield: 11 mg (90%). 
1
H NMR (400 MHz, 
D2O, δ): 6.01–5.92 (m, Ar H, 2H), 5.65 (t, J = 5.6 Hz, Ar H, 1H), 5.54–5.46 (m, Ar H, 
2H), 4.03–3.94 (m, –CH2–, 1H), 3.61–3.52 (m, –CH2–, 1H), 3.35–3.27 (m, –CH2–, 1H), 
3.11–3.00 (m, –CH2–, 2H), 2.85–2.36 (m, –CH2–, 6H), 2.14–2.10 (m, –CH2–, 2H), 
1.75–1.66 (m, –CH2–, 1H), 1.24–1.17 (m, –CH3, 6H). Crystals suitable for X-ray 
diffraction were obtained by slow evaporation of a methanol/tert-butyl methyl ether 
solution at ambient temperature. 
 
[Ru{η6:κ1-C6H5(CH2)2NH2}(en)]Cl2 (7). Ethylenediamine (17 L, 0.26 mmol) was 
added to a suspension of [Ru{η6:κ1-C6H5(CH2)2NH2}Cl2] (64 mg, 0.22 mmol) in dry 
methanol (2 mL). The reaction mixture was stirred at ambient temperature for 2 h. The 
solvent was removed in the rotary evaporator to give a yellow solid, which was 
redissolved in the minimum volume of ethanol. Addition of diethyl ether afforded the 
precipitation of a yellow solid, which was collected by filtration, and dried in vacuum. 
Yield: 61 mg (78%). 
1
H NMR (400 MHz, D2O, δ): 6.07 (t, J = 6.0 Hz, Ar H, 2H), 5.60 
(d, J = 5.9 Hz, Ar H, 2H), 5.33 (t, J = 5.7 Hz, Ar H, 1H), 3.82–3.77 (m, –CH2–,  2H), 
2.73 (t, J = 6.7 Hz, –CH2–, 2H), 2.62–2.59 (m, –CH2–, 2H), 2.41–2.37 (m, –CH2–, 2H). 
ESI-MS (m/z): [M–H]+ calcd. for C11H21N3Ru, 282.1; found, 282.1. Crystals suitable 
for X-ray diffraction were obtained by slow evaporation of a methanol solution at 
ambient temperature. 
 
[Ru{η6:κ1-C6H5(C8H8)NH2}(en)]Cl2 (8). Ethylenediamine (3.7 L, 0.055 mmol) was 
added to a solution of [Ru(η6:κ1-C6H5(C8H8)NH2)Cl2] (20 mg, 0.055 mmol) in dry 
methanol (3 mL). The reaction mixture was stirred at ambient temperature for 30 min. 
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The solvent was removed in the rotary evaporator to give a yellow solid, which was 
redissolved in the minimum volume of ethanol. Addition of diethyl ether afforded a 
yellow solid, which was collected by filtration, and dried in vacuum. Yield: 12 mg 
(51%). 
1
H NMR (400 MHz, D2O, δ): 7.58–7.42 (m, Ar H, 5H), 6.24 (t, J = 5.9 Hz, Ar 
H, 1H), 6.12 (t, J = 5.9 Hz, Ar H, 1H), 5.79 (t, J = 5.9 Hz, Ar H, 1H), 5.70 (t, J = 5.6 
Hz, Ar H, 1H), 5.39 (t, J = 5.9 Hz, Ar H, 1H), 5.11 (dd, J = 12.5, 5.5 Hz, –CH–, 1H), 
3.23 (dd, J = 14.1, 5.7 Hz, –CH2–, 1H), 2.91 (t, J = 13.3 Hz, –CH2–, 1H), 2.66–2.56 (m, 
–CH2–, 2H), 2.49–2.27 (m, –CH2–, 2H).  
 
[Ru{η6:κ1-C6H5CH2(C5H4N)}(en)]Cl2 (9). Ethylenediamine (8 L, 0.193 mmol) was 
added to a suspension of [Ru{η6:κ1-C6H5CH2(C5H4N)}Cl2] (60 mg, 0.176 mmol) in dry 
methanol (5 mL). The reaction mixture was stirred at ambient temperature for 2 h. The 
solvent was removed in the rotary evaporator to give a yellow solid, which was 
redissolved in the minimum volume of ethanol. Addition of diethyl ether afforded the 
precipitation of a yellow solid, which was collected by filtration, and dried in vacuum. 
Yield: 61 mg (87 %). Cald for C14H19Cl2N3Ru (401.30): C, 41.9; H, 4.77; N, 10.47. 
Found: C, 39.79; H, 5.29; N, 9.70. 
1
H NMR (400 MHz, D2O, δ): 8.00 (td, J = 7.8, 1.6 
Hz, Ar H, 1H), 7.56 (d, J = 8.0 Hz, Ar H, 1H), 7.46 (d, J = 4.8 Hz, Ar H, 1H), 7.41 (t, J 
= 7.0 Hz, Ar H, 1H), 6.26 (t, J = 6.0 Hz, Ar H, 2H), 5.95 (d, J = 6.2 Hz, Ar H, 2H), 5.44 
(t, J = 5.7 Hz, Ar H, 1H), 4.43 (s, 2H), 2.90-2.81 (m, 4H). ESI-MS (m/z): [M–H]+ calcd. 
for C14H19N3Ru, 330.1; found, 330.0. Crystals suitable for X-ray diffraction were 
obtained by slow evaporation from a water solution at ambient temperature. 
 
[Ru{η6:κ1-C6H5CH2(C5H4N)}(o-pda)]Cl2 (10). o-phenyldiamine (3 mg, 0.029 mmol) 
was added to a suspension of [Ru{η6:κ1-C6H5CH2(C5H4N)}Cl2] (10 mg, 0.029 mmol) in 
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dry methanol (2 mL). The reaction mixture was stirred at ambient temperature for 2 h. 
The solvent was removed in the rotary evaporator to give a yellow solid, which was 
redissolved in the minimum volume of ethanol. Addition of diethyl ether afforded the 
precipitation of a yellow solid, which was collected by filtration, and dried in vacuum. 
Yield: 6 mg (48 %). Cald for C18H19Cl2N3Ru (449.34): C, 48.11; H, 4.26; N, 8.48. 
Found: C, 46.09; H, 4.62; N, 8.48. 
1
H NMR (400 MHz, D2O, δ): 7.94 (td, J = 7.8, 1.3 
Hz, Ar H, 1H), 7.56 (d, J = 8.0 Hz, Ar H, 1H), 7.49–7.41 (m, Ar H, 4H), 7.09 (td, J = 
6.9, 1.2 Hz, Ar H, 1H), 6.56 (d, J = 6.0 Hz, Ar H, 1H), 6.41 (t, J = 5.9 Hz, Ar H, 2H), 
6.08 (t, J = 6.4 Hz, Ar H, 2H), 5.46 (td, J = 5.8 Hz, Ar H, 1H), 4.52 (s, –CH2–, 2H). ). 
ESI-MS (m/z): [M–H]+ calcd. for C18H19N3Ru, 378.1; found, 378.0. 
 
[Ru{η6:κ1-C6H5CH2(C5H4N)}(phen)](PF6)2 (11). AgPF6 (18 mg, 0.07 mmol) was 
added to a methanolic solution containing [Ru{η6:κ1-C6H5CH2(C5H4N)}Cl2] (12 mg, 
0.035 mmol). The reaction mixture was stirred for 2 h. Then, the precipitated AgCl was 
removed by filtration and phenantroline (6 mg, 0.035 mmol) was added stepwise to the 
remaining solution. The solvent was removed in the rotary evaporator after 2 h of 
reaction to give a yellowish solid, which was re-dissolved in the minimum volume of 
ethanol, which washed with ethanol and diethyl ether, and dried in vacuum. Yield: 16 
mg (62 %). Cald for C24H19F12N3P2Ru (740.44): C, 38.93; H, 2.59; N, 5.68. Found: C, 
39.46; H, 2.68; N, 5.77. 
1
H NMR (400 MHz, D2O, δ): 9.70 (d, J = 5.3 Hz, Ar H, 2H), 
8.89 (d, J = 8.1 Hz, Ar H, 2H), 8.28 (s, Ar H, 2H), 8.05 (dd, J = 8.2, 5.3 Hz, Ar H, 2H), 
7.81 (t, J = 7.8 Hz, Ar H, 1H), 7.56 (d, J = 8.1 Hz, Ar H, 1H), 6.65 (m, Ar H, 3H), 6.52 
(d, J = 6.2 Hz, Ar H, 2H), 5.56 (d, J = 6.1 Hz, –CH2–, 1H), 5.39 (t, –CH2–, 1H). 
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[Ru{η6:κ1-C6H5CH2(C5H4N)}(oxo)] (12). AgPF6 (14 mg, 0.058 mmol) was added to a 
water (2 mL) solution containing [Ru{η6:κ1-C6H5CH2(C5H4N)}Cl2] (10 mg, 0.029 
mmol). The reaction mixture was stirred for 2 h. Then, the precipitated AgCl was 
removed by filtration and sodium oxalate (4 mg, 0.029 mmol) was added to the 
remaining solution. The solvent was removed in the rotary evaporator after 2 h of 
reaction to give a yellowish solid, which was re-dissolved in the minimum volume of 
ethanol, which washed several times with ethanol and diethyl ether, and dried in 
vacuum. Yield: 6 mg (56 %). Cald for C14H11NO4Ru (358.32): C, 46.93; H, 3.09; N, 
3.91. Found: C, 46.18; H, 3.23; N, 3.73. 
1
H NMR (400 MHz, D2O, δ): 8.04 (td, J = 7.8, 
1.5 Hz, Ar H, 1H), 7.63 (d, J = 8.0 Hz, Ar H, 1H), 7.36 (t, J = 6.7 Hz, Ar H, 1H), 6.63 
(d, J = 6.7 Hz, Ar H, 1H), 6.19 (t, J = 6.1 Hz, Ar H, 2H), 5.80 (d, J = 6.0 Hz, Ar H, 2H), 
5.71 (d, J = 5.8 Hz, Ar H, 1H), 4.58 (s, –CH2–, 1H). ESI-MS (m/z): [M+H]
–
 calcd. for 
C14H11NO4Ru, 360.0; found, 360.0. Crystals suitable for X-ray diffraction were 
obtained by slow evaporation from a water solution at ambient temperature. 
 
[Ru{η6:κ1-C6H5(C6H4)NH2}(en)]Cl2 (13). [Ru(η
6:κ1-C6H5(C6H4)NH2)Cl2]  (25 mg, 
0.073 mmol) was suspended in 95% aqueous methanol (5 mL). Ethylenediamine (4.9 
µL, 0.073 mmol) was added, and the mixture was stirred for 2 h at room temperature. 
The solvent was removed on a rotary evaporator, and the product was re-dissolved in 3 
mL of ethanol. The resultant yellow solution was filtered through a 0.45 µm syringe 
filter. The solvent was reduced to ca. 5% of its original volume, and diethyl ether (4 
mL) was added. The sticky solid was sonicated to give a yellowish precipitate, 
centrifuged, washed with diethyl ether and dried in vacuum. Water (11 mL) was added 
and the solution was left to stand overnight. Lyophilization afforded a yellow solid. 
Yield: 36 mg (98 %). Cald for C14H19Cl2N3Ru (401.30): C, 41.90; H, 4.77; N, 10.47. 
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Found: C, 37.3; H, 5.45; N, 9.91.
1
H NMR (400 MHz, D2O, δ): 7.67–7.65 (m, Ar H, 
1H), 7.57–7.50 (m, Ar H, 2H), 7.41–7.38 (m, Ar H, 1H), 6.50 (br s, NH2, 1H), 6.22 (t, J 
= 6.1 Hz, Ar H, 2H), 5.67 (d, J = 5.8 Hz, Ar H, 2H), 5.53 (t, J = 5.8 Hz, Ar H, 1H), 2.69 
(m, –CH2–, 2H), 2.49 (m, –CH2–, 2H). Orange single crystals of 13 suitable for X-ray 
diffraction were obtained by evaporation of water solution at ambient temperature. 
 
[Ru{η6:κ1-C6H5(C6H4)NH2}(ox)] (14). [Ru(η
6:κ1-C6H5(C6H4)NH2)Cl2] (5 mg, 0.015 
mmol) was suspended in water (2 mL). Silver oxalate (18 mg, 0.059 mmol) was added, 
and the mixture was stirred for 6 h at room temperature. The solvent was removed on 
the rotary evaporator and the product was re-dissolved in 3 mL of ethanol. The resultant 
yellow solution was filtered through a 0.45 µm syringe filter. The solvent was reduced 
to ca. 5% of its original volume, and diethyl ether (3 mL) was added. The sticky solid 
was sonicated to give a pale yellow precipitate, which was washed with diethyl ether 
and dried in vacuum. Yield: 8 mg (57 %). Elemental analysis: Cald for C14H11NO4Ru 
(358.31): C, 46.93; H, 3.09; N, 3.91. Found: C, 32.56; H, 2.59; N, 2.39.  
1
H NMR (400 
MHz, D2O, δ): 7.68–7.66 (m, Ar H, 1H), 7.58–7.50 (m, Ar H, 2H), 7.39–7.37 (m, Ar H, 
1H), 6.14 (t, J = 5.9 Hz, Ar H, 2H), 5.75 (t, J = 6.0 Hz, Ar H, 1H), 5.53 (d, J = 6.2 Hz, 
Ar H, 2H).  
 
PREPARATION OF OPEN-TETHER COMPLEXES 15Cl–20 Cl 
[Ru{η6-C6H5(CH2)2OH}(en)Cl]Cl (15Cl). Ethylenediamine (7 L, 0.101 mmol) was 
added to a suspension of [Ru{η6-C6H5(CH2)2OH}(µ-Cl)Cl]2 (30 mg, 0.051 mmol) in 
dry methanol (2 mL). The reaction mixture was stirred at ambient temperature for 2 h. 
The solvent was removed in the rotary evaporator to give a yellow solid, which was 
redissolved in the minimum volume of ethanol. Addition of diethyl ether afforded the 
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precipitation of a yellow solid, which was collected by filtration, and dried in vacuum. 
Yield: 27 mg (75%). Elemental analysis: Cald for C10H18Cl2N2ORu (354.24): C, 33.91; 
H, 5.12; N, 7.91. Found: C, 33.90; H, 5.09; N, 8.17. 
1
H NMR (400 MHz, D2O, δ): 5.80 
(t, J = 5.9 Hz, Ar H, 2H), 5.69–5.66 (m, Ar H, 3H), 3.89 (t, J = 6.1 Hz, –CH2–, 2H), 
2.70 (t, J = 6.1 Hz, –CH2–, 2H), 2.50–2.45 (m, –CH2–, 4H). ESI-MS (m/z): [M–Cl–H]
+
 
calcd. for C10H17N2ORu, 283.0; found, 283.0. Crystals suitable for X-ray diffraction 
were obtained by slow evaporation of a methanol/diethyl ether solution at ambient 
temperature. 
 
[Ru{η6-C6H5(CH2)2OH}(tmen)Cl]Cl (16Cl). N,N,N’,N’-tetramethylethylenediamine (5 
L, 0.034 mmol) was added to a suspension of [Ru(η6-C6H5(CH2)2OH)(µ-Cl)Cl]2 (10 
mg, 0.017 mmol) in dry methanol (2 mL). The reaction mixture was stirred at ambient 
temperature for 3 h. The solvent was removed in the rotary evaporator to give an orange 
solid, which was redissolved in the minimum volume of ethanol. Addition of diethyl 
ether afforded the precipitation of a yellow solid, which was collected by filtration, and 
dried in vacuum. Yield: 11 mg (79%). 
1
H NMR (400 MHz, D2O, δ): 5.90–5.87 (m, Ar 
H, 3H), 5.74–5.72 (m, Ar H, 2H), 3.83 (t, J = 6.2 Hz, –CH2–, 2H), 3.36 (s, –CH3, 6H), 
2.78 (s, –CH3, 6H), 2.68 (t, J = 6.1 Hz, –CH2–, 2H), 2.49 (m, –CH2–, 4H). Crystals 
suitable for X-ray diffraction were obtained by slow evaporation of a methanol/diethyl 
ether solution at ambient temperature. 
 
[Ru{η6-C6H5(CH2)2OH}(azpy-NMe2)Cl]Cl (17Cl). Ethylenediamine (7.7 L, 0.034 
mmol) was added to a suspension of [Ru(η6-C6H5(CH2)2OH)(µ-Cl)Cl]2 (10 mg, 0.017 
mmol) in dry methanol (2 mL). The reaction mixture was stirred at ambient temperature 
for 3 h. The solvent was removed in the rotary evaporator to give a blue solid, which 
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was redissolved in the minimum volume of ethanol. Addition of diethyl ether 
precipitated a purple solid, which was collected by filtration, and dried in vacuum. 
Yield: 9 mg (48%). Elemental analysis: Cald. for C21H25Cl2N4ORu (521.43): C, 48.37; 
H, 4.83; N, 10.75. Found: C, 47.41; H, 5.10; N, 9.72. 
1
H NMR (400 MHz, D2O, δ): 9.23 
(d, J = 5.7 Hz, Ar H, 1H), 8.22–8.17 (m, Ar H, 4H), 7.58 (td, J = 5.8, 3.0 Hz, Ar H, 1H), 
6.94 (d, J = 9.6 Hz, Ar H, 2H), 6.23 (t, J = 6.0 Hz, Ar H, 1H), 6.19 (t, J = 6.1 Hz, Ar H, 
1H), 6.02 (d, J = 6.2 Hz, Ar H, 1H), 5.98 (d, J = 6.2 Hz, Ar H, 1H), 5.85 (t, J = 5.9 Hz, 
Ar H, 1H), 3.81 (t, J = 6.0 Hz, –CH2–, 2H), 3.29 (s, –CH3, 6H), 2.66–2.48 (m, –CH2–, 
2H). Crystals suitable for X-ray diffraction were obtained by slow evaporation of a 
methanol/diethyl ether solution at ambient temperature. 
 
[Ru{η6-C6H5(CH2)2OH}(bip)Cl]Cl (18Cl). A solution of 2,2‘-bipyridine (7 L, 0.101 
mmol) in methanol (1 mL) was added dropwise to a suspension of [Ru(η6-
C6H5(CH2)2OH)(µ-Cl)Cl]2 (30 mg, 0.051 mmol) in methanol (2 mL). The reaction 
mixture was stirred at ambient temperature overnight. The resultant solution was 
filtered through a 0.45 µm syringe filter. The solvent was removed in the rotary 
evaporator to give a yellow solid, which was redissolved in the minimum volume of 
ethanol. Addition of diethyl ether afforded the precipitation of a yellow solid, which 
was collected by filtration, and dried in vacuum. Yield: 34 mg (75%). Elemental 
analysis: Cald for C18H18Cl2N2ORu (450.33): C, 48.01; H, 4.03; N, 6.22. Found: C, 
47.17; H, 4.08; N, 6.08. 
1
H NMR (400 MHz, D2O, δ): 9.44 (d, J = 5.0 Hz, Ar H, 2H), 
8.38 (d, J = 8.1 Hz, Ar H, 2H), 8.21 (t, J = 7.9 Hz, Ar H, 2H), 7.75 (t, J = 7.9 Hz, Ar H, 
2H), 6.22 (t, J = 6.1 Hz, Ar H, 2H), 6.04 (d, J = 6.3 Hz, Ar H, 2H), 5.91 (t, J = 5.8 Hz, 
Ar H, 1H), 3.86 (t, J = 6.1 Hz, –CH2–, 2H), 2.67 (t, J = 6.1 Hz, –CH2–, 2H). Crystals 
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suitable for X-ray diffraction were obtained by slow evaporation of a methanol/diethyl 
ether solution at ambient temperature. 
 
[Ru{η6-C6H5(CH2)2OH}(oxo)Cl]Na (19Cl). A solution of sodium oxalate (5 mg, 0.034 
mmol) in 1 mL of 1:1 (v/v) water/acetone was added to a suspension of [Ru(η6-
C6H5(CH2)2OH)(µ-Cl)Cl]2 (10 mg, 0.017 mmol) in dry methanol (2 mL). The resultant 
solution was filtered through a 0.45 µm syringe filter. The solvent was removed in the 
rotary evaporator to give an orange solid, which was redissolved in the minimum 
volume of ethanol. Addition of diethyl ether afforded the precipitation of a yellow solid, 
which was collected by filtration, and dried in vacuum.  Yield: 5 mg (36%). 
1
H NMR 
(400 MHz, D2O, δ): 5.98 (t, J = 6.1 Hz, , Ar H, 2H), 5.83 (t, J = 5.9 Hz, , Ar H, 1H), 
5.73 (d, J = 5.9 Hz, , Ar H, 2H), 3.94 (t, J = 6.0 Hz, –CH2–, 2H), 2.78 (t, J = 6.1 Hz, –
CH2–, 2H). 
 
[Ru{η6-C6H5CH2COOH}(en)Cl]Cl (20Cl). [Ru(η
6
-C6H5CH2COOH)Cl2]2 (100 mg, 
0.162 mmol) was suspended in anhydrous ethanol (5 mL). Ethylenediamine (22 µL, 
0.324 mmol) was added, and the mixture was stirred for 2 h at reflux. The resultant 
yellow solution was filtered through a 0.45 µm syringe filter. The solvent was reduced 
to ca. 5% of its original volume, and diethyl ether (4 mL) was added. The sticky solid 
was sonicated to give a yellow precipitate, centrifuged, washed with diethyl ether and 
dried in vacuum. Yield: 96 mg (80%). Elemental analysis: Cald. for C10H16Cl2N2O2Ru 
(368.22): C, 31.10; H, 4.70; N, 7.25. Found: C, 32.54; H, 4.87; N, 7.83. 
1
H NMR (400 
MHz, MeOD-d4, δ): 6.43 (br s, NH2, 2H), 5.75 (t, J = 5.7 Hz, Ar H, 2H), 5.67 (d, J = 5.7 
Hz, Ar H, 2H), 5.64 (t, J = 5.5 Hz, Ar H, 1H), 4.04 (br s, NH2, 2H), 3.57 (s, –CH2–, 
2H), 2.54–2.50 (m, –CH2–, 2H), 2.46–2.41 (m, –CH2–, 2H). ESI-MS (m/z): [M–Cl–H]
+
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calcd. for C10H15N2O2Ru, 297.0; found, 297.0. Crystals suitable for X-ray diffraction 
were obtained by slow evaporation of a methanol/diethyl ether solution at ambient 
temperature. 
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3.1 Introduction  
 
As demonstrated in Chapter 2, when the hemilabile ligand contained a nitrogen atom 
as the monodentate ligand Z, the ethylenediamine derivative [Ru{6:1-
C6H5(C6H4)NH2}(en)]Cl2 (13) presented the highest activation of the Ru–Z bond under 
acidic conditions. In this Chapter we have investigated the activation of a series of 
analogues Ru
II
 closed tethered complexes of general formula [Ru{6:1-
C6H5(C6H4)NH2}(XY)]
n+
, where XY is a bidentate chelating ligand, in non-aqueous 
solutions, and in water, within the acidic pH range.  
We demonstrate that pH-activation (cleavage of the RuNtether bond) is not only 
possible in the acidic pH scale but, most importantly, tuneable by using chelating 
ligands with different electronic and steric properties. The pH is a major factor that 
governs the activation and its associated kinetic parameters. Since this type of 
organometallic compounds has been reported to interact with DNA,
1, 2
 we also have 
investigated the interaction of our switchable system with a model nucleobase, 
guanosine monophosphate (GMP). Finally, and most importantly, we prove total 
reversibility, forcing the activated form of the compound to reverse to its inactive form 
(closed-tether), again showing pH-dependent inactivation dynamics. We set the 
parameters that control the ruthenium arene (in)activation to further the design of pH-
responsive switchable anticancer metallodrugs. 
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3.2 Results and Discussion  
 
3.2.1 Synthesis and Characterization  
Eleven closed-tether ruthenium(II) arene complexes, 13 and 21–30, of general 
formula [Ru{η6:κ1-C6H5(C6H4)NH2}(XY)]
n+
 containing primary, secondary and tertiary 
aliphatic amines, ortho-phenylenediamine, and oxalato as chelating ligands (Table 3.1) 
were prepared following the synthesis described by Pizarro et al.,
3
 in good yields. The 
complexes were fully characterized by 
1
H NMR spectroscopy, and CHN analysis for 
13, 21–24 and 27–30. Complexes 25 and 26 were characterized in the solution state by 
1
H NMR spectroscopy and mass spectrometry. The [Ru(6-etb)Cl2]2 dimer was used for 
the arene exchange reaction leading to the precursor complex [Ru{η6:κ1-
C6H5(C6H4)NH2}Cl2].  
Upon reaction of [Ru{η6:κ1-C6H5(C6H4)NH2}Cl2] with the appropriate chelating 
ligand (details in the Experimental Section) a mixture of two structural isomers, closed 
and open-tether Ru
II
 complexes (Figure 3.1), was obtained for complexes 13 and 21–27, 
while complexes 28–30 were obtained as closed-tether isomers only. Usually both 
isomers, closed- and open-tether species, showed a typical set of three resonances 
attributable to the 6-bound arene protons in the range ca. 5.20–6.20 ppm. The 
characteristic chemical shift difference between the most deshielded and most shielded 
η6-bound arene resonances are ca. 0.70 ppm and 0.20 ppm for closed- and open- tether 
complexes, respectively. Analysis of the 
1
H NMR spectra in all solvents used in this 
Chapter proved an instant and reliable evidence for the open- versus closed-tether ring 
status in Ru
II
 arene complexes in solution. Both closed- and open-tether structures were 
confirmed by X-ray crystal structure analysis. 
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Table 3.1. Tether ruthenium(II) arene complexes of general formula [Ru{η6:κ1-
C6H5(C6H4)NH2}(XY)]Cln (n = 0, 2) studied in this Chapter, containing different XY chelating 
ligands. 
 
 
Figure 3.1. Ruthenium(II) arene tether isomers of general formula [Ru{η6:κ1-
C6H5(C6H4)NH2}(XY)]Cl2, closed-tethered complex (left), and [Ru{η
6
-
C6H5(C6H4)NH2}(XY)Cl]Cl, open-tether complex (right). Ru
II
 arene closed-tether complex 30, 
where XY is oxalato, is neutral, and no chloride ions are present in its structure; for the open 
tether obtained in solution, the vacant site would be occupied by a solvent molecule, and the 
complex remains neutral.  
Complex X-Y Ligand Complex X-Y Ligand 
13 en  27 
dpip 
 
21 dap 
 
28 tmen 
 
22 dab  29 
o-pda 
 
23 dach 
 
30 oxo 
 
24 pipma 
 
31Cl dmphe  
 
25 dmen  32Cl 
dtben 
 
26 deen 
 
33Cl bipy 
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Observation of open-to-closed tether conversion in aqueous solution, overnight at 
ambient temperature, allowed for the separation of the closed-tether Ru
II
 complexes 13 
and 21–27. The crude product was re-dissolved in water, left to stand overnight at 
ambient temperature and subsequently lyophilized, affording quantitatively the closed-
tether complexes 13 and 21–27 in good yields (over 95%). Tether-ring-opened 
analogues 13Cl and 21Cl–29Cl, of general structure [Ru{η6-
C6H5(C6H4)NH2}(XY)Cl]Cl, where the κ
1
-bound Ntether is released from the first 
coordination sphere of the metal to allow a chloride ligand bind the ruthenium centre, 
were characterized in solution by 
1
H NMR and LC/MS. While attempts to isolate 
complexes 31 and 32 were unsuccessful, it was possible to isolate pure open tether 
analogues 31Cl and 32Cl (characterized by CHN and NMR analysis). Complex 30Cl 
was not observed in methanol, solvent in which 30 was insoluble. Dissolution of 30 in 
HCl afforded the dichlorido precursor [Ru{η6:κ1-C6H5(C6H4)NH2}Cl2]. Complex 33Cl 
could be dissolved in DMSO-d6, yet instability towards arene loss afforded complex 
[Ru(bipy)3]
2+
.
4
  X-crystal structures of complexes 13, 23, 27, 29, 26Cl, 28Cl, and 
28HCl, were essential to unequivocally assign the open- and closed-tether ring 
structures. Solution experiments with complexes 30–33 were not performed due to their 
instability and/or insolubility under the conditions used in this Chapter.  
 
3.2.2 X-Ray Crystal Structures  
We determined the X-ray crystal structure of the closed-tether complexes 13, 23, 27 
and 29 (Figure 3.2), and open-tether complexes 26Cl, 28Cl and 28HCl (Figure 3.3).   
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Figure 3.2. ORTEP diagrams and atom numbering for X-ray structures for (A) [Ru{η6:κ1-
C6H5(C6H4)NH2}(en)]Cl2 (13), (B) [Ru{η
6:κ1-C6H5(C6H4)NH2}(dach)]Cl2 (23), (C) [Ru{η
6:κ1-
C6H5(C6H4)NH2}(dpip)]Cl2 (27) and (D) [Ru{η
6:κ1-C6H5(C6H4)NH2}(o-pda)]Cl2 (29), with 
thermal ellipsoids drawn at 50% probability. The H atoms (except those on the nitrogen pendant 
from the tether), chloride counterions and solvent molecules have been omitted for clarity. 
 
X-ray diffraction data of suitable crystals corresponding to closed-tether complexes 
were collected for [Ru{η6:κ1-C6H5(C6H4)NH2}(en)]Cl2 (13), [Ru{η
6:κ1-
C6H5(C6H4)NH2}(dach)]Cl2 (23) and [Ru{η
6:κ1-C6H5(C6H4)NH2}(o-pda)]Cl2 (29) from 
aqueous solutions. Single crystals of [Ru{η6:κ1-C6H5(C6H4)NH2}(dpip)]Cl2 (27) were 
obtained from the reaction mixture. Crystals suitable for X-ray analysis of complexes 
[Ru{η6:κ1-C6H5(C6H4)NH2}(deen)Cl]Cl (26Cl) and [Ru{η
6:κ1-
C6H5(C6H4)NH2}(tmen)Cl]Cl (28Cl) were obtained by crystallization from methanol. 
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Single crystals of protonated-open-tether complex [Ru{η6-
C6H5(C6H4)NH3}(tmen)Cl]Cl2 (28HCl) were obtained from a 1 M HCl solution. 
 
Figure 3.3. ORTEP diagrams and atom numbering schemes for (A) [Ru{η6-
C6H5(C6H4)NH2}(deen)Cl]Cl (26Cl), (B) [Ru{η
6
-C6H5(C6H4)NH2}(tmen)Cl]Cl (28Cl), and (C) 
[Ru{η6-C6H5(C6H4)NH3}(tmen)Cl]Cl2 (28HCl), with thermal ellipsoids drawn at 50% 
probability. The hydrogen atoms (with the exception of the tether NH2/NH3 protons), chloride 
counterions and solvent molecules have been omitted for clarity. 
 
The complexes adopted the expected pseudo-octahedral “three-legged piano-stool” 
geometry with the ruthenium η6-bonded to the arene ligand occupying three of the six 
octahedral positions. The other three positions in the first coordination sphere were 
occupied by a bidentate chelating ligand and either a NH2 group (pendant from the η
6
-
bound arene) for 13, 23, 27 and 29, or a chlorido ligand for 26Cl, 28Cl, and 28HCl. 
Closed-tether complexes 13, 27 and 29 crystallized with two molecules, and 23 with 
eight molecules, in the unit cell. Structures corresponding to open-tether complexes 
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7Cl, 28Cl and 28HCl crystallized with four, two and four molecules in the cell unit, 
respectively.  
Selected bond lengths and angles of closed-tether complexes 13, 23, 27 and 29 are 
shown in Table 3.2. The Ru–Carene bond lengths are in the range of 2.108–2.221 Å. The 
Ru–N1 distances are 2.148–2.166 Å, and the distances ruthenium-to-centroid are 1.631–
1.669 Å. The propeller twist of the pendant ring with respect to the coordinated phenyl 
of 2-aminobiphenyl ranges from 82.6º in 23 to 89.9º in 29.  
 
Table 3.2. Selected bond lengths (Å) and angles (deg) for complexes 13, 23, 27 and 29. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coordination of the NH2 group of the pendant arm to the ruthenium centre results in 
different Ru–centroid distances, appearing to be shorter in 13 (1.659 Å), than the 
reported open-tether analogue 13Cl (1.666 Å).
3
 Additional differences are observed in 
C7–offset distances (0.488 Å towards ruthenium for 13 and 0.055 Å for the 
corresponding open-tether counterpart 13Cl).  
Bond / angle 13 23 27 29 
Ru-C6 2.115(13) 2.113(6) 2.114(4) 2.108(7) 
Ru-C5 2.184(13) 2.180(6) 2.188(5) 2.163(8) 
Ru-C4 2.207(14) 2.185(6) 2.179(5) 2.175(8) 
Ru-C3 2.221(15) 2.219(6) 2.211(5) 2.189(7) 
Ru-C2 2.198(13) 2.199(6) 2.218(5) 2.192(7) 
Ru-C1 2.191(13) 2.190(6) 2.203(4) 2.170(8) 
Ru-centroid 1.659 1.656 1.669 1.643 
Ru-X 2.144(11) 2.124(5) 2.128(3) 2.128(6) 
Ru-Y 2.148(11) 2.147(5) 2.131(4) 2.126(6) 
Ru-N1 2.161(11) 2.156(4) 2.167(3) 2.147(5) 
X-Ru-Y 80.4(4) 79.17(18) 79.45(14) 79.6(2) 
X-Ru-N1 88.2(4) 86.89(18) 89.45(13) 88.5(2) 
Y-Ru-N1 88.0(4) 89.72(18) 88.15(16) 87.7(2) 
Propeller twist 89.7 82.6 88.9 89.9 
C7–offset[a] 0.488 (+) 0.460 (+) 0.460 (+) 0.475 (+) 
[a] Offset of C7 with respect to the plane formed by the bound arene 
(carbons C1–C6); (+) toward ruthenium 
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Importantly, the size of the tether arm may influence the strain on the structure as 
indicated by bond lengths and angles. In order to demonstrate the contribution of tether-
ring size to cause such strain we compare complex 13 with X-ray crystallographic data 
of structurally related complexes, containing a five-member and a six-member ring with 
a tethering aliphatic amine. For example, in complex 13 and its analogue 13Cl,
5
 both 
with two carbon atoms between the η6-bound arene and the Ntether, centroid distances are 
similar (1.659 vs 1.651 Å), and Ru-C6-C7 angles are in the same range 113–115º. 
However, when the number of carbon atoms in the tether arm is three, as in [Ru{η6:κ1-
C6H5(CH2)3NH2}(deen)]Cl2,
5
 Ru–centroid distance increases to 1.679 Å and the Ru-C6-
C7 angle to 126º. This suggests that the shorter the pendant arm, the higher the ring 
constraint, since the non-strained Ru-C6-C7 angle in open-tether complexes is ca. 130º. 
As expected, open-tether complexes 26Cl, 28Cl and 28HCl showed longer 
ruthenium-centroid distances (1.684–1.688 Å), in agreement with a non-strained 
structure. Selected bond lengths and angles are shown in Table 3.3. Detailed 
crystallographic data are shown in Annex 2. The propeller twist of the pendant ring with 
respect to the coordinated phenyl of 2-aminobiphenyl is significantly smaller, ranging 
from 41 to 46º. The Ru–Carene bond lengths are accordingly significantly higher (2.168–
2.273 Å) for the open tether complexes, and the Ru–Cl distances are 2.400–2.410 Å.  
The structural analysis shows a pronounced tilt in the η6-bound arene for closed-
tethers in comparison to open-tether complexes, as indicated by the differences in the 
RuC3 versus RuC6 bond lengths. Additional tether-ring strain is defined by the offset 
of C7 with regard to the plane that contains the η6-bound arene. Comparison between 
the propeller twist in closed complexes (83–90º) versus open tether structures (40–46º) 
furthers the evidence of the constraint that the tether ring holds, which has been related 
to instability of the complexes towards arene loss.
6
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Table 3.3. Selected bond lengths (Å) and angles (deg) for complexes 26Cl, 28Cl and 28HCl. 
 
 
 
 
 
 
 
 
 
 
No significant differences are observed between the open-tether 28Cl and its 
corresponding protonated species 28HCl. However, a longer distance for the N1–C12 
bond is observed in 28HCl versus 28Cl, indicating nitrogen protonation and subsequent 
loss of conjugation of the amine group (1.378 vs 1.462 Å). 
In all complexes the chloride counterions were involved in weak bonding 
interactions with the N(tether) hydrogen atoms and the hydrogen atoms on the N(XY-
chelate ligand) (Table 3.4). No intermolecular π-π stacking interactions were observed. 
 
 
 
 
 
 
Bond / angle 26Cl 28Cl 28HCl 
Ru–C6 2.274(4) 2.245(3) 2.235(3) 
Ru–C5 2.193(4) 2.195(3) 2.210(3) 
Ru–C4 2.181(4) 2.182(3) 2.195(3) 
Ru–C3 2.170(4) 2.174(3) 2.193(3) 
Ru–C2 2.204(4) 2.191(3) 2.169(3) 
Ru–C1 2.198(4) 2.185(3) 2.168(3) 
Ru–centroid 1.688 1.686 1.684 
Ru–X 2.163(3) 2.198(2) 2.229(3) 
Ru–Y 2.148(3) 2.258(2) 2.200(3) 
Ru–Cl 2.4096(9) 2.406(7) 2.4006(9) 
X-Ru-Y 79.46(11) 80.03(8) 80.12(11) 
X-Ru-Cl 82.62(8) 87.56(6) 89.83(9) 
Y-Ru-Cl 85.66(9) 88.74(6) 86.86(8) 
Propeller twist 40.43 40.54 45.75 
C7–offset 0.228 (-) 0.121 (+) 0.017(-) 
Chapter 3 
99 
Table 3.4. Selected hydrogen-bonding interactions with the Ntether [N(t)] hydrogen atoms, and 
the hydrogen atoms on the NXY-chelating ligand [N(l)] for complexes 13, 23, 27, 29, 26Cl, 28Cl, and 
28HCl. 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.3 Solution Studies in Non-aqueous Solvents  
It has been reported that when the tether pendant group is poorly coordinating, such 
as alcohol or amine, coordination/dissociation can occur depending on the experimental 
conditions.
3, 6-9
 We have investigated here the effects of varying the XY chelating ligand 
in [Ru{η6:κ1-C6H5(C6H4)NH2}(XY)]
2+
 on the tether ring opening in different solvents 
(methanol and dimethyl sulfoxide) with the aim of exploiting these systems as 
activatable organometallic switches, in drug design or otherwise.
  
1
H NMR or UV-visible spectroscopy were used to study the lability of the Ru–
Ntether bond of closed-tether Ru
II
 complexes in different solvents over 24 h. All 
Closed D–H···A d(H···A) d(D···A)  DHA 
13 
N(t)–H···Cl 2.268 3.180 176 
N(l)–H···Cl 2.430 3.286 155 
23 
N(t)–H···Cl 2.288 3.194 168 
N(l)–H···Cl 2.357 3.286 176 
N(l)–H···Cl 2.310 3.234 171 
27 
N(t)–H···Cl 2.575 3.403 150 
N(t)–H···Cl 2.288 3.194 168 
N(l)–H···Cl 2.357 3.286 176 
N(l)–H···Cl 2.310 3.234 171 
29 
N(t)–H···Cl 2.242 3.155 171 
N(t)–H···Cl 2.247 3.165 176 
Open D–H···A d(H···A) d(D···A)  DHA 
26Cl 
N(t)–H···Cl 2.505 3.279 147 
N(l)–H…Cl 2.265 3.193 175 
28Cl 
O–H···Cl 2.389 3.240 175 
O–H···Cl 2.423 3.269 175 
N(t)–H···Cl 2.169 3.000 162 
Protonated D–H···A d(H···A) d(D···A)  DHA 
28HCl 
N(t)–H···Cl 2.467 3.217 142 
N(t)–H···Cl 2.246 3.133 174 
N(t)–H···Cl 2.230 3.113 172 
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quantification data (extent of open-tether species versus closed-tether complex at 
equilibrium) were generated by NMR spectroscopy, while kinetic data were obtained by 
UV-vis spectroscopy in the case of methanol, and by NMR for DMSO.  
 
 
Figure 3.4. 
1
H NMR low-field spectral region of 6 mM solutions of [Ru{η6:κ1-
C6H5(C6H4)NH2}(en)]
2+
 (13, ) showing resonances of the η6-bounded arene ligand at various 
times in (A) MeOD-d4 at 298 K (Z = Cl, X = NH2), (B) DMSO-d6 at 298 K (Z = DMSO, X = 
NH2), and (C) 1 M DCl solution at 310 K (Z = Cl, X = NH3
+
). New sets of peaks appear (), 
corresponding to an open-tether species, in all solvents over 24 h. 
 
Activation in methanol of the Ru–Ntether bond can provide important information 
about the tuneability of the ring-opening process since methanol readily dissolves our 
complexes and appears to be non-coordinating.
 
Ring-opening dynamics were followed 
with complexes 13 and 2129 by 1H NMR spectroscopy. 1H NMR data of freshly 
prepared 6–7 mM solutions of complexes 13 and 2129 were recorded directly after the 
complex was dissolved (t ≤ 10 min) and at 24 h, at 298 K in MeOD-d4. The 
1
H NMR 
spectra initially contained one major set of peaks attributable to the closed-ring form. A 
second set of peaks appeared over time (Figure 3.4A), increasing in intensity until 
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reaching equilibrium (2–24 h). The new set of peaks were assigned to the open-tether 
counterparts, 13Cl and 21Cl–29Cl, of general formula [Ru{η6-
C6H5(C6H4)NH2}(XY)Cl]
+
, formed to different extents at equilibrium. The 
crystallographic structures of 26Cl and 28Cl were obtained from methanol and 
unequivocally confirmed the chlorido open-tether complexes. The extent of the 
conversion of closed-to-open-tether at equilibrium varied depending on the chelating 
ligand (Figure 3.5).  
 
Figure 3.5. Percentage of Ru
II
 open species at equilibrium, corresponding to the activation of 
the complexes 13 and 21–29 in MeOD-d4. 
 
Only complexes bearing a secondary or tertiary aliphatic diamines as chelating 
ligand XY (25–28) underwent full conversion over 24 h at 298 K. Chelating ligands 
binding through primary amines RNH2 (13, 21–24 and 29) showed percentages of the 
open-tether complex at equilibrium in the range of 57–71%. Since the basicity of the 
chelating amines is similar and seems not to govern this trend (Table 3.5), we suggest 
that this effect might be attributable to a higher steric hindrance effect by the secondary 
and tertiary XY amines. 
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Table 3.5. Theoretical pKa values corresponding to the free XY ligand. 
XY in 13 21 22 23 24 25 26 27 28 29 30 31 32 
pKa 8.9 10.4 9.9 10.7 10.4 10.5 11.2 10.8 8.9 4.5 1.7 8.6 10.5 
 
 
In order to determine the ring opening rate constants in methanol, 0.2 mM solutions 
of the Ru
II
 complexes were monitored over 24 h by UV-visible spectroscopy (Table 3.6 
and Figure 3.6). The rate of tether-ring opening for complexes 21, 22, 25, 26, 28 and 29 
was too fast to be determined by this method (equilibrium reached in < 5 min).  
 
Table 3.6. Opening-tether kinetic data for complexes 13 and 21–30 in methanol, 
dimethylsulfoxide and 1 M HCl. 
 
Complex Ligand 
k  10–4 (s–1) t1/2 (min) 
Methanol
[a]
 DMSO
[b]
 
1 M 
HCl
[a]
 
Methanol
[a]
 DMSO
[b]
 
1 M 
HCl
[a]
 
13 en 1.1 0.70 2.65 107 168 44 
21 dap n.d. n.d. 3.48 < 5 < 5 33 
22 dab n.d. n.d. 3.62 < 5 < 5 32 
23 dach 0.61 0.68 1.63 191 170 71 
24 pipma 0.81 0.86 0.73 142 135 158 
25 dmen n.d. n.d. n.d. < 5 < 5 < 5 
26 deen n.d. n.d. n.d. < 5 < 5 < 5 
27 dpip 8.8 1.7 1.10 13 67 105 
28 tmen n.d. n.d. 27.80 < 5 < 5 4 
29 o-pda n.d. n.d. 2.48 < 5 < 5 47 
30 oxo - n.d. - - < 5 - 
[a]  Determined by UV-visible spectroscopy 
[b]  Determined by 
1
H NMR spectroscopy 
n.d., too rapid to be determined 
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Figure 3.6. (A) UV-visible difference spectra of complex 13 in methanol showing that the 
largest changes in absorbance occurs at 225 and 315 nm. (B) Change in absorbance at 315 nm 
over 24 h during the opening of complex 13, from which the kinetic data (t1/2 and k) were 
determined. 
 
In DMSO, the high coordinating nature of the solvent results in total tether-opening 
for all complexes in the series, following nucleophilic attack by dimethyl sulfoxide and 
subsequent formation of the DMSO adduct within 12 h. 
1
H NMR data of freshly 
prepared 6–7 mM solutions of complexes 13 and 21–30 were recorded directly after the 
complex was dissolved (t ≤ 10 min) and at 24 h, at 298 K in DMSO-d6. The initial 
1
H 
NMR spectra of complexes 13 and 21–30 after sample preparation (ca. 10 min) showed 
peaks corresponding to the intact closed-tethered species, as well as some low-intensity 
peaks assignable to Ru
II
 open-tether complexes (5–65%). After 24 h at 298 K, the peaks 
corresponding to the closed-tether precursor [Ru{η6:κ1-C6H5(C6H4)NH2}(XY)]
2+
 
disappeared while the intensity of the signals corresponding to the open ring-tether 
complex reached 100% (Figure 3.4B) in all cases. The new open-tether Ru
II
 arene 
species were identified as [Ru{η6-C6H5(C6H4)NH2}(XY)(DMSO)]
n+
, 13dmso and 
21dmso–30dmso. The conversion of closed-tether RuII complexes into the open-tether 
dmso-adducts occurred at different rates, and the rate constants were determined based 
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on data obtained by 
1
H NMR (Table 3.6 and Figure 3.7). For complexes 21, 22, 25– 26 
and 28–30 the tether opening rates in DMSO were too rapid to be determined.  
 
Figure 3.7. (A) Time evolution of the signals corresponding to the low-field arene region of the 
1
H NMR spectra of [Ru{η6:κ1-C6H5(C6H4)NH2}(en)]
2+
 (13) in DMSO-d6 at 298 K (6 mM Ru). 
(B) Plot of the concentration of open (▲) and closed-tether () complexes versus time for the 
conversion of [Ru{η6:κ1-C6H5(C6H4}NH2)(en)]
2+
 (13) into [Ru{η6-
C6H5(C6H4)NH2}(en)(DMSO)]
2+
 (13dmso) in DMSO-d6 at 298 K. 
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The observed trend for the tether-ring opening process in DMSO is similar to that of 
methanol throughout the entire series (Table 3.6). We observed rapid reactivity in 
complexes 25, 26 and 28, which bear sterically demanding XY diamines of the type 
RR'NCH2CH2NRR', where at least one of the R substituents is a carbon chain (methyl 
or ethyl) with free 360 rotation along the N–C(R) bond. This observation would be in 
agreement with an associative mechanism
10
 for the substitution reaction. According to 
this mechanism, a molecule of solvent enters the ruthenium coordination sphere before 
the tether unbuckles from the Ru
II
 center, and therefore a more crowded intermediate 
would favor rapid dissociation of the Ntether from the ruthenium. Complex 23 shows - in 
both solvents - the slowest k and the longest half-life times of the series, which is in 
contrast with the rapid ring-opening rate of its aromatized counterpart, complex 29, 
demonstrating how the tether ring dynamics can be finely tailored by the nature of XY. 
In their crystal structure a longer Ru–Ntether bond (2.156 Å) in 23 is observed, as 
opposed to a shorter (2.148 Å) bond in 29. This is in agreement with electron back 
donation by phenylenediamine in 29, thus rendering the ruthenium center more 
electrophilic and subsequently more prone to nucleophilic attack.
11
 Such attack could be 
enhanced in 29 due to the less sterically demanding sp
2
 ligand phenylenediamine in 
comparison to sp
3
 diaminocyclohexane. 
 
3.2.4 Activation Under Acidic Conditions  
Since our aim was to prove the pH-dependent on-and-off switching capability and 
tuneability of our system, we investigated the possibility of activating the Ru–Ntether 
bond in aqueous solution at 310 K.  
Very few studies where protonation of the binding functional group in the tether 
plays an important role in the dynamics of metal–tether bond in aqueous solution have 
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been reported.
9, 12-14
 Pizarro et al. reported the synthesis of [Ru{η6-C6H5(C6H4)NH3}Cl3] 
from its closed-tether counterpart, [Ru{η6:η1-C6H5(C6H4)NH2}Cl2], by suspending the 
former in concentrated HCl (ca. 12 M) at ambient temperature for 18 h. The tethered 
nitrogen dissociated from the ruthenium upon protonation.
3
 Activation of a Ru–Ntether 
bond was also proved in the Ru
II
 tether complex [Ru{η6:κ1-C6H5(C6H4)NH2}(en)]Cl2 in 
12 M HCl for 18 h, yielding [Ru{η6:κ1-C6H5(C6H4)NH3}(en)Cl]
2+
. Acidic activation 
had been deemed unsuccessful at pH as low as 2.  
Complexes 13HCl and 21HCl–29HCl were dissolved in 1 M DCl and their 1H 
NMR spectra were recorded at 310 K over 24 h (Figure 3.4C). In all cases the open-ring 
tethered cation [Ru{η6-C6H5(C6H4)NH3}(XY)Cl]
2+
, 13HCl and 21HCl–29HCl, was 
identified as the only species at equilibrium. The 
1
H NMR data showed that complexes 
13HCl and 21HCl–29HCl were fully converted into the corresponding open-tether 
ruthenium arene hydrochloride salt upon dissociation of the NH2(tether) group from the 
ruthenium center, position now occupied by a chlorido ligand. Under these acidic 
conditions, the NH2 is protonated to become NH3
+
. X-ray crystallographic structure of 
complex 28HCl allowed the unequivocal assignment of these complexes (Figure 3.3C). 
The conversion of closed-tethered species into the protonated open-tether Ru
II
 
complexes occurred at different rates as determined by UV-visible spectroscopy (shown 
in Table 3.6 and Figure 3.8 for 13).  
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Figure 3.8. Time dependency (min) of the absorbance at 224 nm for the opening process of 0.2 
mM [Ru{η6:κ1-C6H5(C6H4)NH2}(en)]
2+
 (13) in 1 M HCl solution at 310 K. The full line 
represents computer fit giving the first order rate constant. 
 
The trend of the rates of activation for the series 13 and 21–28 shared similarities 
with those in methanol and DMSO. Complex 28, bearing tetramethylethylenediamine as 
a chelating ligand, showed the highest rate constant for the pH-dependent tether-
opening process. Complexes 25 and 26 were converted too rapidly into their protonated 
open-tether form (fully opened within 5 min), so their rate constants could not be 
determined by 
1
H NMR nor UV-visible spectroscopy. The slowest rates of ring-opening 
in strong acidic conditions were for complexes 13, 23, 24, 27, and 29, where the XY 
chelating ligand forms a 5-member chelating ring, which bears no freely rotating 
substituents in the N,N-chelating diamines. As observed for the tether/opening 
dynamics in non/aqueous solvents, this is in agreement with an associative mechanism 
for the substitution reaction (vide supra). Complexes 24 and 27, bearing secondary 
amines with restricted rotation of the NC bond in the chelating ligand, present the 
slowest rate constants, perhaps due to a more stable intermediate in the substitution 
reaction. This rational would explain why 25, 26 and 28 show the most rapid tether-ring 
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opening, attributable to the high steric hindrance imposed by the methyl or ethyl groups, 
freely rotating along the NC(R) axes in the chelating RR'NCH2CH2NRR' ligand.  
In order to investigate the behavior of the Ru–NH2(tether) bond under milder acidic 
conditions, complexes 13  and 21–29 in 0.1 M DCl solutions were followed over time at 
310 K by 
1
H NMR. A mixture of closed- and protonated open-tether Ru
II
 complexes, 
[Ru(η6:κ1-C6H5(C6H4)NH2)(XY)]
2+
 and [Ru(η6-C6H5(C6H4)NH3)(XY)Cl]
2+
, was 
observed for all complexes at equilibrium. In general, higher percentages of open-tether 
Ru
II
 species are observed with increasing steric hindrance on the nitrogen atoms of the 
N,N-chelating diamine (Figure 3.9). Strikingly, complex 28 (XY = 
tetramethylethylenediamine, tmen), with the highest rate constant for the opening 
process of the series, showed the least percentage of open species at equilibrium, 
perhaps attributable to the lack of H-bond formation capability by tmen.
15
 
 
Figure 3.9. Percentage of Ru
II
 open species at equilibrium, corresponding to the activation of 
the complexes 13 and 21–29 in 0.1 M DCl. 
 
A decrease in the concentration of DCl (0.01 M) resulted in a modest extent of 
activation of the Ru–Ntether bond (ca. 2–5% of open-tether species at equilibrium). 
Further dilutions of DCl did not lead to the activation of the Ru–NH2(tether) bond as 
observed by NMR spectroscopy.  
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1
H NMR experiments of complexes 13, 25, 26 and 28 in DClO4 (0.1 M) were also 
carried out in presence and absence of 0.1 M NaCl, in order to investigate the role of the 
chloride ions in the opening process in acidic conditions. In the absence of NaCl, the 
percentage of protonated open species 13HCl, 25HCl, 26HCl and 28HCl were 17, 77, 
50 and 3%, respectively, significantly lower than in the presence of sodium chloride 
(56, 79, 65 and 18%, respectively) as seen in Figure 3.10. Complex 25 and 26 showed 
the lowest activation dependency to the presence of excess chloride ions. The 
importance of the pH was demonstrated when complex 25 afforded merely 15% of the 
open tether complex 25Cl when exposed to a 2 M NaCl solution for 24 h at 298 K. 
When experiments of tether ring activation of 13, 25, 26 and 28, using a mixture of 0.1 
M DClO4 and 0.1 M NaCl were carried out, identical extent of activation to that of 0.1 
M DCl solutions was obtained after 24 h. 
 
Figure 3.10. Percentage of Ru
II
 open species at equilibrium, corresponding to the 
activation of the complexes 13, 25, 26 and 28 in aqueous solutions of different proton 
and chloride concentrations. 
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3.2.5 pKa Values and Reversibility of the Activation 
Process 
The activation (opening) and deactivation (closing) of the ruthenium complex can 
be understood as the unbuckling and buckling of the pendant NH2(tether) to Ru
II
. For 
this reason, control over the availability of this group to bind to the metal center through 
its acid/base equilibrium (unavailable NH3
+
 versus available for metal coordination 
NH2) appears as an elegant way of controlling compound activation. For this purpose 
we have determined the acid/base equilibrium (pKa values) of the pendant tether-
nitrogen for complexes 25HCl and 28HCl. 
The pH dependency of the 
1
H NMR chemical shifts of the 6-bound arene of 
[Ru{η6-C6H5(C6H4)NH3}(dmen)Cl]
2+
 (25HCl) and [Ru{η6-
C6H5(C6H4)NH3}(tmen)Cl]
2+
 (28HCl) was probed over the pH range 010 and the pKa 
of the amine group of the pendant arm was determined. Complexes 25 and 28 were 
dissolved in 1 M DCl to obtain 25HCl and 28HCl. At pH 0, the species in solution was 
identified as [Ru{η6-C6H5(C6H4)NH3}(dmen/tmen)Cl]
2+
.
 
With increasing pH, the 
1
H 
NMR triplet resonance corresponding to Hm (meta- proton of the 
6
-bound arene) 
shifted to high-field accompanied with a decrease in intensity (see Figure 3.11 for 
28HCl). A plot of the change in chemical shift of the Hm(25HCl) and Hm(28HCl) 
versus pH is shown in Figure 3.12. The data were fitted to the Henderson-Hasselbach 
equation which yielded pKa values of 2.51 and 2.64 for 25HCl and 28HCl, respectively. 
These values are ca. 1.5 units lower than that of the free ligand (pKa 3.81). This 
suggests that electron density from the aniline pendant ring is more readily delocalized 
when 2-aminobiphenyl is η6-coordinated to RuII. The higher pKa for 28HCl versus 
25HCl may be understood on the basis of the more electron rich tmen in comparison 
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with dmen, perhaps ultimately conferring more basicity to the tether NH2 through the 
arene ligand on the Ru
II
.  
 
Figure 3.11. pH-dependence of the signals corresponding to the η6-bound arene spectral region 
of [Ru{η6-CH5(C6H4)NH3}(tmen)Cl]
2+
 () in DCl/D2O. Note that a new species (▲), the 
closed tether counterpart [Ru{η6-CH5(C6H4)NH2}(tmen)]
2+
, appears over time to finally 
dominate the spectrum at pH 5.3. 
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Figure 3.12. 
1
H NMR chemical shift dependency of the Hm proton of the 
6
-bound arene on pH 
of the protonated open-tether complexes [Ru{η6-C6H5(C6H4)NH3}(dmen)Cl]
2+
 (25HCl) and 
[Ru{η6-C6H5(C6H4)NH3}(tmen)Cl]
2+
 (28HCl). The curve represents the best fit to the 
Henderson-Hasselbalch equation and corresponds to pKa value of 2.51 and 2.64, respectively. 
 
Since our aim is to design systems capable of reversible switching, we investigated 
the pH effect in the reverse tether-ring closure. This process, to our understanding 
mediated by hydrolysis,
3
 was followed for complex 25Cl in water at different pH values 
above the pKa of the amine tether group. Open-tether complex 25Cl (6 mM) was 
dissolved in different pH buffered aqueous solutions at 310 K. The closure rate to form 
25 in these solutions was monitored by 
1
H NMR spectroscopy. Data were fitted to the 
Henderson-Hasselbach equation which yielded half-life values of 84, 75, 63 and 15 min 
for pH 3.4, 4.3, 5.8 and 7.2, respectively. The rate constants were calculated as 8.2, 9.3, 
11.0 and 50.8 × 10
–3
 min
–1
. The data revealed that inactivation (ring closure) of the Ru
II
 
complex is slower at the more acidic pH. The results, shown in Figure 3.13, clearly 
illustrate that tether-ring fastening is governed by pH. 
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Proton concentration plays a key role both in the activation and in the deactivation 
process, as protons appear to compete with the electrophilic ruthenium center for the 
nucleophilic free dangling amine. 
 
Figure 3.13. The rate of reversion  of the open-tether species [Ru{η6-
C6H5(C6H4)NH2}(dmen)Cl]Cl
 
(25Cl), to [Ru{η6:κ1-C6H5(C6H4)NH2}(dmen)]
2+
 (25) in four 
different citrate/phosphate buffered solutions over time at 310 K. 
 
3.2.6 Interaction with Nucleobases and Biological 
Activity 
Irreversible DNA damage is often believed to be the mechanism of action of metal-
based anticancer complexes, with guanine N7 nitrogen being the preferred metal 
binding site on DNA.
2, 16-18
 We propose that open (activated) tether Ru
II
 complexes are 
prone to nucleobase interaction, while the corresponding closed tether complex, with no 
vacant site in the first coordination sphere around the ruthenium centre, should not 
interact with the model nucleobase. 
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We were interested in knowing if closed-to-open tether Ru
II
 arene activation could 
lead to DNA interaction, hence the reaction of 25Cl with guanosine monophosphate 
(GMP) was investigated. The binding of the open-tether complex 25Cl, [Ru{η6-
C6H5(C6H4)NH2}(dmen)Cl]
+
, to 5'-GMP in either water or methanol was monitored by 
1
H NMR spectroscopy. Upon mixing 25Cl with 5'-GMP (1:5 metal:nucleobase ratio, 5 
mM Ru
II
) in deuterated methanol, total disappearance of the peaks corresponding to 
complex 25Cl and the appearance of new peaks assignable to Ru-guanine adducts, 
including three new peaks in the H8 region of guanine, was observed in the 
1
H NMR 
spectra at 298 K over 24 h (equilibrium).  
 
 
Figure 3.14. Region of H8-guanine in the 
1
H NMR spectrum. (A) Three new peaks assignable 
to Ru-guanine adducts are observed upon mixing open complex 25Cl and 5'-GMP in methanol 
for 24 h. (B) No new signals corresponding to guanine adducts are observed in the reaction of 
closed complex 25 and 5'-GMP in water over 24 h at 310 K. 
 
The three new peaks (Figure 3.14) were tentatively assigned to the Ru–N7GMP, 
Ru–O(PO3)GMP and Ru–N1GMP adducts, according to literature.
19, 20
 We hoped to 
investigate the pH-dependency of the binding of complex 25Cl to nucleobases. 
However, the pKa of the tether NH3
+
 (ca. 2.5) is inconveniently close to that of the N7 
of guanine (pKa 2.57).
19, 21 
This implies that prevention of Ru–Ntether bond formation by 
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carrying out the reaction at pH < pKa(NH3
+
tether) would also render the guanine unable 
for interaction with the ruthenium.  
Reaction of closed-tether 25 with 5 mol equiv of 5'-GMP in D2O at 310 K did not 
afford any new H8-guanine signals over 24 h (Figure 3.14) as observed by 
1
H NMR. 
These results support that opening of the tether-ring equals Ru
II
 complex activation, 
while a closed tether Ru
II
 complex is rendered unreactive towards nucleobases. These 
results are in agreement with the lack of cytotoxic activity in our cell viability 
experiments in the human ovarian cancer cell line A2780 for complexes 13 and 2130 
(Table 3.7). At the maximum concentration tested (100 M), well within the range of 
cytotoxic activity for the type of drugs of general structure [Ru(η6-arene)(XY)Cl]Cl as 
reported in literature,
22
 no significant inhibition of cell growth was observed (with the 
exception of complex 29, perhaps attributable to redox-active o-pda ligand) and thus the 
complexes were deemed inactive. This demonstrates the inactivated state of the 
compounds at physiological pH, and represents the first step towards rational design of 
a pH-responsive organometallic pro-drug. 
Table 3.7. Percentage of viable A2780 cells (human ovarian cancer) exposed to 100 M of Ru 
complex as determined by the sulforhodamine B (SRB) assay,
5
 following a reported protocol.
6
 
Cisplatin was used as the positive control, with an IC50 value of 1.00.3 M. The SD (7%) of 
the values is determined based on the negative control (100% of cell survival of drug-free cells). 
 
Complex % cell viability complex % cell viability 
13 78 26 100 
21 100 27 100 
22 100 28 80 
23 100 29 63* 
24 100 30 100 
25 100 cisplatin 0 
* This value was not reproduced in subsequent experiments, which upon 
further investigation was attributed to lack of stability of 29 in aqueous 
solution over 24 h. 
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3.3 Conclusions  
 
In this Chapter we have presented a series of Ru
II
 arene complexes capable of on-
and-off switching in a pH-dependent manner. The complexes have a general structure of 
[Ru(η6:κ1-C6H5(C6H4)NH2)(XY)]Cln, and show structural stability in solution. We have 
used this ruthenium platform to understand the chelate-based ring-opening and ring-
closing reactions in view of the development of new pH-activatable inorganic drugs. 
The complexes bear a η6:κ1-arene:N tether-ring capable of locking and unlocking by 
the Ru–Ntether bond. We have demonstrated that once activated (tether-ring open) the 
Ru
II
 complexes are prone to interaction with nucleophiles, such as chloride ions, as well 
as with model DNA nucleobases. The activation kinetics and thermodynamic equilibria 
of the Ru–Ntether bond can be finely tuned in methanol, dimethylsulfoxide and, more 
importantly, in acidic water by varying the N,N-chelating ligand. In general, both 
electronic and steric effects play a role in Ru–Ntether activation in a substitution reaction 
that appears to occur via an associative mechanism. 
We have demonstrated that organometallic drug activation via dissociation of the 
Ru–Ntether bond in acidic water solution is possible within the pH scale. Importantly, 
protonation of the tethering group locks the complex in its activated form. Reversibly, 
deprotonation triggers metal binding thus rendering the complex unsuited for 
biomolecule interaction, conveniently inactivating the drug. The dynamics of tether ring 
opening (activation) and closure (inactivation) are both pH dependent. The process is 
fully reversible, and the system robust to such reversibility. 
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3.4 Experimental Section  
 
3.4.1 Instrumentation 
NMR Spectroscopy, Mass Spectrometry, Elemental Analysis and pH 
Measurements have been described in Chapter 2. 
 
Single Crystal X-ray Diffraction. Suitable crystals of compounds 13, 23, 26Cl, 27, 
28Cl, 28HCl, and 29, were coated with mineral oil and mounted on Mitegen 
MicroMounts. The samples were measured in a Bruker D8 KAPPA APEX II 
diffractometer with CCD area-detector, equipped with graphite-monochromated Mo Kα 
radiation (λ = 0.71073 Å). The substantial redundancy in data allowed empirical 
absorption corrections (SADABS)
23
 to be applied using multiple measurements of 
symmetry-equivalent reflections. Raw intensity data frames were integrated with the 
SAINT program, which also applied corrections for Lorentz and polarization effects. 
The Bruker SHELXTL Software Package was used for space group determination, 
structure solution, and refinement.
24
 The space group determination was based on a 
check of the Laue symmetry, and systematic absences were confirmed using the 
structure solution. The structures were solved by direct methods (SHELXL-2014/7),
25, 26
 
completed with different Fourier syntheses, and refined with full-matrix least-squares 
using SHELXS minimizing ω(Fo
2
 – Fc
2
)
2
. Weighted R factors (Rw) and goodness of fit 
(S) are based on F
2
; conventional R factors (R) are based on F. All non-hydrogen atoms 
were refined with anisotropic displacement parameters. Hydrogen atom positions were 
geometrically calculated and allowed to ride on their parent carbon or nitrogen atoms 
with fixed isotropic U. All scattering factors and anomalous dispersion factors are 
contained in the SHELXTL 6.10 program library.  
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UV-visible Spectroscopy. A Cary 5000 UV-Vis-NIR spectrophotometer (Agilent 
Technologies, CA), was used with 1 cm path length cuvettes (850 L) provided with a 
Temperature Controller. Spectra (500–200 nm) were recorded at 310 K when the 
samples were in water and at 298 K for methanol samples. The data were processed 
using OriginPro version 9.0 (OriginLab, Northampton, MA). 
 
3.4.2 Methods 
Solution Studies. The tether ring-opening process of closed-tether complexes was 
monitored by 
1
H NMR or UV-visible spectroscopy in methanol, dimethylsulfoxide and 
acidic aqueous solutions. The concentration of Ru
II
 for the NMR studies was 6–7 mM, 
and 0.2 mM for UV-visible spectroscopy, unless otherwise stated. The relative amounts 
of closed- and open-tether species in DMSO-d6, MeOD-d4 (298 K) and DCl solutions 
(1, 0.1, and 0.01 M DCl) at 310 K at equilibrium (1–8 h) were quantified by integration 
of peaks in the 
1
H NMR spectra. The extent of the ring opening process by 
1
H NMR 
spectroscopy in acidic conditions at equilibrium was also determined in 1 M 
DClO4/D2O and 0.1 M DClO4/D2O (with and without 0.1 M NaCl) at 310 K in ca. 6 
mM Ru
II
 solutions for selected complexes of the series. 
In order to determine the rate of the ring-opening process in DMSO-d6, 
1
H NMR spectra 
were acquired at 10 minutes intervals over 12 h at 298 K. The data following time-
course dynamics of the DMSO-adduct formation, based on peak integrals, were fitted to 
a pseudo-first-order kinetic equation. OriginPro was used to fit the exponential decay 
and to obtain the rate constant (k, min
–1
). Experiments with 25 and 26 were performed 
by adding a 10 µL aliquot of a 15 mM heavy water solution to 690 µL of DMSO-d6. In 
methanol and 1 M HCl ([Ru
II
] = 200 M), the rate constants were calculated from the 
time-course data obtained by following the opening process by UV-visible 
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spectroscopy. Experiments with complexes 25 and 26 were performed by adding an 
aliquot of a Ru
II
 6 mM water solution to either methanol or 1 M HCl for a final Ru
II
 
concentration of ca. 100 M. The absorbance was recorded at several time intervals 
over 24 h at 298 K for methanol and at 310 K for 1 M HCl. A plot of the change in 
absorbance with time was fitted to the appropriate equation for pseudo-first-order 
kinetics using OriginPro to give the half-lives (t1/2, min) and rate constants (k, min
–1
). 
The tether ring-closure of open tether complex 25Cl was monitored by 
1
H NMR using 
different buffered aqueous solutions. Citric acid/Na2HPO4 buffer was used to prepare 
pH 3.4, 4.3, 5.8 and 7.2 D2O solutions and chosen based on the weak coordinating 
properties of the anions. Complex 25Cl was dissolved (ca. 6 mM) in each buffered 
solution and the spectra were acquired at 10 min intervals over 12 h at 310 K. The data 
of the time-course dynamics to form the closed-tether complex (25) was determined by 
integration of the 
1
H NMR peaks and data were fitted to the equation for pseudo-first-
order kinetics. 
 
Calculation of pKa Values. In order to determine the pKa values of the pendant NH2 
group in open tether complexes, the pH of aqueous solutions of complexes 25HCl and 
28HCl was varied from pH 0 to 10 by the addition of dilute aliquots of NaOD and DCl, 
measuring the solution pH before and after recording the 
1
H NMR spectra. The 
chemical shifts of the bound-arene ring protons were plotted against pH. The pH 
titration curves were fitted to the Henderson-Hasselbach equation using the program 
OriginPro, with the assumption that the observed chemical shifts are weighted averages 
according to the populations of the protonated (25HCl and 28HCl) and the 
deprotonated (25Cl and 28Cl) species, i.e., the NH3
+
/NH2 equilibrium on the pendant 
NH2 tether arm. 
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Interaction with Nucleobases. 25Cl was allowed to react with 5'-GMP (9 mol equiv) 
in methanol-d4 at 298 K. The reaction was monitored by 
1
H NMR over 24 h, when 
equilibrium had been reached. In addition, reaction of closed-tether complex 25 with 5'-
GMP (5 mol equiv) was followed in D2O at 310 K for 24 h. Their 
1
H NMR spectra were 
recorded at various time intervals. 
 
3.4.3 Synthesis 
MATERIALS 
 RuCl33H2O was acquired from Precious Metals Online. Ethylendiamine (en), 1,3-
diaminopropane (dap), trans-1,2-diaminocyclohexane (dach), 2-piperidinemethanamine 
(pipma), N,N,N′,N′-tetramethylethylenediamine (tmen), sodium oxalate (oxo), 2,2'-
bipyridyl (bipy), ethyl benzoate, and 5'-guanosine monophosphate were purchased from 
Sigma-Aldrich. N,N′-dimethylethylenediamine (dmen), N,N′-diethylethylenediamine 
(deen), and 1,2-bis(dimethylphosphino)ethane (dmphe) were acquired from Alfa Aesar. 
1,4-Diaminobutane (dab), 2,2'-bipiperidine (dpip), and N,N'-di-tert-
butylethylenediamine (dtben) were purchased from TCI Europe. Dichloroethane, 
magnesium, 2-aminobiphenyl, and o-phenylenediamine (o-pda) were acquired from 
Acros Organics, and iodine from Fisher. Ethanol, dry methanol, diethyl ether, 
tetrahydrofuran, dimethylsulfoxide, sodium metal, and sodium chloride were purchased 
from Sharlau. The solvents used for UV-visible absorption spectroscopy were dry 
methanol, and deionized water. For NMR spectroscopy, the solvents used were MeOD-
d4, DMSO-d6, DCl, DClO4 and D2O obtained from VWR International.  
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PREPARATION OF COMPLEXES 
The Ru
II
 dimer [Ru(6-etb)Cl2]2 where etb is ethyl benzoate was synthesized following 
the reported synthesis by Habtemariam et al.
27
 The dichlorido complex [Ru{η6:κ1-
C6H5(C6H4)NH2}Cl2] was synthesized via thermal displacement of ethyl benzoate in the 
Ru
II
 dimer [Ru(6-etb)Cl2]2 by 2-aminobiphenyl in 1,2-dichloroethane under pressure 
overnight as reported by Pizarro et al.
3
 Complexes 13 and 21–30, 31Cl and 32Cl (Table 
3.1) were isolated as chloride salts using slight variations of a reported procedure.
3
 
Typically, 1 mole equivalent of the bidentate chelating ligand (XY) was added to a 
suspension of the dichlorido ruthenium complex [Ru{η6:κ1-C6H5(C6H4)NH2}Cl2] in 
methanol or methanol/water to afford [Ru{η6:κ1-C6H5(C6H4)NH2}(XY)]
2+
. Complexes 
13Cl and 2129Cl, 31, 32 and 33Cl were characterized in solution. Details of the 
amount of reactants, volume of solvents, color changes, stirring times, and nature of the 
product are given below for the individual reactions, as well as any variation in the 
synthetic procedure. 
 
The experimental procedures for the synthesis of complexes [Ru(η6-etb)Cl2]2, 
[Ru{η6:κ1-C6H5(C6H4)NH2}Cl2] and [Ru{η
6:κ1-C6H5(C6H4)NH2}(en)]Cl2 (13) have 
been described in Chapter 2. 
 
[Ru{η6:κ1-C6H5(C6H4)NH2}(dap)]Cl2 (21). [Ru{η
6:κ1-C6H5(C6H4)NH2}Cl2] (22 mg, 
0.059 mmol) was suspended in methanol (3 mL). 1,3-diaminopropane (4.9 µL, 0.059 
mmol) was added, and the mixture was stirred for 6 h at room temperature. The solvent 
was removed under vacuum, and the product was re-dissolved in 2 mL of ethanol. The 
resultant yellow solution was filtered through a 0.45 µm syringe filter. The solvent was 
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reduced to ca. 5% of its original volume, and diethyl ether (3 mL) was added. The 
sticky solid was sonicated to give a yellowish precipitate, which was washed with 
diethyl ether and dried in vacuum. Water (7 mL) was added and the solution was left to 
stand overnight. Lyophilization afforded a dark solid. Yield: 22 mg (90%). Elemental 
analysis: Cald for C15H21Cl2N3Ru (415.32): C, 43.38; H, 5.10; N, 10.12. Found: C, 
41.17; H, 5.84; N,9.21. 
1
H NMR (400 MHz, D2O, δ): 7.64 (dd, J = 7.4, 1.8 Hz, Ar H, 
1H), 7.56–7.48 (m, Ar H, 2H), 7.39 (dd, J = 7.4, 1.8 Hz, Ar H, 1H), 6.29 (t, J = 5.9 Hz, 
Ar H, 2H), 5.60 (t, J = 5.8 Hz, Ar H, 1H), 5.53 (d, J = 5.8 Hz, Ar H, 2H), 3.15–3.09 (m, 
2H), 2.93 (td, J = 11.0, 2.6 Hz, 2H), 1.97–1.90 (m, 1H), 1.67–1.57 (m, 1H). 
 
[Ru{η6:κ1-C6H5(C6H4)NH2}(dab)]Cl2 (22). [Ru{η
6:κ1-C6H5(C6H4)NH2}Cl2] (20 mg, 
0.059 mmol) was suspended in methanol (3 mL). 1,4-diaminobutane (5.8 µL, 0.059 
mmol) was added, and the mixture was stirred for 3 h at room temperature. The solvent 
was removed on a rotary evaporator, and the product was re-dissolved in 3 mL of 
ethanol. The resultant yellow solution was filtered through a 0.45 µm syringe filter. The 
solvent was reduced to ca. 5% of its original volume, and diethyl ether (3 mL) was 
added. The sticky solid was sonicated to give a pale yellow precipitate, which was 
washed with diethyl ether and dried in vacuum. Water (7 mL) was added and the 
solution was left to stand overnight. Lyophilization afforded a pale yellow solid. Yield: 
24 mg (95%). Elemental analysis: Cald for C16H23Cl2N3Ru (429.35): C, 44.76; H, 5.40; 
N, 9.79. Found: C, 41.96; H, 6.04; N, 9.29. 
1
H NMR (400 MHz, D2O, δ): 7.64 (dd, J = 
6.9, 1.9 Hz, Ar H, 1H), 7.53 (td, J = 7.3, 2.1 Hz, Ar H, 2H), 7.38 (dd, J = 6.8, 1.5 Hz, Ar 
H, 1H), 6.34 (t, J = 4.9 Hz, Ar H, 2H), 5.71 (t, J = 4.8 Hz, Ar H, 1H), 5.56 (d, J = 5.8 
Hz, Ar H, 2H), 3.15–3.09 (m, 2H), 3.05–2.98 (m, 2H), 1.96–1.89 (m, 2H), 1.70–1.63 
(m, 2H).  
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[Ru{η6:κ1-C6H5(C6H4)NH2}(dach)]Cl2 (23). [Ru{η
6:κ1-C6H5(C6H4)NH2}Cl2] (30 mg, 
0.088 mmol) was suspended in methanol (4 mL). Trans-1,2-diaminocyclohexane (10.5 
µL, 0.088 mmol) was added, and the mixture was stirred for 6 h at room temperature. 
The solvent was removed in vacuo, and the product was re-dissolved in 4 mL of 
ethanol. The resultant yellow solution was filtered through a 0.45 µm syringe filter. The 
solvent was reduced to ca. 5% of its original volume, and diethyl ether (3 mL) was 
added. The sticky solid was sonicated to give a pale yellow precipitate, which was 
centrifuged, washed with diethyl ether and dried in vacuum. Water (10 mL) was added 
and the solution was left to stand overnight. Lyophilization afforded a yellow solid. 
Yield: 34 mg (85%). Elemental analysis: Cald for C18H25Cl2N3Ru (455.39): C, 47.47; 
H, 5.53; N, 9.23. Found: C, 45.19; H, 5.96; N, 8.92. 
1
H NMR (400 MHz, D2O, δ): 7.66 
(dd, J = 7.2, 1.9 Hz, Ar H, 1H), 7.54 (td, J = 7.3, 1.9 Hz, Ar H, 2H), 7.41 (dd, J = 7.1, 
1.9 Hz, Ar H, 1H), 6.23 (t, J = 5.8 Hz, Ar H, 1H), 6.18 (t, J = 5.8 Hz, Ar H, 1H), 5.67 
(d, J = 5.9 Hz, Ar H, 1H), 5.65 (d, J = 5.9 Hz, Ar H, 1H), 5.51 (t, J = 5.8 Hz, Ar H, 1H), 
2.31–2.22 (m, 1H), 2.15–2.07 (m, 2H), 1.69–1.63 (m,3H), 1.35–1.07 (m, 4H). The 
yellow single crystals grown from a water solution (298 K) were suitable for X-ray 
diffraction. 
 
[Ru{η6:κ1-C6H5(C6H4)NH2}(pipma)]Cl2 (24). [Ru{η
6:κ1-C6H5(C6H4)NH2}Cl2] (40 mg, 
0.120 mmol) was suspended in methanol (4 mL). 2-piperidinemethanamine (14.2 µL, 
0.120 mmol) was added, and the mixture was stirred for 4 h at room temperature. The 
solvent was removed in vacuo, and the product was re-dissolved in 3 mL of ethanol. 
The resultant yellow solution was filtered through a 0.45 µm syringe filter. The solvent 
was reduced to ca. 5% of its original volume, and diethyl ether (3 mL) was added. The 
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sticky solid was sonicated to give a pale yellow precipitate, which was centrifuged, 
washed with diethyl ether and dried in vacuum. Water (14 mL) was added and the 
solution was left to stand overnight. Lyophilization afforded a yellow solid. Yield: 51 
mg (93%). Elemental analysis: Cald for C18H25Cl2N3Ru (455.39): C, 47.47; H, 5.53; N, 
9.23. Found: C, 44.16; H, 6.04; N, 8.84. 
1
H NMR (400 MHz, D2O, δ): 7.66–7.63 (m, Ar 
H, 1H), 7.57–7.49 (m, Ar H, 2H), 7.45–7.40 (m, Ar H, 1H), 6.25–6.15 (m, Ar H, 2H), 
5.70–5.53 (m, Ar H, 3H), 3.87–3.48 (m, 1H), 2.95–2.77 (m, 2H), 2.33–2.03 (m, 1H), 
1.93–1.58 (m,5H), 1.57–1.44 (m, 1H), 1.28–1.24 (m, 1H).   
 
[Ru{η6:κ1-C6H5(C6H4)NH2}(dmen)]Cl2 (25). [Ru{η
6:κ1-C6H5(C6H4)NH2}Cl2] (60 mg, 
0.180 mmol) was suspended in methanol (6 mL). Dimethylethylendiamine (18.9 µL, 
0.180 mmol) was added, and the mixture was stirred for 7 h at room temperature. The 
solvent was removed in vacuo, and the product was re-dissolved in 3 mL of ethanol. 
The resultant yellow solution was filtered through a 0.45 µm syringe filter. The solvent 
was reduced to ca. 5% of its original volume, and diethyl ether (4 mL) was added. The 
sticky solid was sonicated to give a yellow precipitate, which was centrifuged, washed 
with diethyl ether and dried in vacuo. Water (21 mL) was added and the solution left to 
stand in water for 24 h to afford closed complex 25 in aqueous solution. 
1
H NMR (400 
MHz, D2O, δ): 7.67–7.65 (m, Ar H, 1H), 7.58–7.50 (m, Ar H, 2H), 7.44-7.41 (m, Ar H, 
1H), 6.29 (t, J = 5.9 Hz, Ar H, 1H), 6.22 (t, J = 5.9 Hz, Ar H, 1H), 5.77 (d, J = 6 Hz, Ar 
H, 1H), 5.72 (t, J = 5.8 Hz, Ar H, 1H), 5.65 (d, J = 5.9 Hz, Ar H, 1H), 3.19 (s, CH3, 
3H), 2.98 (dd, J = 12.7, 3.0 Hz, CHH, 1H), 2.92 (dd, J = 13.1, 3.7 Hz, CHH, 1H), 2.80 
(s, CH3, 3H), 2.49 (td, J = 13.4, 3.8 Hz, CHH, 1H), 1.98 (td, J = 13.3, 3.8 Hz, CHH, 
1H). ESI-MS (m/z): [M–H]+ calcd for C16H23N3Ru, 358.1; found, 358.0.  
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[Ru{η6:κ1-C6H5(C6H4)NH2}(deen)]Cl2 (26). [Ru{η
6:κ1-C6H5(C6H4)NH2}Cl2] (10 mg, 
0.029 mmol) was suspended in methanol (4 mL). Diethylethylendiamine (4.2 µL, 0.029 
mmol) was added, and the mixture was stirred for 6 h at room temperature. The solvent 
was removed on the rotary evaporator, and the product was re-dissolved in 0.2 mL of 
ethanol. The resultant yellow solution was filtered through a 0.45 µm syringe filter. The 
solvent was reduced to ca. 5% of its original volume, and diethyl ether (4 mL) was 
added. The sticky solid was sonicated to give a yellow precipitate, which was 
centrifuged, washed with diethyl ether and dried in vacuum. Water (4 mL) was added 
and the solution was left to stand in water for 24 h to afford closed complex 26 in 
aqueous solution. 
1
H NMR (400 MHz, D2O, δ): 7.67–7.65 (m, Ar H, 1H), 7.58–7.50 (m, 
Ar H, 2H), 7.43–7.41 (m, Ar H, 1H), 6.28 (t, J = 5.8 Hz, Ar H, 1H), 6.19 (t, J = 5.9 Hz, 
Ar H, 1H), 5.74 (d, J = 5.4 Hz, Ar H, 1H), 5.72 (t, J = 5.85 Hz, Ar H, 1H), 5.62 (d, J = 
5.9 Hz, Ar H, 1H), 3.69 (m, 1H), 3.42–3.32 (m, 2H), 3.21 (dd, J = 9.3, 3.6 Hz, 1H), 3.18 
(dd, J = 9.7, 3.6 Hz, 1H), 2.93–2.84 (m, 1H), 2.40 (td, J = 13.3, 3.7 Hz, 1H), 1.82 (td, J 
= 13.4, 3.8 Hz, 1H), 1.27 (m, 6H). ESI-MS (m/z): [M–H]+ calcd for C18H27N3Ru, 386.1; 
found, 386.1.  
 
[Ru{η6:κ1-C6H5(C6H4)NH2}(dpip)]Cl2 (27). [Ru{η
6:κ1-C6H5(C6H4)NH2}Cl2] (20 mg, 
0.059 mmol) was suspended in methanol (3 mL). Bis-piperidine (9.9 µL, 0.059 mmol) 
was added, and the mixture was stirred for 6 h at room temperature. The solvent was 
removed in vacuo, and the product was re-dissolved in 2 mL of ethanol. The resultant 
yellow solution was filtered through a 0.45 mm syringe filter. The solvent was reduced 
to ca. 5% of its original volume, and diethyl ether (3 mL) was added. The sticky solid 
was sonicated to give a brown precipitate, which was washed with diethyl ether and 
dried in vacuum. Water (5 mL) was added and the solution was left to stand in water for 
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24 h to afford the closed complex. Lyophilization afforded a brown solid.  Yield: 20 mg 
(67%). Elemental analysis: Cald for C22H31Cl2N3Ru (509.48): C, 51.86; H, 6.13; N, 
8.25. Found: C, 48.92; H, 6.35; N, 7.66. 
1
H NMR (400 MHz, D2O, δ): 7.67–7.64 (m, Ar 
H, 1H), 7.59–7.49 (m, Ar H, 2H), 7.48–7.44 (m, Ar H, 1H), 6.33–6.16 (m, Ar H, 2H), 
5.96–5.53 (m, Ar H, 3H), 3.84–2.04 (m, 6H), 1.98–1.19 (m, 12H).  Single crystals of 27 
suitable for X-ray diffraction were obtained from the reaction mixture. 
 
[Ru{η6:κ1-C6H5(C6H4)NH2}(tmen)]Cl2 (28). [Ru{η
6:κ1-C6H5(C6H4)NH2}Cl2] (30 mg, 
0.088 mmol) was suspended in 12 mL of 1:1 (v/v) methanol/water. 
Tetramethylethylendiamine (13.2 µL, 0.088 mmol) was added, and the mixture was 
stirred for 3 h at room temperature. The solvent was removed in vacuo, and the product 
was re-dissolved in 3 mL of ethanol. The resultant brown solution was filtered through a 
0.45 µm syringe filter. The solvent was reduced to ca. 5% of its original volume, and 
diethyl ether (4 mL) was added. The sticky solid was sonicated to give a yellow 
precipitate, which was washed with diethyl ether and dried in vacuum. Yield: 38 mg (94 
%). Elemental analysis: Cald for C18H27Cl2N3Ru (457.4): C, 47.27; H, 5.95; N, 9.19. 
Found: C, 45.82; H, 6.23; N, 8.24. 
1
H NMR (400 MHz, D2O, δ): 7.68–7.66 (m, Ar H, 
1H), 7.57–7.49 (m, Ar H, 2H), 7.44–7.42 (m, Ar H, 1H), 6.34 (t, J = 6.3 Hz, Ar H, 2H), 
6.03 (d, J = 6.0 Hz, Ar H, 2H), 5.86 (t, J = 6.0 Hz, Ar H, 1H), 3.53 (s, 2CH3, 6H), 2.93–
2.86 (m, 2H), 2.66 (s, 2CH3, 6H), 2.59–2.52 (m, 2H).  
 
[Ru{η6:κ1-C6H5(C6H4)NH2}(o-pda)]Cl2 (29). [Ru{η
6:κ1-C6H5(C6H4)NH2}Cl2] (60 mg, 
0.176 mmol) was suspended in 10 mL of 1:1 (v/v) methanol/water. o-Phenylenediamine 
(17.9 µL, 0.165 mmol) was added, and the mixture was stirred for 6 h at room 
temperature. The solvent was removed in vacuo, and the product was re-dissolved in 4 
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mL of ethanol. The resultant dark solution was filtered through a 0.45 µm syringe filter. 
The solvent was reduced to ca. 5% of its original volume, and diethyl ether (4 mL) was 
added. The sticky solid was sonicated to give a violet precipitate, which was washed 
with diethyl ether and dried in vacuum. Yield: 45 mg (57 %). Elemental analysis: Cald 
for C18H19Cl2N3Ru (449.34): C, 48.11; H, 4.26; N, 9.35. Found: C, 46.73; H, 4.98; N, 
9.10. 
1
H NMR (400 MHz, D2O, δ): 7.70–7.68 (m, Ar H, 1H), 7.53–7.51 (m, Ar H, 2H), 
7.41–7.38 (m, Ar H, 2H), 7.34–7.31 (m, Ar H, 2H), 7.27–7.25 (m, Ar H, 1H), 6.38 (t, J 
= 5.9 Hz, Ar H, 2H), 5.76 (d, J = 5.8 Hz, Ar H, 2H), 5.63 (t, J = 5.8 Hz, Ar H, 1H). 
Dark single crystals of 29 suitable for X-ray diffraction were obtained by evaporation of 
water solution at ambient temperature. 
 
[Ru{η6:κ1-C6H5(C6H4)NH2}(oxo)] (30). [Ru{η
6:κ1-C6H5(C6H4)NH2}Cl2] (5 mg, 0.015 
mmol) was suspended in water (2 mL). Silver oxalate (18 mg, 0.059 mmol) was added, 
and the mixture was stirred for 6 h at room temperature. The solvent was removed on 
the rotary evaporator and the product was re-dissolved in 3 mL of ethanol. The resultant 
yellow solution was filtered through a 0.45 µm syringe filter. The solvent was reduced 
to ca. 5% of its original volume, and diethyl ether (3 mL) was added. The sticky solid 
was sonicated to give a pale yellow precipitate, which was washed with diethyl ether 
and dried in vacuum. Yield: 8 mg (57 %). Elemental analysis: Cald for C14H11NO4Ru 
(358.31): C, 46.93; H, 3.09; N, 3.91. Found: C, 32.56; H, 2.59; N, 2.39.  
1
H NMR (400 
MHz, D2O, δ): 7.68–7.66 (m, Ar H, 1H), 7.58–7.50 (m, Ar H, 2H), 7.39–7.37 (m, Ar H, 
1H), 6.14 (t, J = 5.9 Hz, Ar H, 2H), 5.75 (t, J = 6.0 Hz, Ar H, 1H), 5.53 (d, J = 6.2 Hz, 
Ar H, 2H). 
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[Ru{η6:κ1-C6H5(C6H4)NH2}(en)Cl]Cl (13Cl). [Ru{η
6:κ1-C6H5(C6H4)NH2}(en)]Cl2 (2 
mg, 0.005 mmol) was dissolved in methanol (0.6 mL). The solution was left to stand 
overnight to afford a mixture of complex 1 and the open-tether complex 1Cl. 
1
H NMR 
(400 MHz, MeOD-d4, δ): 7.44 (dd, J = 7.7, 1.5 Hz, Ar H, 1H), 7.23 (ddd, J = 8.2, 7.3, 
1.6 Hz, Ar H, 1H), 6.89 (dd, J = 8.1, 1.0 Hz, Ar H, 1H), 6.83 (td, J = 7.6, 1.2 Hz, Ar H, 
1H), 6.05 (d, J = 5.9 Hz, Ar H, 2H), 6.02 (t, J = 5.6 Hz, Ar H, 1H), 5.74 (t, J = 6.1 Hz, 
Ar H, 2H), 2.59–2.53 (m, 2H), 2.46–2.40 (m, 2H). Crystallographic data of complex 
13Cl have been published previusly.
3
  
 
[Ru{η6:κ1-C6H5(C6H4)NH2}(dap)Cl]Cl (21Cl). [Ru{η
6:κ1-C6H5(C6H4)NH2}(dap)]Cl2 
(3 mg, 0.007 mmol) was dissolved in methanol (0.6 mL). The solution was left to stand 
overnight to afford a mixture of complex 21 and the open-tether complex 21Cl. 
1
H 
NMR (400 MHz, MeOD-d4, δ): 7.45 (dd, J = 7.8, 1.5 Hz, Ar H, 1H), 7.24 (td, J = 7.4, 
1.6 Hz, Ar H, 1H), 6.89 (dd, J = 8.1, 1.0 Hz, Ar H, 1H), 6.83 (td, J = 7.6, 1.2 Hz, Ar H, 
1H), 6.09 (d, J = 5.9 Hz, Ar H, 2H), 6.01 (t, J = 5.6 Hz, Ar H, 1H), 5.79 (t, J = 5.7 Hz, 
Ar H, 2H), 3.11–3.06 (m, 2H), 2.72–2.66 (m, 2H), 1.84–1.78 (m, 1H), 1.55–1.45 (m, 
1H).  
 
[Ru{η6:κ1-C6H5(C6H4)NH2}(dab)Cl]Cl (22Cl). [Ru{η
6:κ1-C6H5(C6H4)NH2}(dab)]Cl2 
(3 mg, 0.007 mmol) was dissolved in methanol (0.6 mL). The solution was left to stand 
overnight to afford a mixture of complex 22 and the open-tether complex 22Cl. 
1
H 
NMR (400 MHz, MeOD-d4, δ): 7.47 (dd, J = 7.7, 1.5 Hz, Ar H, 1H), 7.25 (ddd, J = 8.2, 
7.3, 1.5 Hz, Ar H, 1H), 6.91 (dd, J = 8.2, 1.0 Hz, Ar H, 1H), 6.85 (td, J = 7.7, 1.2 Hz, Ar 
H, 1H), 6.12 (d, J = 5.9 Hz, Ar H, 2H), 6.03 (t, J = 5.6 Hz, Ar H, 1H), 5.85 (t, J = 5.7 
Hz, Ar H, 2H), 2.97–2.81 (m, 4H), 1.89–1.77(m, 2H), 1.67–1.56 (m, 2H).  
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[Ru{η6:κ1-C6H5(C6H4)NH2}(dach)Cl]Cl (23Cl). [Ru{η
6:κ1-
C6H5(C6H4)NH2}(dach)]Cl2 (3 mg, 0.007 mmol) was dissolved in methanol (0.6 mL). 
The solution was left to stand overnight to afford a mixture of complex 23 and the open-
tether complex 23Cl. 
1
H NMR (400 MHz, MeOD-d4, δ): 7.44 (dd, J = 7.7, 1.5 Hz, Ar 
H, 1H), 7.22 (td, J = 7.4, 1.5 Hz, Ar H, 1H), 6.88 (dd, J = 8.1, 1.0 Hz, Ar H, 1H), 6.82 
(td, J = 7.6, 1.2 Hz, Ar H, 1H), 6.10 (d, J = 5.8 Hz, Ar H, 1H), 6.07 (d, J = 5.8 Hz, Ar 
H, 1H), 6.01 (t, J = 5.8 Hz, Ar H, 1H), 5.73–5.68 (m, Ar H, 2H), 2.12–1.99 (m, 3H), 
1.71–1.65(m, 2H), 1.46–1.10 (m, 5H).  
 
[Ru{η6:κ1-C6H5(C6H4)NH2}(pipma)Cl]Cl (24Cl). [Ru{η
6:κ1-
C6H5(C6H4)NH2}(pipma)]Cl2 (3 mg, 0.007 mmol) was dissolved in methanol (0.6 mL). 
The solution was left to stand overnight to afford a mixture of complex 24 and the open-
tether complex 24Cl. 
1
H NMR (400 MHz, MeOD-d4, δ): 7.46–7.41 (m, Ar H, 1H), 
7.25–7.20 (m, Ar H, 1H),  6.89–6.79 (m, Ar H, 2H), 6.26–6.00 (m, Ar H, 3H), 5.83–
5.71 (m, Ar H, 2H), 3.72–1.20 (m, 11H). 
 
[Ru{η6:κ1-C6H5(C6H4)NH2}(dmen)Cl]Cl (25Cl). [Ru{η
6:κ1-
C6H5(C6H4)NH2}(dmen)]Cl2 (3 mg, 0.007 mmol) was dissolved in methanol (0.6 mL). 
The solution was left to stand overnight to quantitatively afford open-tether complex 
25Cl. Elemental analysis: Cald for C16H23Cl2N3Ru (429.35): C, 44.76; H, 5.40; N, 9.79. 
Found: C, 43.15; H, 5.73; N, 9.07. 
1
H NMR (400 MHz, MeOD-d4, δ): 7.48 (dd, J = 7.8, 
1.4 Hz, Ar H, 1H), 7.24 (td, J = 7.3, 1.6 Hz, Ar H, 1H), 6.88 (dd, J = 8.2, 1.0 Hz, Ar H, 
1H), 6.81 (td, J = 7.8, 1.2 Hz, Ar H, 1H), 6.30–6.12 (m, Ar H, 2H), 6.18 (t, J = 5.7 Hz, 
Ar H, 1H),  5.83–5.70 (m, Ar H, 2H), 2.91–2.89 (m, 3H), 2.80–2.79 (m, 3H), 2.76–2.69 
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(m, CHH, 1H), 2.54–2.49 (m, CHH, 1H), 2.37–2.27 (m, CHH, 1H), 2.21–2.11 (m, 
CHH, 1H). 
 
[Ru{η6:κ1-C6H5(C6H4)NH2}(deen)Cl]Cl (26Cl). [Ru{η
6:κ1-
C6H5(C6H4)NH2}(deen)]Cl2 (3 mg, 0.007 mmol) was dissolved in methanol (0.6 mL). 
The solution was left to stand overnight to quantitatively afford open-tether complex 
26Cl. Elemental analysis: Cald for C18H27Cl2N3Ru (457.40): C, 47.27; H, 5.95; N, 9.19. 
Found: C, 46.08; H, 6.07; N, 8.85. 
1
H NMR (400 MHz, MeOD-d4, δ): 7.48 (dd, J = 7.8, 
1.4 Hz, Ar H, 1H), 7.21 (td, J = 7.3, 1.5 Hz, Ar H, 1H), 6.86 (dd, J = 8.1, 1.0 Hz, Ar H, 
1H), 6.77 (td, J = 7.8, 1.2 Hz, Ar H, 1H), 6.27 (d, J = 6.0 Hz, Ar H, 1H), 6.24 (d, J = 6.1 
Hz, Ar H, 1H),  6.08 (t, J = 5.7 Hz, Ar H, 1H), 5.77 (t, J = 5.8 Hz, Ar H, 1H), 5.72 (t, J 
= 5.9 Hz, Ar H, 1H), 3.48–3.39 (m, 1H), 3.22–3.05 (3H, m), 3.00 (dd, J = 12.0, 2.7 Hz, 
1H), 2.78 (dd, J = 12.4, 3.2 Hz, 1H), 2.27 (td, J = 12.1, 4.1 Hz, 1H), 1.98 (td, J = 13.0, 
3.7 Hz, 1H), 1.22 (m, 6H). Yellow crystals were obtained from a methanol solution 
affording the structure of complex 7Cl. 
 
[Ru{η6:κ1-C6H5(C6H4)NH2}(dpip)Cl]Cl (27Cl). [Ru{η
6:κ1-C6H5(C6H4)NH2}(dpip)]Cl2 
(3 mg, 0.005 mmol) was dissolved in methanol (0.6 mL). The solution was left to stand 
overnight to quantitatively afford open-tether complex 27Cl. Elemental analysis: Cald 
for C22H31Cl2N3Ru (509.48): C, 51.86; H, 6.13; N, 8.25. Found: C, 50.04; H, 6.38; N, 
7.5. 
1
H NMR (400 MHz, MeOD-d4, δ): 7.59–7.48 (m, 1H), 7.24–7.20 (m, 1H), 6.89–
6.79 (m, 2H), 6.43–6.40 (m, 1H), 6.27–6.14 (m, 2H), 5.80–5.69 (m, 2H), 3.58–1.13 (m, 
18H). 
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[Ru{η6:κ1-C6H5(C6H4)NH2}(tmen)Cl]Cl (28Cl). [Ru{η
6:κ1-
C6H5(C6H4)NH2}(tmen)]Cl2 (10 mg, 0.022 mmol) was dissolved in methanol (0.6 mL). 
The solution was left to stand overnight to quantitatively afford open-tether complex 
28Cl. 
1
H NMR (400 MHz, MeOD-d4, δ): 7.54 (dd, J = 7.9, 1.5 Hz, Ar H, 1H), 7.25 (td, 
J = 7.2, 1.5 Hz, Ar H, 2H), 6.89 (dd, J = 8.2, 1.1 Hz, Ar H, 1H), 6.82 (td, J = 7.3, 1.2 
Hz, Ar H, 2H), 6.45 (d, J = 6.5 Hz, Ar H, 2H), 6.45 (t, J = 5.7 Hz, Ar H, 1H), 5.77 (t, J 
= 5.8 Hz, Ar H, 2H), 3.25 (s, 6H), 2.77 (s, 6H), 2.47 (br s, 4H). Yellow crystals were 
obtained from a methanol solution affording the structure of complex 28Cl. 
 
[Ru{η6:κ1-C6H5(C6H4)NH2}(o-pda)Cl]Cl (29Cl). [Ru{η
6:κ1-C6H5(C6H4)NH2}(o-
pda)]Cl2 (3 mg, 0.007 mmol) was dissolved in methanol (0.6 mL). The solution was left 
to stand overnight to afford a mixture of complex 29 and the open-tether complex 29Cl. 
1
H NMR (400 MHz, MeOD-d4, δ): 7.47-7.43 (m, Ar H, 6H), 6.91 (dd, J = 8.1, 1.1 Hz, 
Ar H, 1H), 6.82 (t, J = 7.7, 1.2 Hz, Ar H, 1H), 6.23 (d, J = 5.9 Hz, Ar H, 2H), 6.10 (t, J 
= 5.7 Hz, Ar H, 1H), 5.82 (t, J = 5.7 Hz, Ar H, 2H). 
 
[Ru{η6:κ1-C6H5(C6H4)NH2}(dmphe)Cl]Cl (31Cl). [Ru{η
6:κ1-C6H5(C6H4)NH2}Cl2] 
(10 mg, 0.029 mmol) was suspended in dry methanol (2 mL). 1,2-
bis(dimethylphosphino)ethane (4.9 µL, 0.029 mmol) was added, and the mixture was 
stirred for 2 h under argon at room temperature. The solvent was removed on the rotary 
evaporator and the product was re-dissolved in 3 mL of ethanol. The resultant solution 
was filtered through a 0.45 µm syringe filter. The solvent was reduced to ca. 5% of its 
original volume, and diethyl ether (3 mL) was added. The sticky solid was sonicated to 
give a pale yellow precipitate, which was washed with diethyl ether and dried in 
vacuum. Yield: 7 mg (49 %). Elemental analysis: Cald for C18H27Cl2N3Ru (491.34): C, 
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44.00; H, 5.54; N, 2.85. Found: C, 41.2; H, 6.04; N, 2.17. 
1
H NMR (400 MHz, D2O, δ): 
7.40–7.33 (m, 2H), 7.00 (d, J = 7.9 Hz, Ar H, 2H), 6.89 (t, J = 6.3 Hz, Ar H, 1H), 6.36 
(d, J = 6.2 Hz, Ar H, 2H), 6.14 (t, J = 5.7 Hz, Ar H, 1H), 5.84 (t, J = 5.9 Hz, Ar H, 2H), 
2.05–1.17 (m, 16H). 
 
[Ru{η6:κ1-C6H5(C6H4)NH2}(tben)Cl]Cl (32Cl). [Ru{η
6:κ1-C6H5(C6H4)NH2}Cl2] (19 
mg, 0.056 mmol) was suspended in 4 mL of 1:1 (v/v) methanol/water. N,N'-di-tert-
butylethylenediamine (12.2 µL, 0.057 mmol) was added, and the mixture was stirred for 
6 h at room temperature. The solvent was removed on the rotary evaporator and the 
product was re-dissolved in 3 mL of ethanol. The resultant solution was filtered through 
a 0.45 µm syringe filter. The solvent was reduced to ca. 5% of its original volume, and 
diethyl ether (3 mL) was added. The sticky solid was sonicated to give a brown 
precipitate, which was washed with diethyl ether and dried in vacuum. Yield: 21 mg (72 
%). Elemental analysis: Cald for C22H35Cl2N3Ru (513.51): C, 51.46; H, 6.87; N, 8.18. 
Found: C, 46.84; H, 6.47; N, 6.57. 
1
H NMR (400 MHz, D2O, δ): 7.58 (dd, J = 7.7, 1.5 
Hz, Ar H, 2H), 7.34 (td, J = 7.7, 1.6 Hz, Ar H, 2H), 7.01 (td, J = 7.6, 1.1 Hz, Ar H, 2H), 
6.95 (dd, J = 8.1, 1.0 Hz, Ar H, 2H), 5.70–5.68 (m, 2H), 5.61–5.57 (m, 3H), 3.27 (s, 
4H), 1.36 (s, 18H). 
 
[Ru{η6:κ1-C6H5(C6H4)NH2}(bipy)Cl]Cl (33Cl). [Ru{η
6:κ1-C6H5(C6H4)NH2}Cl2] (25 
mg, 0.073 mmol) was suspended in 2 mL of methanol. 2,2'-bipyridyl (25 mg, 0.160 
mmol) was added dropwise, and the mixture was stirred for 2 h at 55 ºC. The solution 
turned dark red. The solvent was removed on the rotary evaporator and the product was 
re-dissolved in 2 mL of ethanol. The resultant solution was filtered through a 0.45 µm 
syringe filter. The solvent was reduced to ca. 5% of its original volume, and diethyl 
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ether (3 mL) was added. The sticky solid was sonicated to give a red precipitate, which 
was washed with diethyl ether and dried in vacuum. 
1
H NMR (400 MHz, MeOD-d4, δ): 
9.28 (d, J = 5.0 Hz, Ar H, 2H), 8.50 (d, J = 8.0 Hz, Ar H, 2H), 8.20 (td, J = 7.9, 1.4 Hz, 
Ar H, 2H), 7.63 (ddd, J = 7.3, 5.7, 1.3 Hz, Ar H, 2H), 7.19 (td, J = 1.5, 7.3, 5.9 Hz, Ar 
H, 1H), 7.03 (dd, J = 7.8, 1.4 Hz, Ar H, 1H), 6.87 (d, J = 7.3, 0.8 Hz, Ar H, 1H), 6.62 
(m, Ar H, 1H), 6.50 (d, J = 6.1 Hz, Ar H, 2H), 6.33 (t, J = 5.8 Hz, Ar H, 1H), 6.19 (t, J 
= 6.1 Hz, Ar H, 2H). 
 
NOTE: Isolation of complexes 25 and 26 as chloride salts proved difficult. Although 
they are readily obtained pure in water (full characterization was carried out in solution 
state, vide supra), removal of the solvent causes tether ring opening to afford 25Cl and 
26Cl up to ca. 50% as observed by 
1
H NMR. We suggest that an increase in the chloride 
concentration (present in solution as counterions of the Ru
II
 complexes) following 
solvent removal triggers the chloride nucleophilic attack on the ruthenium centre and 
subsequent opening of the tether ring. Isolation of pure 25 and 26 was possible as PF6
– 
salts. 
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4.1 Introduction 
 
In Chapter 3, we have presented the effect of chelating-ligand (XY) variation on the 
activation dynamics of [Ru{6:1-C6H5(C6H4)NH2}(XY)]
n+
 and showed how this 
activation is fully reversible and can be controlled by the choice of solvent. 
Additionally, in water the closure process is mediated by the aqua adduct, and 
reversibly controlled by the pH. However, the 2-aminobiphenyl system presents some 
limitations: (i) structurally -acceptor XY ligands compromise the stability of the Ru-
arene binding by withdrawing the electron density from the metal centre, (ii) the pH of 
activation regarding activation in water is very low, and (iii) the opening and closing 
processes in aqueous solution are so fast that the aqua intermediate, which is the active 
species, is not stable in solution, providing a narrow reactivity window. 
In this Chapter we present a family of tethered Ru
II
-arene complexes with a pendant 
carboxylic acid functionality. These tethered complexes form 5-member tether rings 
when closed, and the labile bond is Ru–Ocarboxylate. We have investigated the intricate 
aqueous behaviour of the system regarding the interconversion of the open and closed 
species in the pH scale 1–12. We have tested the cytotoxic activity of these complexes 
and since some appear to possess some cytotoxic activity even under conditions where 
the closed tether should predominate (inactive towards macromolecule interaction), we 
have tried to explain such activity on the basis of their capability as mediators in 
transfer hydrogenation reactions. 
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4.2 Results and Discussion 
 
4.2.1 Synthesis and Characterization 
 
Ruthenium(II) arene complexes with typical half-sandwich structure synthesized for 
this Chapter are shown in Chart 4.1. Complexes 20Cl and 35Cl–37Cl, containing 
ethylenediamine (en), o-phenylenediamine (o-pda), 1,10-phenanthroline (phen) and 
oxalate (oxo) as chelating ligands were synthesized as open-tether complexes, where the 
carboxylate group pendant from the 6-bound arene is protonated in its carboxylic acid 
form. These complexes bear a RuCl bond susceptible to hydrolysis. The Scheme 2.3 
displayed in Chapter 2 shows the synthetic route for obtaining these complexes, using 
dimer [Ru(η6-C6H5CH2COOH)(µ-Cl)Cl]2 (34dimer) as precursor. Complex 38, with 
N,N,N',N'-tetramethylethylenediamine (tmen) as chelating bidentate ligand, was 
however isolated and characterized as the closed-tether ruthenium(II) isomer, even 
following the similar synthetic procedure than for the open tether counterparts. In this 
complex the pendant carboxylate group has lost its proton and the negatively charged 
O
–
 of the carboxylate group is bound to the Ru
II
 centre, occupying one of the pseudo-
octahedral positions of the three-legged piano-stool structure.  
All complexes were prepared as chloride (or sodium in 37Cl) salts in good yields 
(57–91%) via the Cl-bridged dimer [Ru(η6-C6H5CH2COOH)(µ-Cl)Cl]2. The complexes 
exhibited good solubility in aqueous solution (up to 2 mM). They were characterized by 
elemental analysis, LC-MS, 
1
H NMR spectroscopy and/or X-ray crystallography. 
As a general feature, the 
1
H NMR spectra of open-tether complexes (20Cl and 35Cl–
37Cl) displayed distinct patterns for the resonances of the η6-bound arene protons in 
comparison to the equivalent protons in the closed-tether counterparts (37). The distance 
between the most deshielded and most shielded η6-bound arene signals spaned ca. 0.1–
0.4 ppm for open (20Cl and 35Cl–37Cl) and 0.9 ppm for the closed-tether (38) 
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complexes (Figure 4.1). We have observed similar features in the NMR spectra of 
complexes synthesized in Chapter 3 of general formula [Ru{6:1-
C6H5(C6H4)NH2}(XY)]
n+
 (XY = aliphatic diamine, o-phenylenediamine, oxalato, 
bis(phosphino)ethane). X-ray crystallographic data of these complexes confirmed 
unequivocally their structure.  
 
Chart 4.1. Ruthenium(II) arene complexes synthesized in this Chapter. The formal charge of 
the organometallic complexes is not specified for clarity. 
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Figure 4.1. 
1
H NMR spectra of complexes 20Cl and 38 in MeOD-d4 at 298 K. The selected 
spectral region shows the signals corresponding to the η6-bound arene protons (, ortho-; , 
meta-; and ▲, para-). (A) 1H NMR spectrum of open-tether chlorido complex 20Cl showing 
the typical short span between the meta- and para- peaks of the η6-bound arene. (B) Closed-
tether complex 38 shows a wider span in the signals corresponding to the η6-bound arene 
protons. This feature provides a useful tool to distinguish between open- and closed-tether 
analogous complexes.  
 
We determined the X-ray crystal structures of dimer [Ru(η6-C6H5CH2COOH)(µ-
Cl)Cl]2 (34dimer), and monomers [Ru(η
6
-C6H5CH2COOH)(en)Cl]Cl (20Cl), [Ru(η
6
-
C6H5CH2COOH)(phen)Cl]Cl (36Cl) and [Ru(η
6
-C6H5CH2COOH)(oxo)Cl]Na (37Cl). 
X-ray diffraction quality crystals of 38·PF6, [Ru(η
6
:1-C6H5CH2COO)(tmen)]PF6, were 
obtained by exchanging the chloride counterion in 38 by addition of excess (5 mol 
equiv) of ammonium hexafluorophosphate. To the best of our knowledge the crystal 
structures of these complexes, including the Ru
II
-arene dimer, are the first to be reported 
with phenylacetic acid η6-coordinated to ruthenium(II). Selected bond lengths and 
angles are shown in Table 4.1. Detailed crystallographic data are shown in Annex 1.  
Chlorido-bridged complex [Ru(η6-C6H5CH2COOH)(µ-Cl)Cl]2 (34dimer) crystallized 
as shown in Figure 4.2. Two chlorido ligands tie the ruthenium atoms together forming 
a central Ru2Cl2 rhombus. There is a centre of inversion located at the midpoint of the 
central Ru2Cl2 entity and the asymmetric cell contains two half molecules of [Ru(η
6
-
C6H5CH2COOH)(µ-Cl)Cl]2. The bonds between Ru1 and the bridging chloride ligands 
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are somewhat longer (2.4462(15) and 2.4450(14) Å) than those to the terminal one 
(2.4146(17) Å), feature usually observed for such dichlorido-bridged dimers, such as 
[(η6-C6Me6)RuCl2]2 (Ru–Cl(terminal), 2.394 Å, and Ru–Cl(bridge), 2.460 Å).
1
 
 
Table 4.1. Crystallographic selected bond lengths (Å) and angles (deg) for dimer [Ru(η6-
C6H5CH2COOH)(µ-Cl)Cl]2 (34dimer), and monomers [Ru(η
6
-C6H5CH2COOH)(en)Cl]Cl 
(20Cl), [Ru(η6-C6H5CH2COOH)(phen)Cl]Cl (36Cl), [Ru(η
6
-C6H5CH2COOH)(oxo)Cl]Na 
(37Cl), and [Ru(η6:1-C6H5CH2COO)(tmen)]PF6 (38·PF6). 
 
 
 
 
 
 
 
 
 
Bond / angle 34dimer 20Cl 36Cl 37Cl 38·PF6 
Ru–C6 2.168(6) 2.1819(19) 2.228(6) 2.170(17) 2.116(4) 
Ru–C5 2.162(6) 2.182(2) 2.206(7) 2.146(17) 2.168(5) 
Ru–C4 2.148(7) 2.202(2) 2.182(7) 2.161(18) 2.188(5) 
Ru–C3 2.169(4) 2.180(2) 2.188(8) 2.182(17) 2.211(5) 
Ru–C2 2.152(6) 2.186(2) 2.188(7) 2.170(15) 2.188(5) 
Ru–C1 2.163(6) 2.158(2) 2.190(7) 2.170(15) 2.178(5) 
Ru–centroid 1.644 1.666 1.688 1.651 1.659 
Ru–X 2.4462(15) 2.1255(17) 2.093(5) 2.094(11) 2.164(4) 
Ru–Y 2.4450(14) 2.1229(16) 2.090(5) 2.116(10) 2.187(4) 
Ru–Cl/O 2.4146(17) 2.4114(5) 2.3917(17) 2.398(5) 2.080(3) 
X-Ru-Y 81.24(5) 78.84(7) 77.5(2) 77.8(4) 80.51(16) 
X-Ru-Cl/O 87.46(6) 83.95(5) 85.36(16) 84.0(2) 84.58(14) 
Y-Ru-Cl/O 86.55(6) 85.10(5) 85.27(16) 84.2(3) 85.84(13) 
Ru-C6-C7 127.10 127.71 130.25 126.72 113.48 
C7-offset 0.087(+) 0.069(+) 0.018(+) 0.061(+) 0.548(+) 
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Figure 4.2. ORTEP representation (thermal ellipsoids drawn at 50% probability level), 
including atom numbering scheme, of the dimer precursor [Ru(η6-C6H5CH2COOH)(µ-Cl)Cl]2 
(34dimer). Hydrogen atoms have been removed for clarity, except those of the carboxylic-
tether group. 
 
Open-tether complexes 20Cl, 36Cl and 37Cl (Figure 4.3) adopted the typical pseudo-
octahedral three-legged piano stool geometry, with the metal π-bonded to the 
phenylacetic acid (the ―seat‖) and σ-bonded to a chlorido ligand and two donor atoms of 
the chelating ligand (the ―legs‖) common to other RuII 6-arene structures.2, 3 The Ru–C, 
Ru–centroid, Ru–Cl and Ru–XY bond lengths are in agreement with previously 
reported Ru
II
-arene analogues.
2-4
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Figure 4.3. X-ray structure and atom numbering schemes of the complexes [Ru(η6-
C6H5CH2COOH)(en)Cl]Cl (20Cl), [Ru(η
6
-C6H5CH2COOH)(phen)Cl]Cl (36Cl) and [Ru(η
6
-
C6H5CH2COOH)(oxo)Cl]Na (37Cl). Thermal ellipsoids show 50% probability. The hydrogen 
atoms and counter ions have been omitted for clarity (except hydrogen of the carboxylic tether 
group).  
 
 
The X-ray crystal structures of complexes 20Cl and 36Cl showed extensive H-
bonding, as observed before for this type of crystal structures.
5, 6
 The crystal structure of 
complex 36Cl also shows -stacking interactions between the central phen ring of two 
adjacent molecules (centroid-to-centroid distance is 3.504 Å; Figure 4.4).  
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Figure 4.4. Diagram showing π-stacking between the central ring of the phenanthroline ligand 
of adjacent molecules in the X-ray crystal structure of 36Cl. The centroids are separated by 
3.504 Å. The counter ions and hydrogen atoms (except hydrogens of the carboxylic-tether 
group) have been omitted for clarity. 
 
The structure of 37Cl showed dimer formation between equivalent molecules, held 
together by non-covalent interactions between oxygen atoms of bound oxalate with both 
sodium (as a counter ion) and solvent water molecules (distances within the range 
2.313–2.888 Å). Hydrogen-bond interactions between the hydrogen atom of the OH-
tethered group and solvent water molecules were present. Interestingly, hydrogen bonds 
were observed between arene C–H and O(oxo) of adjacent molecules (C–H···O 
distance 2.514 Å).  
X-ray diffraction data of suitable crystals were collected for the closed-tether complex 
38·PF6, [Ru(η
6
:1-C6H5CH2COO)(tmen)]PF6. Here we present the first crystal structure 
determined by X-ray diffraction of a η6:κ1-arene:carboxylate ruthenium(II) complex, 
and also the first Ru
II
 five-membered η6:κ1-arene:O chelate. Its structure and atom 
numbering scheme are shown in Figure 4.5. Selected bond angles and distances are 
included in Table 4.1. The complex adopted the expected pseudo-octahedral half-
sandwich geometry with the oxygen atom pendant from the η6-bound arene forming an 
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additional chelate, or tether ring, in the structure. No H-bonding nor intermolecular π-π 
stacking interactions were observed.  
 
Figure 4.5. X-ray structure and atom numbering scheme of the closed tether complex 
[Ru(η6:1-C6H5CH2COO)(tmen)]PF6 (38·PF6). Thermal ellipsoids show 50% probability. The 
hydrogen atoms and counter ions have been omitted for clarity. 
 
Structural analysis corroborates the strain in the closed-tether structure of complex 
38·PF6 compared to its related open complexes 20Cl, 36Cl and 37Cl. Not only a 
pronounced tilt in the η6-bound arene is observed (as indicated by the differences in the 
RuC3 versus RuC6 bond lengths; 2.211(5) vs 2.116(4) Å, respectively), but also 
there is a strong offset of C7 toward the Ru
II
 atom with regard to the plane that contains 
the η6-bound arene, 0.548 Å versus < 0.069 Å in the open-tether structures. A similar 
C7-offset in the range 0.4600.488 Å was found for closed complexes of general 
structure [Ru(η6:κ1-arene:NH2)(XY)]
2+
.
7
 The Ru-C6-C7 is also an important 
geometrical parameter discussed in previous Chapters and which correlates with the 
strain imposed on the arene by the tether arm, indicates that complex 38·PF6 presents a 
strained angle of 113.48º, while 20Cl, 36Cl and 37Cl have it in the range 126.72–
130.25º, very close to the non-strained 130º. These observations are in agreement with 
others Ru
II
 η6:κ1-arene:N closed tether complexes where the same angle for a five-
member tether ring has been found to range within 113114º.7  
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In general, we have found that η6:κ1-arene:O complexes present a weaker 
coordination to the ruthenium(II) centre by the Otether in comparison to the analogues 
investigated in Chapter 3 (Ntether),
8, 9
 which is particularly true for complexes with two-
carbon tether arms.
10
 This might explain why there are only few reported complexes 
with this type of tethered Ru
II
-arene bearing RuO coordination. 
 
4.2.2 Speciation in Water of the Tethered Ru
II
-arene 
Complexes and Interconversion of Open and Closed 
Species in Aqueous Solution 
 
The reactivity of Ru
II
 arene complexes is generally thought to involve aquation. The 
additional complexity of our systems due to the possibility of association/dissociation of 
the tether group to the ruthenium(II) centre proves the hydrolysis process rather 
attractive. To elucidate the aqueous behaviour of these Ru
II
-tethered complexes a series 
of experiments in water were carried out. 
Figure 4.6 shows the speciation percentage of open-tether-chlorido/open-tether-
aqua/closed-tether species) of complexes 20Cl and 35Cl–37Cl at equilibrium (24 h) in 
aqueous solution by 
1
H NMR. Closed-tether complex 38 was included for comparative 
reasons. After dissolving the complexes the pH of these solutions varied in the range 
2.4–2.8 as a result of the deprotonation of the dangling carboxylic acid in the tether.  
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Figure 4.6. Percentage of species (closed-, chlorido- and aqua-) as determined by 
1
H NMR after 
24 h (at equilibrium) when complexes 20Cl and 35Cl–37Cl and 38 were dissolved in D2O (pH 
in the range 2.4–2.8). 
 
For complexes 20Cl, 35Cl and 36Cl in D2O two major species were observed by 
1
H 
NMR immediately after dissolution (ca. 10 min); open-tether-chlorido complexes 20Cl, 
35Cl and 36Cl, and closed-tether complexes 20, 35 and 36, respectively. Over time, as 
the solution approaches equilibrium, Ru
II
-arene speciation evolved and a new species 
appeared in the 
1
H NMR spectra, which was attributed to the open-tether aqua 
complexes 20A, 35A and 36A and confirmed by addition of excess of chloride (Figure 
4.7 for aqueous equilibrium of complex 36Cl as an example). For complex 37Cl, the 
spectra show a majority of the open-tether aqua adduct 37A. The behaviour of 37Cl can 
be explained on the basis of an increased electron density at the metal centre due to the 
dianionic oxalate ligand, as well as stabilising interactions between hydrogen atoms of 
coordinated water and the oxygen atoms of the oxalato, which may be contributing to 
the high stabilization of the aqua adduct 37A. Complex 38 was dissolved in D2O to 
show no changes over time.  
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Figure 4.7. (A) 
1
H NMR spectra showing the different species obtained after dissolving 
complex 36Cl in a non-buffered aqueous solution (final pH = 2.7); (bottom spectrum) 
immediately after dissolving (ca. 10 min), (middle spectrum) at equilibrium after 24 h, (top 
spectrum) upon addition of 100 mM NaCl to the solution at equilibrium. (B) Scheme of the 
species that are observed in the 
1
H NMR regarding the dynamic equilibria of complex 36Cl 
resulting from its dissolution in water. 
 
4.2.2.1 pKa Determination 
 
Both the carboxylic acid group and the water ligand in the aqua adduct have key roles 
in the chelate ring-opening and closing (switchability) of our system: (i) the carboxylate 
binds to the Ru
II
 centre when deprotonated, while protonation renders it unable to metal 
coordination; and (ii) the aqua ligand in Ru–OH2 can be displaced making the Ru 
susceptible for nucleophilic attack, while Ru–OH is much less reactive. Given the 
complexity of our system in aqueous solution, we determined the pKa1 (of the pendant 
carboxylate) and pKa2 (of the OH2 ligand in the aqua adduct) of our complexes in order 
to understand their aqueous dynamics in the pH scale (0–12). 
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Scheme 4.1.  
 
In order to determine the pKa values of the OH2 ligand of the aqua adducts, as well as 
the deprotonation of the carboxylic group of the complexes under study in this Chapter, 
aqueous solutions of ca. 10 mM of the deuterated versions of [Ru(η6-
C6H5CH2COOH)(en)(OD2)]
2+ 
(20A),  [Ru(η6-C6H5CH2COOH)(phen)(OD2)]
2+ 
(36A) 
and [Ru(η6-C6H5CH2COOH)(oxo)(OD2)]
 
(37A) were prepared by addition of AgOTf to 
complexes 20Cl, 36Cl and 37Cl in D2O, and subsequent removal of the resulting AgCl 
precipitate. The pH was adjusted to <1. Changes in the 
1
H NMR chemical shifts of the 
Hmeta η
6
-arene protons of 20A, 36A and 37A were recorded at 298 K over the pH range 
0–12 by the addition of dilute NaOD (or DNO3 for adjustment purposes). Scheme 4.1 
shows the main species detected in the titration of complexes 20A, 36A and 37A.  
Variation of the pH led to interconversion between the species, which was fully 
reversible as shown by NMR spectroscopy. As an example, selected 
1
H NMR spectra 
for complex 36A in D2O are depicted in Figure 4.8A in the pH range 0.5–11.0. The 
aqua complex [Ru(η6-C6H5CH2COOH)(phen)(OH2)]
2+ 
(36A) predominates at low pH 
(0.5) and exhibits two deprotonation steps to afford [Ru(η6-
C6H5CH2COO)(phen)(OH2)]
+ 
(36B) and subsequently [Ru(η6-
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C6H5CH2COO)(phen)(OH)]
 
(36C). The chemical shift of the η6-bound arene protons in 
meta position were plotted against pH and the data were fitted to the Henderson-
Hasselbalch equation, from which the pKa values of both carboxylic group and 
coordinated water were determined (Figure 4.8B for complex 36A). It is worth 
mentioning that the closed-tether complex 36 is the mayor species in the range of pH ca. 
2–8, matching, as expected, the predominant presence of  species 36B (COO–/H2O). 
 
Figure 4.8. (A) pH dependency of the chemical shift of resonances corresponding to the meta 
η6-bound arene protons on the 1H NMR spectra of the different species resulting from the 
titration of the aqueous solution of complex 36A in D2O  (36A→ 36B →36C). As we go up in 
the pH scale complex 36 appears, as the major species in the range 2-8 where 36B is the 
preferred species in the acid/base equilibria of 36A (see Scheme 4.1) (B) The curve is a 
HendersonHasselbalch computer-best fit with pKa values of 2.8 (pKa1; carboxylic acid) and 7.3 
(pKa2; aqua adduct) for 36A.  
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The pKa1 and pKa2 values for the aqua adducts 20A, 36A and 37A are listed in Table 
2. The pKa1 values are ca. 1–1.5 units lower than that of the free arene ligand; 3.3, 2.8 
and 3.5, for complexes 20A, 36A and 37A, respectively (versus pKa 4.31 for the free 
ligand). This appears to suggest that electron density on the carboxylate pendant arm is 
more readily delocalized when phenylacetate is η6-coordinated to RuII. Since the pKa 
decreases in the order 37A (oxo) > 20A (en) > 36A (phen), this may imply that a better 
-acceptor chelating ligand (phen) aids such a delocalization. The pKa2 values measured 
for the coordinated water molecule to the ruthenium(II) centre (7.8, 7.3 and 8.5 for 20A, 
36A and 37A, respectively) increase in the same fashion, 37A (oxo) > 20A (en) > 36A 
(phen), which could be explained in a similar manner (coordinated water to 
ruthenium(II) bound to a π-acceptor group such as phenanthroline is more acidic). The 
pKa2 values found for these complexes are in the same range (ca. 8) than those reported 
for other Ru
II
 arene complexes of general formula [Ru(η6-arene)(XY)(OH2)]
2+ 
.
3, 4
  
 
Table 4.2. pKa values of the carboxylic group and the aqua ligand in complexes 20A, 36A and 
37A. 
 
 
 
 
 
In the pH range 0–7, the (more reactive) aqua adduct predominates. This reactivity 
might explain why deprotonation of the carboxylic acid (pH > 2) in 36A to produce 36B 
triggers the formation of the closed-tether complex 36 (via intramolecular re-
arrangement), which is susceptible at higher pH values to OH
–
 attack and eventually 
converts into 36C. The latter hydroxido complex predominates in alkaline solution at 
pH > 9. Closed-tether complex [Ru(η6:κ1-C6H5CH2COO)(phen)]
+
 (36) is present in 
Complex 
C(O)–OH 
(pKa1) 
Ru–OH2 
(pKa2) 
[Ru(η6-C6H5CH2COOH)(en)OH2]
2+
 (20A) 3.3 7.8 
[Ru(η6-C6H5CH2COOH)(phen)OH2]
2+
 (36A) 
 
2.8 7.3 
[Ru(η6-C6H5CH2COOH)(oxo)OH2] (37A) 3.5 8.5 
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solution in the pH range ca. 2–9. The assignment of these signals was confirmed by 
their pH titration curves. Closed-tether complex 38 remained unaltered in the pH range 
covered by our experiments; its 
1
H NMR spectra, as expected, showed no variations. 
Additionally, solutions of complexes 20Cl, 35Cl–37Cl and 38 were prepared 
containing 100 mM of NaCl at pH 7.3 using Na2HPO3/citric acid buffer (Figure 4.9A) 
to mimic extracellular conditions. 
1
H NMR spectra were recorded directly after sample 
preparation (10 min, 298 K) and after incubation for 24 h. As expected, chemical shifts 
of complexes 20Cl and 35Cl–37Cl showed no changes over 24 h, they did not 
hydrolyse nor form the closed form under these conditions, with the exception of 36Cl 
that exhibited ca. 10% of closed species (36). Complex 38 did not exhibit any changes. 
Finally, we observed the solutions of complexes 20Cl, 35Cl–37Cl and 38 upon 
chloride/chlorido sequestration with AgOTf (and subsequent AgCl removal; Figure 
4.9B). As expected, no presence of chlorido species was observed. Complexes bearing 
o-pda and phen favour the closed-tether species 35 and 36 while en and oxalato favour 
the aqua adduct 20A and 37A. No significant changes were observed for 38. We would 
have expected that total aquation would render the complexes susceptible towards 
carboxylate binding and tether-ring closure. However, we found the coexistence of open 
aqua and closed species at equilibrium. This is in contrast to the aqueous behaviour of 
analogous complexes of general formula [Ru{η6:1-C6H5(C6H4)NH2}(XY)]
2+
 described 
in Chapter 3.
 
For the latter, opening of the tether occurred at a pH lower than the pKa 
value.
7
 For the complexes in this Chapter however, the activation pH is up to one unit 
higher than the pKa. This indeed opens up a window for the interaction of the highly 
reactive Ru
II
-aqua adduct upon cell and nuclear internalization, where the chloride 
concentration drops significantly (from 100 mM to 23 mM in the cytosol, to 4 mM in 
the nucleus). 
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Figure 4.9. Different percentage of species (closed-, chlorido-, and aqua-) observed by 
1
H NMR 
after 24 h (at equilibrium) when complexes 20Cl, 35Cl–37Cl and 38 were dissolved in: (A) 
buffered D2O solution at pH 7.3 and 100 mM NaCl; and (B) D2O and upon addition of AgOTf 
(the pH of the solutions ranges between 2.6–3.3) and subsequent removal of AgCl. This bar 
chart shows that complexes 35 and 36 bearing -acceptor XY ligands favour the closed tether 
species, attributable to acidification of the metal centre. 
 
4.2.2.2  pH-Dependent Activation of Closed-Tether Complexes 
 
Following the understanding of the tether-ring closure and its dependence on pH, we 
wanted to investigate the reversibility of this process aiming at developing 
organometallics switchable between open and closed forms.  
Complex 38 was synthesized and isolated directly in its closed form. Closed tethered 
complexes 20 and 35–37 were isolated in solution state (> 90%) and characterized as 
described in the Experimental Section.  
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Acidic activation of closed-tether complexes 20, 36 and 38 to afford 20B/A, 36B/A 
and 38B/A was investigated at increasing proton concentration from pH ca. 7 and 
followed by 
1
H NMR spectroscopy. A new set of peaks assignable to open-tether aqua 
adducts (20A, 36A and 38A) appeared during the acidic titration of complexes over the 
pH range 7–0. As depicted in Figure 4.10, the three complexes underwent tether-ring 
opening to different extents following the titration where both [Ru(η6:κ1-
C6H5CH2COO)(XY)]
+ 
and [Ru(η6-C6H5CH2COOH)(XY)(OH2)]
2+ 
species coexisted at 
different ratios as a response to the concentration of protons in solution.  
 
Figure 4.10. Percentages of Ru
II
 open tether species corresponding to the activation of the 
complexes 20 (en), 36 (phen) and 38 (tmen), in aqueous solutions at different pH values in the 
acidic range 05. 
 
Lowering the pH to 4 resulted in a modest extent of activation of the Ru–Otether bond 
(ca. 2–12% of open-tether aqua species at equilibrium) for complexes 20 and 36. At pH 
3 the 
1
H NMR spectra showed some high-intensity peaks assignable to Ru
II
 open-tether 
complexes (13 and 29%, respectively). At pH 2 the percentages of species 20A and 36A 
are 42 and 64% respectively and below pH 1 the complexes are mostly present in 
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solution as the open aqua adducts. It is notable that complex 36 exhibited a modestly 
higher activation than 20, perhaps related to its capability as -acceptor that 
subsequently makes the metal more acidic. 
Complex 38 showed the smallest percentage of open species at equilibrium. A similar 
behaviour was observed in the activation of analogous complex [Ru{η6:k1-
C6H5(C6H4)NH2}(tmen)]
2+ 
bearing a different hemilabile ligand (2-aminobiphenyl) but 
the same XY chelating ligand (Chapter 3).
7
 The lack of reactivity can be attributed to 
the absence of H-bond formation capability by tmen, together with the higher steric 
hindrance in tmen Ru
II
 complexes for incoming nucleophiles. 
 
4.2.3 Cell Viability Studies 
 
Given the aqueous behaviour of our systems, we believed they would have little to no 
effect in cell growth. The cytotoxicity of complexes 20Cl, 35Cl–37Cl and 38 toward 
the human ovarian A2780 cancer cell line was investigated. Cisplatin was used as 
positive control, giving an IC50 value of 2.20.3 M. Complexes 36Cl, 37Cl and 38 did 
not have any effect on A2780 cancer cells at maximum concentrations of 200 M 
(Table 4.2). Complexes 20Cl and 35Cl, however, showed IC50 values of 130 and 117 
M, respectively. In general, the RuII complexes studied in this Chapter did not show a 
cytotoxic activity towards A2780 comparable to those related Ru
II
-arene complexes of 
the type developed by Sadler (IC50 close to that of cisplatin). Even for complexes 20Cl 
and 35Cl, their IC50 values are well above the values of complexes of similar 
structure.
11, 12
 The lack of activity was expected as it is attributable to the Ru
II
 
inactivation upon tether-ring closure, and subsequent incapability to bind to DNA. The 
mild cytotoxic activity shown by 20Cl and 35Cl was somewhat surprising. 
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Table 4.2. Cell viability data for the Ru
II
 complexes studied in this Chapter (20Cl, 35Cl–37Cl 
and 38)  in A2780 human ovarian cancer cells. 
Complex IC50 (M) 
20Cl 130.21.7 
35Cl 116.722.5 
36Cl >200 
37Cl >200 
38 >200 
cisplatin 2.20.3 
 
4.2.4 Catalytic Reduction of NAD
+
 to NADH and Possible 
Effect in Cells 
 
In order to gain additional information about the cytotoxicity of complexes 20Cl and 
35Cl, we looked into the possibility of our systems exerting catalytic activity within 
cells. Ruthenium(II) half sandwich complexes have previously been reported to catalyse 
the reduction of pyruvate to lactate, a reduction carried out in vivo by NADH as a 
cofactor for the enzyme lactate dehydrogenase.
13
 Additionally, they have been shown to 
reduce NAD
+
 via transfer hydrogenation using sodium formate (NaHCO2) as a hydride 
source.
14, 15
 
Inspired by these findings, conversion of pyruvate to lactate in the presence of sodium 
formate by our systems was investigated. Lactate formation mediated by complex 20Cl 
was followed by 
1
H NMR at a ratio 1:2:200, Ru:pyruvate:formate. 
1
H NMR spectra at 
310 K were recorded until completion of the reaction (ca. 42 h). Molar ratios of 
pyruvate and lactate were determined by integrating the signals of pyruvate (3H, singlet, 
2.36 ppm) and of lactate (1H, quartet, 4.11 ppm). After recording the initial spectrum 
(ca. 15 min) conversion to lactate was not identified. However, the percentage of lactate 
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increased to 67% after 18 h incubation. After 42 h of reaction almost total reduction 
(95%) of pyruvate to lactate was achieved (Figure 4.11).  
 
Figure 4.11. 
1
H NMR spectra showing the conversion of pyruvate to lactate mediated by 
complex 20Cl in the presence of NaHCO2 (mol ratio 1:2:200, Ru:pyruvate:formate) in D2O at 
310 K. 
 
We also investigated the catalytic conversion of NAD
+
 to NADH using complexes 
20Cl (because of its cytotoxicity) and 38 (because of its stability as a closed tether 
complex) in the presence of sodium formate as hydride source by 
1
H NMR 
spectroscopy in D2O.  
Complex 20Cl was reacted with AgOTf (2 mol equiv) to ensure full removal of 
chloride and .chlorido ligands. Subtraction of chloride has been reported to increase the 
catalytic activity of this class of Ru
II
 arene complexes because chloride may compete to 
a significant extent with formate for the catalytic binding site.
16
 The solution was mixed 
with NAD
+
 (23.2 mM) and sodium formate (2.3 M), final ratio 1:2:200, 
Ru:NAD
+
:formate. The pH of the reaction mixture was adjusted to 7.1 and the sample 
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incubated at 310 K. 
1
H NMR spectra were recorded over time for 42 h (Figure 4.12). 
The spectrum initially contained two major sets of peaks corresponding to the expected 
aqua-adduct/closed-tether complexes, and a third set of peaks attributed to the formation 
of the Ru
II
-formate adduct, [Ru(η6-C6H5CH2COOH)(en)(HCOO)]
+
. This adduct (Ru–
OOCH) is generated by the direct substitution of H2O by formate which binds through 
the negatively-charged carboxylate oxygen, as has been previously reported for similar 
metal complexes.
17
 The binding of formate to Ru
II
 was confirmed by the appearance of 
a sharp singlet at 8.20 ppm in the 
1
H NMR spectrum (free formate appears at 8.46 ppm). 
The high field shift has been previously observed for analogous Ru
II
 arene formate 
complexes.
18
 Within the first 3 h of reaction some additional changes were observed in 
the 
1
H NMR spectrum. These initially suggested the regioselective reduction of NAD
+
 
to 1,4-NADH as indicated by a decrease in the intensity of the signals of free NAD
+
 (H2 
at 9.31 ppm) and the sole appearance of new peaks assignable to 1,4-NADH (H2‘ at 
6.91 ppm and H4a/H4b at 2.70 ppm). The 
1
H NMR spectra within 18 h of reaction also 
revealed the emergence of a second singlet around 7.23 ppm that was assigned to the 
H2‘‘ of 1,6-NADH. After a total of 24 h, all NAD+ had been consumed. Analysis of the 
percentages of the reduced species at 24 h (52% for 1,4-NADH and 48% of 1,6-NADH) 
and at 42 h (32% for 1,4-NADH and 68% of 1,6-NADH) indicates the conversion of  
1,4-NADH to 1,6-NADH over time. In contrast to the findings by Sadler,13, 17 who 
found regioselectivity favouring 1,4- over 1,6-NADH, this result shows no selectivity, 
in fact 1,6-NADH predominates at longer reaction times, which is unusual. Eventhough 
the mechanism of the isomerisation favouring the thermodynamic product 1,6-NADH is 
unknown, it might have an impact inside the cell, whereby sequestration of the 
biologically active 1,4-NADH isomer might break the NAD
+
/NADH balance, necessary 
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for survival. No arene loss and no formation of RuH species were detected over this 
period.  
 
Figure 4.12. 
1
H NMR spectra recorded during the reaction of a 11.6 mM solution in D2O of 
[Ru(η6-C6H5CH2COOH)(en)Cl]
+ (20Cl) with NAD+ and NaHCO2 (molar ratio 1:2:200, 
respectively) at 310 K and pH ca. 7.1. NAD
+
 is labelled in red (H2); 1,4-NADH in green (H2‘), 
and 1,6-NADH in blue (H2‘‘). 
 
In contrast to 20Cl, the initial spectrum in the analogous experiment with complex 38 
contained only a set of signals corresponding to the closed tethered species. Signals 
attributable to the reduced species NADH appeared at 18 h of reaction (25% NAD
+
 
consumed). At 24 h only 33% of NAD
+
 had been reduced, and 59% at 42 h. As shown 
in Figure 4.13, the presence of formate appears to trigger ring opening in complex 38 
mediating the conversion of NAD
+
 to NADH, even though in a much lower percentage 
than 20Cl.  
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Figure 4.13. Plot showing the conversion of NAD
+
 to NADH versus time for the transfer 
hydrogenation of NAD
+
 (23.3 mM) using complexes 20Cl and 38 in presence of NaHCO2 (2.3 
M) in D2O at 310 K (pH ca. 7.1). 
 
A second series of experiments on the reduction of NAD
+
, varying the concentration 
of sodium formate, was performed for 20Cl (complex 20Cl, NAD
+
 and sodium formate 
in the ratio 1:2:X, X = 25, 100, 200 or 500 equiv). A notable increase in the catalytic 
activity was observed with increase of the hydride source sodium formate (Figure 
4.14A). The largest difference can be appreciated after 18 h where NAD
+ 
has been 
reduced in a 28, 68, 82 and 100 % for 25, 100, 200 and 500 equiv of formate. A second 
reduction product was detected in the later stages of the reaction, 1,6-NADH. 
Strikingly, regioselectivity towards 1,6-NADH was proved  to be formate concentration 
dependent (Figure 4.14B). The percentage of the latter isomer was determined to be as 
follows: 11, 31, 48 and 87% for 25, 100, 200 and 500 equiv of formate, respectively, 
after 24 h of reaction. Again, over time the 1,4-isomer seems to evolve to 1,6-NADH. In 
contrast to reported studies on analogous Ru
II
 arene complexes,
16
 the catalytic reduction 
of NAD
+
 in the presence of formate by complex 20Cl appear not to be regioselctive 
toward the 1,4-NADH isomer. The ratio of the formation of the hydrogenation products 
is dependent of the concentration of the hydride-source. Production of up to 25% of 1,6-
NADH has been observed for complexes of general formula [Ru(arene)(L-L)Cl] (where 
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arene = p-cymene or benzene and L-L = DPEN, 1,2-diphenyl-1,2-diaminoethane 
derivates).
19
  
 
Figure 4.14. (A) Conversion versus time plot for the transfer hydrogenation of NAD
+
 to NADH 
using complex 20Cl with different NaHCO2 concentrations in D2O at pH ca. 7 at 310 K. (B) 
Representation of the different percentages of the reduced species 1,4-NADH and 1,6-NADH as 
dependent on the formate concentration over 24 h at 310 K. 
 
These results make us think that the capability of undergoing transfer hydrogenation 
reactions might be responsible for the cell viability effect of 20Cl. Therefore, we 
decided to test the cytotoxic activity of 20Cl in A2780 again, this time in the presence 
of non-toxic doses of formate. Given the slow reaction of 20Cl with formate, we 
tailored the cytotoxicity protocol, avoiding cell washing after 24 h of drug exposure, 
and leaving the cells for 96 h exposed to the drugs. Cisplatin presented an IC50 value of 
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2.9 M and formate was completely innocuous at all concentrations tested. Under this 
protocol, the IC50 of 20Cl alone was determined to be 122 M. Co-incubation of 20Cl 
with 1 mM formate had no significant effect in its IC50 (3% decrease), while 2 mM of 
formate decreased the IC50 of 20Cl by 14% and 4 mM formate decreased the IC50 of 
20Cl by 24% (Figure 4.15). These results appear to indicate that the catalytic 
capabilities of these complexes might have an impact on their cytotoxicity. 
 
Figure 4.15. Cell viability – as dose response curves – of complex 20Cl when co-incubated 
with different concentrations (M) of sodium formate.  
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4.3 Conclusions 
 
In this Chapter we have described the first crystal structure of a 5-member tether ring 
with a Ru(6:1- arene:O) bond, showing the stability of our system.  
We pursue to develop reversible pH-triggered activation of complexes. In Chapter 3 
we had reported complexes of general formula [Ru{6:1-C6H5(C6H4)NH2}(XY)]
n+
, 
which undergo reversible activation at highly acidic pH (12). The complexes presented 
in this Chapter fulfil the main requirements of our goal, that is, complexes that show 
reversible pH-dependent responsiveness. Additionally, these complexes represent 
further advancement toward our aim: (i) the closed tether Ru
II
 complex can be activated 
(the tether ring opens up) at pH as high as 4 if we introduce the appropriate XY 
bidentate ligand in the structure (e.g., complex 36Cl); and (ii) the open-tether chlorido 
species coexists with its Ru
II
-aqua adduct counterpart, active toward biomolecule 
binding. We have studied the complexity of the speciation of this system, finding how 
to control what species predominates in aqueous solution. Control over the accessibility 
of a free pendant carboxylate on a ruthenium(II) arene is in fact highly attractive for 
further functionalization or labelling studies. 
Strikingly, complexes 20Cl and 35Cl, inactivated (closed tether) in aqueous solution 
at physiological pH, show micromolar cytotoxicity (range 100 M). We investigated the 
possible causes of such activity and found that perhaps intracellular hydrogen-transfer 
reactions could be implicated, since complex 20Cl seems to interact with formate to 
reduce both pyruvate and NAD
+
in solution, and co-incubation with non-toxic doses of 
formate in the cell viability test seemed to increase the cytotoxic activity of 20Cl. The 
reduction of NAD
+
 appears to produce 1,4-NADH and 1,6-NADH in a non-
regioselective manner, yet overtime the non-biologically active 1,6-NADH seems to 
predominate. The effects of complex 20Cl at the intracellular level might be related 
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with a decrease of the concentration of NAD
+
 to produce the non-biological active 
species as 1,6-NADH, disrupting numerous enzymatic processes that require the 1,4-
NADH as a cofactor.  
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4.4 Experimental Section 
 
4.4.1 Instrumentation 
 
NMR Spectroscopy, Mass Spectrometry, Elemental Analysis and pH 
Measurements have been described in Chapter 2. 
 
Single Crystal X-ray diffraction. Suitable crystals of compounds 20Cl, 34dimer, 
36Cl, 37Cl and 38 were coated with mineral oil and mounted on Mitegen MicroMounts. 
The samples were measured in a Bruker D8 KAPPA APEX II diffractometer with CCD 
area-detector, equipped with graphite-monochromated Mo Kα radiation (λ = 0.71073 
Å). The substantial redundancy in data allowed empirical absorption corrections 
(SADABS)
20
 to be applied using multiple measurements of symmetry-equivalent 
reflections. Raw intensity data frames were integrated with the SAINT program, which 
also applied corrections for Lorentz and polarization effects. The Bruker SHELXTL 
Software Package was used for space group determination, structure solution, and 
refinement.
21
 The space group determination was based on a check of the Laue 
symmetry, and systematic absences were confirmed using the structure solution. The 
structures were solved by direct methods (SHELXL-2014/7),
22, 23
 completed with 
different Fourier syntheses, and refined with full-matrix least-squares using SHELXS 
minimizing ω(Fo
2–Fc
2
)
2
. Weighted R factors (Rw) and goodness of fit (S) are based on 
F
2
; conventional R factors (R) are based on F. All non-hydrogen atoms were refined 
with anisotropic displacement parameters. Hydrogen atom positions were geometrically 
calculated and allowed to ride on their parent carbon or nitrogen atoms with fixed 
isotropic U. All scattering factors and anomalous dispersion factors are contained in the 
SHELXTL 6.10 program library.  
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CCDC identifiers are 1579131 (20Cl), 1579130 (34dimer), 1579138 (36Cl), 1579141 
(37Cl) and 1579135 (38), which contain the supplementary crystallographic data for 
this Chapter. These data are provided free of charge by the Cambridge Crystallographic 
Data Centre. 
 
4.4.2 Methods 
 
Calculation of pKa values. Complexes 20Cl, 36Cl and 37Cl were dissolved in D2O in 
the presence of AgOTf, AgCl was filtered off after stiring for 30 min and then the pH 
was adjusted to ca. 0.5 to afford aqua complexes [Ru(η6-C6H5CH2COOH)(en)(OH2)]
2+
 
(20A), [Ru(η6-C6H5CH2COOH)(phen)(OH2)]
2+
 (36A), and [Ru(η6-
C6H5CH2COOH)(oxo)(OH2)] (37A). pH titration curves were traced by plotting the 
variation of the 
1
H NMR chemical shifts of the aqua complexes over the pH range 012 
by the addition of dilute NaOD or DNO3. The pH titration curves were fitted to the 
Henderson–Hasselbalch equation using the OriginPro version 9.0 program (OriginLab, 
Northampton, MA), with the assumption that the observed chemical shifts are weighted 
averages according to the populations of the protonated and deprotonated species. The 
pKa values of both the pendant carboxylic group as well as the aqua ligand of the Ru
II
 
complexes 20A, 36A and 37A were determined from these plots. 
 
Hydrolysis. Aqueous solutions of the Ru
II
 complexes (ca. 6 mM at 298 K) were 
prepared by dissolving 20Cl, 35Cl–37Cl and 38 in D2O. 
1
H NMR spectra were 
recorded directly after sample preparation (data collection at ca. 10 min after 
dissolution) and after 24 h. Speciation of each complex into chlorido, aqua and closed-
tether species was quantified by integration of signals of Hm (meta proton of the η
6
-
arene) in the 
1
H NMR spectra. After equilibrium was reached (24 h), an excess of NaCl 
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(100 mM) was added and 
1
H NMR spectra were recorded after 24 h incubation. In 
another set of experiments for the speciation study in the absence of chloride ions, 
AgOTf (2 mol equiv for 20Cl, 35Cl and 36Cl, and 1 mol equiv for 37Cl and 38) was 
added to D2O solutions of 20Cl, 35Cl–37Cl and 38, which were left to stir for 30 min. 
After removal of AgCl precipitate by filtration the 
1
H NMR spectra were acquired, and 
again after 24 h. Finally, Na2HPO4/citric acid buffer was used to prepare pH 7.3 D2O 
solutions containing 100 mM of NaCl. Complexes 20Cl, 35Cl–37Cl and 38 were 
dissolved (ca. 6 mM) in the buffered solution and the 
1
H NMR spectra were acquired 
after dissolution and at 24 h at 298 K. 
 
Cell culture and cytotoxicity toward A2780 human ovarian cancer cell line. The 
A2780 ovarian cell line was obtained from Sigma-Aldrich. The cells were maintained in 
RPMI 1640 media, which was supplemented with 10% foetal calf serum, 1% L-
glutamine, and 1% penicillin/streptomycin. All cells were grown at 310 K in a 
humidified atmosphere containing 5% CO2. 
After plating, human ovarian A2780 cancer cells were treated with Ru
II
 complexes 
20Cl, 35Cl–37Cl and 38 on day two at concentrations ranging from 0.5 to 200 M. 
Cells were exposed to the complexes for 24 h, washed, supplied with fresh medium, and 
allowed to grow for three doubling times (72 h). The protein content was then measured 
(proportional to cell survival) using the sulforhodamine B (SRB) assay.
24
 The data were 
analysed using OriginPro. IC50 values were obtained from plots of the percentage 
survival of cells versus the logarithm of the concentration expressed in micromolar units 
and fitted to a sigmoidal curve. Cisplatin was used as a positive control (max DMSO 
concentration to aid metal complex solubility, 0.25%).  
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The protocol for co-incubation with formate was carried out as described above with 
the following modification: the incubation time was 96 h, followed by the SRB assay. 
The IC50 values of complex 20Cl (dose response curves) were determined at fixed 
concentrations of formate: 1.0, 2.0, and 4.0 mM. Cisplatin was used as a positive 
control (max DMSO concentration, 0.25%) in all the experiments. 
 
Transfer hydrogenation reactions. Pyruvate (2 mg, 0.018 mmol) was added to 700 L 
of a stock solution (12.9 mM) of complex 20A (prepared by reaction of 20 with of 2 
mol equiv of AgOTf at room temperature for 30 min followed by removal of AgCl). 
NaHCO2 (122 mg, 1.8 mmol) was then added to the mixture. Final concentrations were 
as follows: 20Cl, 12.9 mM; pyruvate 25.7 mM; NaHCO2 2.6 M; molar ratio 1:2:200. 
The pH of the solution was adjusted to ca. 7.1 by adding dilute solutions of NaOD and 
finely adjusting with DNO3. The mixture was stirred to dissolve the sodium formate and 
transferred into a 5 mm NMR tube. A series of 
1
H NMR spectra was then recorded at 
310 K at different time intervals up to 42 h. Percentages of the different species in 
solution (remaining substrate and product formed) were determined by integration of 
signals corresponding to pyruvate (3H, singlet, 2.36 ppm) and to lactate (1H, quartet, 
4.11 ppm). 
Experiments to investigate the conversion of NAD
+
 to NADH by complex 20A 
followed the same experimental protocol using pyruvate as substrate and the molar 
ratios were: 1:2:200 for 20Cl:NAD
+
:formate. Percentages of species of NAD
+
 and its 
reduced forms 1,4-NADH and 1,6-NADH were determined by integrating the signals 
corresponding to H2 of NAD
+
 (9.31 ppm), H2' of 1,4-NADH (6.91 ppm), and H2'' of 
1,6-NADH (7.23 ppm). Experiments to investigate the reactivity towards transfer 
hydrogenation reactions by complex 38 followed the same protocol. 
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4.4.3 Synthesis 
 
Complexes 20Cl and 35Cl–37Cl were synthesised as described below for the 
individual reactions. Complex 38 was synthesized and isolated directly in its closed 
form.  
Closed tethered complexes 20 and 35–37 were characterized in aqueous solution (vide 
infra). The complexes had been previously observed as part of a mixture of species by 
1
H NMR during the pH titrations (see main text), yet rapid total conversion from 20Cl, 
35Cl and 36Cl to closed-tether cations 20, 35 and 36 took place when solutions of 
hydroxo complexes (20C, 35C and 36C) at pH 12 were acidified to neutrality (pH ca. 
7). The increase in intensity of the proton resonance signals of the closed tether species 
was accompanied by a concurrent decrease in the intensity of peaks for hydroxo 
complexes, which disappeared altogether at about pH 6–7. The total conversion of 
complex 37Cl to form complex 37 was not achieved by this method (although 60% of 
37 was observed at equilibrium with its open-tether counterpart).  
 
[Ru(η6-C6H5CH2COOH)(µ-Cl)Cl]2 (34dimer). 2,5-Dihydrophenylacetic acid (400 
mg, 2.9 mmol) and RuCl33H2O (473 mg, 1.81 mmol) were suspended in 10 mL of 1:4 
(v/v) water/acetone in a closed pressure tube. The reaction mixture was heated at 100 ºC 
for 3 h. The red precipitate was filtered off, washed with cold ethanol and diethyl ether, 
and dried in vacuum. Yield: 445 mg, 80%. Elemental analysis: Cald. for 
C16H16Cl4O4Ru2 (616.24): C, 31.19; H, 2.62. Found: C, 31.66; H, 2.55.  
1
H NMR (400 
MHz, DMSO-d6, δ): 12.79 (br s, OH, 1H), 6.01 (t, J = 5.9 Hz, Ar H, 2H), 5.91 (d, J = 
6.1 Hz, Ar H, 2H), 5.83 (t, J = 5.6 Hz, Ar H, 1H), 3.49 (s, CH2, 2H). Suitable red 
crystals for X-ray diffraction were collected by filtration from the reaction mixture. 
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[Ru(η6-C6H5CH2COOH)(en)Cl]Cl (20Cl). [Ru(η
6
-C6H5CH2COOH)Cl2]2 (100 mg, 
0.162 mmol) was suspended in anhydrous ethanol (5 mL). Ethylenediamine (22 µL, 
0.324 mmol) was added, and the mixture was stirred for 2 h under reflux. The resultant 
yellow solution was filtered through a 0.45 µm syringe filter. The solvent was reduced 
to ca. 5% of its original volume, and diethyl ether (4 mL) was added. The sticky solid 
was sonicated to give a yellow precipitate, centrifuged, washed with diethyl ether and 
dried in vacuum. Yield: 96 mg (80%). Elemental analysis: Cald. for C10H16Cl2N2O2Ru 
(368.22): C, 31.10; H, 4.70; N, 7.25. Found: C, 32.54; H, 4.87; N, 7.83.
1
H NMR (400 
MHz, MeOD-d4, δ): 6.43 (br s, NH2, 2H), 5.75 (t, J = 5.7 Hz, Ar H, 2H), 5.67 (d, J = 5.7 
Hz, Ar H, 2H), 5.64 (t, J = 5.5 Hz, Ar H, 1H), 4.04 (br s, NH2, 2H), 3.57 (s, CH2, 2H), 
2.54–2.50 (m, 2H), 2.46–2.41 (m, 2H). ESI-MS (m/z): [M–Cl–H]+ calcd. for 
C10H15N2O2Ru, 297.0; found, 297.0. X-ray diffraction-quality crystals were grown from 
a methanol solution at ambient temperature over a period of 2 days.  
 
[Ru(η6:κ1-C6H5CH2COO)(en)]
+
 (20). During the aquation experiments carried out on 
complex 20Cl in the presence of AgOTf, intramolecular rearrangement afforded cation 
20, which was characterised in solution state. 
1
H NMR (400 MHz, D2O, δ): 6.08 (t, J = 
5.9 Hz, Ar H, 2H), 5.63 (d, J = 6.1 Hz, Ar H, 2H), 5.12 (t, J = 5.5 Hz, Ar H, 1H), 3.34 
(s, CH2, 2H), 2.56–2.39 (m, 4H). 
 
[Ru(η6-C6H5CH2COOH)(o-pda)Cl]Cl (35Cl). [Ru(η
6
-C6H5CH2COOH)Cl2]2 (60 mg, 
0.097 mmol) was suspended in 5 mL of 1:1 water/ethanol. o-phenylenediamine ( 22 mg,  
0.195 mmol) was added, and the mixture was stirred for 2 h at ambient temperature. 
The solvent was reduced to dryness and the remaining solid was redissolved in 2 mL of 
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ethanol. The resultant yellow solution was filtered through a 0.20 µm syringe filter.  The 
solvent was reduced to ca. 5% of its original volume, and diethyl ether (4 mL) was 
added. The sticky precipitate was sonicated to give a yellow solid, which was separated 
by centrifugation, washed with diethyl ether and dried in vacuum. Yield: 49 mg (61%). 
Elemental analysis: Cald. for C14H16Cl2N2O2Ru (416.26): C, 40.40; H, 3.87; N, 6.73. 
Found: C, 40.84; H, 3.87; N, 6.50.
1
H NMR (400 MHz, MeOD-d4, δ): 7.34–7.31 (m, 
2H), 7.26–7.23 (m, 2H), 5.84 (t, J = 5.7 Hz, Ar H, 2H), 5.79 (d, J = 5.7 Hz, Ar H, 2H), 
5.74 (t, J = 5.5 Hz, Ar H, 1H), 3.64 (s, CH2, 2H).  ESI-MS (m/z): [M–Cl–H]
+
 calcd. for 
C14H15N2O2Ru, 345.0; found, 345.0. 
 
[Ru(η6:κ1-C6H5CH2COO)(o-pda)]
+
 (35). During the aquation experiments carried out 
on complex 35Cl in the presence of AgOTf, intramolecular rearrangement afforded 
cation 35, which was characterised in solution state. 
1
H NMR (400 MHz, D2O, δ): 7.36–
7.27 (m, Ar H, 4H), 6.23 (t, J = 6.0 Hz, Ar H, 2H), 5.75 (d, J = 6.0 Hz, Ar H, 2H), 5.22 
(t, J = 5.6 Hz, Ar H, 1H), 3.77 (s, CH2, 2H). 
 
[Ru(η6-C6H5CH2COOH)(phen)Cl]Cl (36Cl). [Ru(η
6
-C6H5CH2COOH)Cl2]2 (60 mg, 
0.097 mmol) was suspended in ethanol (5 mL). 1,10-Phenanthroline (35 mg, 0.195 
mmol) was added, and the mixture was stirred for 2 h at ambient temperature. The 
solvent was reduced to dryness and redissolved in 2 mL of ethanol. The resultant yellow 
solution was filtered through a 0.20 µm syringe filter. The solvent was reduced to ca. 
5% of its original volume, and diethyl ether (4 mL) was added. The sticky precipitate 
was sonicated to give a pale yellow solid, which was separated by centrifugation, 
washed with diethyl ether and dried in vacuum. Yield: 86 mg (91%). Elemental 
analysis: Cald. for C20H16Cl2N2O2Ru (488.33): C, 49.19; H, 3.30; N, 5.74. Found: C, 
Chapter 4 
173 
49.37; H, 3.28; N, 5.71.
1
H NMR (400 MHz, MeOD-d4, δ): 9.86 (dd, J = 5.3, 1.2 Hz, Ar 
H, 2H), 8.83 (dd, J = 8.2, 1.2 Hz, Ar H, 2H), 8.20 (s, Ar H, 2H), 8.09 (dd, J = 8.2, 5.3 
Hz, Ar H, 2H), 6.33 (t, J = 6.1 Hz, Ar H, 2H), 6.25 (d, J = 6.1 Hz, Ar H, 2H), 5.94 (t, J 
= 5.7 Hz, Ar H, 1H), 3.71 (s, CH2, 2H).  ESI-MS (m/z): [M–Cl–H]
+
 calcd. for 
C20H15N2O2Ru, 417.0; found, 417.0. Crystals suitable for X-ray diffraction were 
obtained by slow evaporation from a methanol/diethyl ether solution of 36Cl at ambient 
temperature. 
 
[Ru(η6:κ1-C6H5CH2COO)(phen)]
+
 (36). During the aquation experiments carried out 
on complex 36Cl in the presence of AgOTf, intramolecular rearrangement afforded 
cation 36, which was characterised in solution state. 
1
H NMR (400 MHz, D2O, δ): 9.76 
(d, J = 5.0 Hz, Ar H, 2H), 8.73 (d, J = 8.1 Hz, Ar H, 2H), 8.08 (s, Ar H, 2H), 8.01 (m, 
Ar H, 2H), 6.55 (t, J = 6.0 Hz, Ar H, 2H), 6.13 (d, J = 6.5 Hz, Ar H, 2H),  5.23 (t, J = 
5.5 Hz, Ar H, 1H), 3.75 (s, CH2, 2H). 
 
[Ru(η6-C6H5CH2COOH)(oxo)Cl]Na (37Cl). [Ru(η
6
-C6H5CH2COOH)Cl2]2 (60 mg, 
0.097 mmol) was suspended in ethanol (5 mL). Sodium oxalate (26 mg, 0.195 mmol) 
was added, and the mixture was stirred for 2 h at ambient temperature. The solvent was 
reduced to dryness and redissolved in 2 mL of ethanol. The resultant yellow solution 
was filtered through a 0.20 µm syringe filter. The solvent was reduced to ca. 5% of its 
original volume, and diethyl ether (4 mL) was added. The sticky precipitate was 
sonicated to give an orange solid, which was separated by centrifugation, washed with 
diethyl ether and dried in vacuum. Yield: 44 mg (57%). Elemental analysis: Cald. for 
C10H10Cl3Na3O7Ru (518.57): C, 23.16; H, 1.94. Found: C, 24.85; H, 1.89. 
1
H NMR 
(400 MHz, MeOD-d4, δ): 5.83 (t, J = 5.8 Hz, Ar H, 2H), 5.68 (t, 5.6 Hz, Ar H, 1H), 5.61 
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(d, J = 6.1 Hz, Ar H, 2H), 3.60 (s, CH2, 2H).  ESI-MS (m/z): [M–ClH]
+
 calcd. for 
C10H9O6Ru, 326.9; found, 326.9. Yellow crystals grown from a warm methanol solution 
were suitable for X-ray diffraction studies. 
 
[Ru(η6:κ1-C6H5CH2COO)(oxo)]
-
 (37). During the aquation experiments carried out on 
complex 37Cl in the presence of AgOTf, intramolecular rearrangement afforded anion 
37, which was characterised in the solution state. 
1
H NMR (400 MHz, D2O, δ): 6.01 (t, J 
= 5.6 Hz, Ar H, 2H), 5.53 (d, J = 5.7 Hz, Ar H, 2H), 5.39 (t, J = 5.5 Hz, Ar H, 1H), 3.87 
(s, CH2, 2H).   
 
[Ru(η6:1-C6H5CH2COO)(tmen)]Cl (38). [Ru(η
6
-C6H5CH2COOH)Cl2]2 (60 mg, 0.097 
mmol) was suspended in 5 mL of 1:1 (v/v) water/ethanol. N,N,N´,N´-
Tetramethylethylenediamine (29 µL, 0.195 mmol) was added, and the mixture was 
stirred for 1 h at ambient temperature. The solvent was reduced to dryness and 
redissolved in 2 mL of ethanol. The resultant orange solution was filtered through a 
0.20 µm syringe filter. The solvent was reduced to ca. 5% of its original volume, and 
diethyl ether (4 mL) was added. The sticky precipitate was sonicated to give an orange 
solid, which was separated by centrifugation, washed with diethyl ether and dried in 
vacuum. Yield: 70 mg (85%). Elemental analysis: Cald for C14H23ClN2O2Ru (387.87): 
C, 39.63; H, 5.70; N, 6.60.  Found: C, 39.40; H, 5.98; N, 6.54. 
1
H NMR (400 MHz, 
MeOD-d4, δ): 6.31 (t, J = 6.0 Hz, Ar H, 2H), 5.62 (d, J = 6.4 Hz, Ar H, 2H), 5.46 (t, J = 
5.7 Hz, Ar H, 1H), 3.73 (s, CH2, 2H), 3.41 (s, 2CH3, 6H), 2.71 (s, 2CH3, 6H), 2.67–2.60 
(m, 2H), 2.40–2.33 (m, 2H). ESI-MS (m/z): [M]+ calcd. for C14H23N2O2Ru, 353.1; 
found, 353.1. Complex 38·PF6 with PF6

 as counterion was obtained by reaction of 
complex 38 with an excess of NH4PF6 in water. Precipitation of a yellow solid afforded 
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the desired product. Its 
1
H NMR spectrum was indistinguishable from that of the 
starting complex 38, confirming that the cationic complex remained unaltered.  
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5.1 Introduction 
 
In previous chapters, we have discussed the advantages of tethering the monodentate 
ligand (Z) to the Ru–arene structure. This appears to provide an attractive strategy to 
create not only pH-dependent complexes but also switchable compounds that turn-on 
and -off in a reversible manner. In fact, in Chapters 3 and 4 we have demonstrated the 
reversible activation of the Ru–Z bond in closed tethered complexes of formula 
[Ru{η6:κ1-C6H5(C6H4)NH2}(XY)]
n+ 
and [Ru(η6:1-C6H5CH2COO)(XY)]+ under acidic 
conditions (proton concentration dependent), where the activation dynamics could be 
modulated by rational variation of both the XY chelating ligand and the hemilabile 
ligand. 
Photochemical metal-ligand bond activation is an attractive approach for achieving 
the selective bond cleavage by the absorption of light, promoting the release of the 
leaving group and offering the possibility of controlling the location and timing activity 
of the metal complex.
1
 This requires breaking of the coordination bond by the use of 
high-energy UV-visible light photons. In addition, light is already used to treat certain 
cancers by means of the Food and Drug Administration-approved technique of 
photodynamic therapy (PDT).
2
 Some examples of half-sandwich Ru
II
 arene complexes, 
[Ru(η6-p-cym)(N,N‘)(Z)]2+ (where N,N‘ = bidentate chelated ligand, and Z = pyridine 
or a pyridine derivate) have been proved to be activated by UV-visible light to photo-
dissociate selectively the monodentate ligand (Z) in aqueous solution and in the 
presence of a nucleobase (9-ethylguanine or 9-ethyladenine).
3
  
With the aim of searching how structural features related to the tether ring can 
influence the stability and activation of these Ru
II 
arene complexes, in this Chapter we 
present the synthesis, spectroscopic data, activation studies at different pH values, and 
photochemical behaviour of two families of ruthenium(II) complexes containing 
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ethylenediamine (en) as chelating ligand: tethered Ru
II
 complexes  of general formula 
[Ru(η6:κ1-arene:N)(en)]2+, with 2-phenylethylamine, 2-benzylpyridine and 2-
aminobiphenyl as the arene:N ligand; and two of the corresponding un-tethered 
analogues with structure [Ru(η6-bz)(en)(L)]2+ where bz = benzene and L = 2-picoline or 
aniline. Additionally, DFT calculations performed by Prof. Luca Salassa (Donostia 
International Physics Center) have been employed to gain a deeper understanding on the 
light-mediated activation of such complexes. 
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5.2 Results and Discussion 
 
5.2.2 Synthesis and Characterization 
 
Five ruthenium(II) arene complexes were prepared in good yields (Figure 5.1). 
Closed-tether complexes 7·PF6, 9·PF6 and 13·PF6 (as hexafluorophosphate salts of the 
corresponding cationic complexes 7, 9 and 13, respectively) were synthesised according 
to previously reported methods,
4, 5
 using the benzoate dimer, [Ru(η6-etb)Cl2]2, as a 
precursor. As discussed in the previous Chapters, the hemilabile ligand (2-
phenylethylamine, 2-benzylpyridine or 2-aminobiphenyl) was added to a dichloroethane 
solution of [Ru(η6-etb)Cl2]2 and the reaction mixture was stirred at ambient temperature. 
The solution was then heated at 120 ºC and arene thermal displacement occurred to 
afford the precursor complexes of general formula [Ru(η6:κ1-arene:N)Cl2] in good 
yields over short periods of time (4–18 h). Subsequent reaction of the corresponding 
dichlorido complex with ethylenediamine (en) in methanol afforded complexes 7·PF6, 
9·PF6 and 13·PF6.  
 
 
Figure 5.1. Structure of the complexes studied in this Chapter. Complexes 7·PF6, 9·PF6 and 
13·PF6 are closed-tether complexes. Complexes 39·PF6 and 40·PF6 are the un-tethered versions 
of 9·PF6 and 13·PF6, respectively. 
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The 
1
H NMR spectra of closed tether complexes 7·PF6, 9·PF6 and 13·PF6 in D2O at 
298 K confirmed η6-coordination of the corresponding arene ligand to the metal by the 
observation of a typical NMR pattern of the η6-bound arene resonances containing three 
characteristic peaks (triplet:doublet:triplet in a ratio 2:2:1), which are upfield-shifted 
(ca. 1.8 ppm) in all cases in comparison to those of the free ligands. 
The large distance between the most deshielded and most shielded η6-bound arene 
signals (ca. 0.8 ppm) demonstrated coordination of the tethering nitrogen to the metal 
centre (closed-tether complex), as described in previous Chapters.
4
 The X-ray crystal 
structures of complexes 7 (complex 7 with Cl
–
 as counterion instead of PF6
–
) and 9·PF6 
unequivocally verified the structure of these complexes. The crystal structure of 
complex 13 was discussed in depth in Chapter 3.
4, 5
  
Dimer [Ru(η6-bz)Cl2]2 was synthesised following the reported synthesis by Heim et 
al.
6
 The synthetic route of complexes 39·PF6 and 40·PF6 involved the reaction of the 
benzene dimer [Ru(η6-bz)Cl2]2 with ethylenediamine (en) in methanol to afford 
complex [Ru(η6-bz)(en)Cl]Cl. Following a published procedure,3 reaction of the latter 
with AgPF6 in methanol, and in the presence of an excess of the appropriate ligand 2-
picoline (pic) or phenylamine (pha), led to the corresponding complexes [Ru(η6-bz)(en)( 
pic/pha)](PF6)2 (39·PF6 /40·PF6).  
The details for individual reactions are described in the Experimental Section. All 
complexes were characterised by elemental analysis, 
1
H NMR spectroscopy and LC/MS 
spectroscopy.  
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5.2.3 X-Ray Crystallography and Density Functional 
Theory Modelling 
 
The molecular and crystalline structures of compounds 7 and 9·PF6 were determined 
by single crystal X-ray diffraction. The new structures along with their atom numbering 
schemes are shown in Figure 5.2.  
 
Figure 5.2. ORTEP diagrams and atom numbering schemes for (A) [Ru{η6:κ1-
C6H5(CH2)2NH2}(en)]Cl2 (7) and (B) [Ru{η
6:κ1-C6H5(CH2)C5H4N}(en)](PF6)2 (9·PF6). The 
hydrogen atoms (with the exception of the NH2-tether protons in 7), counterions and solvent 
molecules have been omitted for clarity. 
 
The complexes adopted the typical ―piano stool‖ geometry of ruthenium(II) arene 
structures.
4, 7, 8
 The arene rings displayed the common π-bonded η6-coordination mode, 
whereas the ethylenediamine ligand adopted a bidentate-chelate coordination mode, 
occupying two coordination positions. The remaining site in the coordination sphere 
was occupied by the nitrogen atom pendant from the tethered arene. The chloride 
counterions in 7 was extensively involved in H-bonding with the NH2(tether) hydrogens 
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(N–H···Cl distances 2.310–2.406 Å) and to the hydrogens of the NH2(ethylenediamine) 
ligand (N–H···Cl distances in the range 2.325–2.433 Å). No H-bonding or π-π stacking 
interactions were presented in the crystal structure of 9·PF6. Selected bond lengths and 
angles are given in Table 5.1. This table includes reported X-ray data of complex 13
5
 
for comparison purposes. Relevant crystallographic parameters are listed in the 
Appendix II. 
Table 5.1. Selected bond lengths (Å) and angles (deg) for complexes 7, 9·PF6 and 13. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All complexes crystallized with four independent molecules in the unit cell. The Ru–
C(arene) bond lengths were in the range of 2.113(2)–2.206(2) Å. The Ru–centroid 
distances for the different complexes fell into a narrow interval (1.636–1.654 Å) and 
were similar to reported tethered complexes, such as [Ru{η6:κ1-C6H5(CH2)2NH2}Cl2],
9
 
[Ru{η6:κ1-C6Me5(CH2)C5H4N}Cl2]
10
 and [Ru{η6:κ1-C6H5(C6H4)NH2}(dach)]Cl2,
4
 with 
distances 1.631, 1.656, and 1.641 Å, for comparison with complex 7, 9·PF6 and 13·PF6, 
respectively. The Ru–N(en) distances were in the range 2.116(3)–2.1368(17) Å, and the 
Bond / angle 7 9·PF6 13
5
 
Ru–C6 2.125(2) 2.117(5) 2.115(13) 
Ru–C5 2.175(2) 2.182(5) 2.184(13) 
Ru–C4 2.186(2) 2.176(4) 2.207(14) 
Ru–C3 2.203(2) 2.195(5) 2.221(15) 
Ru–C2 2.183(2) 2.175(5) 2.198(13) 
Ru–C1 2.176(2) 2.163(5) 2.191(13) 
Ru–centroid 1.651 1.636 1.659 
Ru–N1 2.1269(17) 2.121(4) 2.144(11) 
Ru–N2 2.1238(17) 2.143(3) 2.148(11) 
Ru–N3 2.1258(19) 2.116(3) 2.161(11) 
N2-Ru-N3 79.85(7) 78.83(13) 80.4(4) 
N2-Ru-N1 89.87(6) 91.65(13) 88.2(4) 
N3-Ru-N1 86.63(7) 90.19(14) 88.0(4) 
Propeller twist 82.91 89.93 89.7 
Ru-C6-C7 114.49 114.44 112.99 
Offset C7
[a]
 0.444(+) 0.436(+) 0.488 (+) 
Sigma 1.78 5.95 0.75 
[a] Offset of C7 with respect to the plane formed by the bound 
arene (carbons C1C6); (+) toward ruthenium 
Chapter 5 
186 
Ru–N1(tether) distances varied from 2.121(4) to 2.1481(17) Å, also comparable to 
reported analogues. 
No major differences were observed between the structures of complexes 7, 9·PF6 
and 13. However, a smaller Ru-C6-C7 angle was observed in 13 versus 7 and 9·PF6 
(112.9 vs ca. 114.5º). The Ru-C6-C7 angle, where C6 is the arene carbon connected to 
the tether and C7 is the first carbon atom in the tether arm, is an important parameter 
which correlates with the strain imposed on the tether ring by the 5-member tether ring. 
It is interesting to note that while the non-strained Ru-C6-C7 angle lies around 130º,
5, 11
 
for complexes 7, 9·PF6 and 13 such an angle is significantly smaller (112.9–114.5º). 
This suggests that complex 13, with the smallest angle 112.9º, bears the highest strain of 
the series. Further evidence of the ring strain in the three closed-tether complexes can be 
observed by the offset of C7 with respect to the plane containing the bound arene, 
ranging 0.436–0.488 Å toward ruthenium (with again the longest offset for 13, 0.488 
Å), as well as by the tilt of the 6-bound arene, whereby the Ru–C3 distance was 
consistently longer than the Ru–C6 one throughout the series. 
Table 5.2 lists relevant bond lengths and structural parameters obtained for cations 7, 
9 and 13 using Density Functional Theory (DFT) calculations at the LC-WPBE/SDD/6-
31G** level. This method was selected after benchmarking the performance of five 
functional and five basis sets combinations against the X-ray structure of 9·PF6 
(Appendix III, Section A). We found a good agreement between the computed and X-
ray structures with differences in bond lengths smaller than 0.03 Å. The LC-
WPBE/SDD/6-31G** method was used for additional computational studies aimed at 
elucidating the photochemical behaviour of 7, 9 and 13 (vide infra). 
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Table 5.2. Calculated bond lengths (Å) and angles (deg) for complexes 7, 9 and 13 (ground 
state) using DFT at the LC-WPBE_SDD/6-31G** level. 
 
 
 
 
 
 
 
 
 
5.2.4 Aqueous Solution Chemistry of Non-Irradiated RuII 
Complexes 
 
5.2.4.1 Activation at Neutral pH 
We investigated how structural features (tethered versus un-tethered) influence the 
stability and activation profile of the Ru–N(tether) bond of RuII complexes.  
The aqueous solution chemistry of the complexes was studied by means of 
1
H NMR 
spectroscopy of the corresponding aqueous solutions (6 mM) at 298 K over 24 h at pH 7 
(Figure 5.3). The spectra of complexes 7·PF6, 9·PF6 and 13·PF6  initially contained one 
major set of peaks corresponding to cations [Ru{η6:κ1-C6H5(CH2)2NH2}(en)]
2+
, 
[Ru{η6:κ1-C6H5(CH2)C5H4N}(en)]
2+
 and [Ru{η6:κ1-C6H5(C6H4)NH2}(en)]
2+
, 
respectively. No changes were observed over 24 h, therefore no activation of the Ru–Z 
bond at this pH was observed (Figure 5.3A). The lack of changes in the 
1
H NMR also 
demonstrates the high stability of this type of compounds against hemilabile ligand loss 
under these conditions, contrary to analogous ruthenium(II) complexes,
12
 such as 
complex [Ru{η6:κ1-C6H5(CH2)2NH2}Cl2] that was reported to decompose in 
approximately 20% after 40 min in solution. 
Bond / angle 7 9 13 
Ru–centroid 1.654 1.650 1.653 
Ru–N1 2.145 2.157 2.133 
Ru–N2 2.131 2.132 2.114 
Ru–N3 2.128 2.128 2.143 
N2-Ru-N3 79.48 79.44 78.91 
N2-Ru-N1 89.86 89.51 89.31 
N3-Ru-N1 88.20 88.74 93.82 
Propeller twist 74.42 88.11 79.22 
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Figure 5.3. 
1
H NMR at t=15 min (bottom) and t=24 h (up) of (A) complexes 7·PF6, 9·PF6 and 
13·PF6, and (B) complexes 39·PF6 and 40·PF6; at pH 7 at 298 K. In (A) we show the NMR 
region corresponding to the η6-bound arene protons; while in (B) the NMR area corresponds to 
the bound/free aniline (for complex 39·PF6) and 2-picoline (for complex 40·PF6). Only 
complex 40·PF6 (bottom right) shows loss of monodentate ligand aniline (grey dots) over time. 
 
We also studied complexes 39·PF6 and 40·PF6 in aqueous solution by 
1
H NMR at 
298 K (Figure 5.3B). Complex 39·PF6, [Ru(η
6
-bz)(en)(pic)]
2+
, showed high stability 
over time towards aquation, comparable to its analogue closed-tether complex 9·PF6. 
Similar stability of related complexes containing pyridine derivatives, such as [Ru(η6-p-
cymene)(2,2'-bipyrimidine)(py)]
2+
, has been described in aqueous solution.
13
 Aquation 
of the Ru–Z bond was only observed for complex 40·PF6, and monodentate ligand 
aniline was released to afford the corresponding aqua complex [Ru(η6-bz)(en)OH2]
2+
 
(52% of aqua adduct was formed over 24 h). Reactivity toward aquation in complexes 
13·PF6 vs 40·PF6 supports the stability induced by tethering the monodentate ligand to 
the arene.  
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5.2.4.2 Activation at Acidic pH 
Acidic activation of the RuN(tether) bond was investigated at pH 0 over 24 h. 
Complexes 7·PF6, 9·PF6 and 13·PF6  were dissolved in D2O, the pH of their solutions 
was adjusted to 0. The 
1
H NMR spectra were recorded at 298 K immediately after pH 
adjustment (ca. 15 min) and after 24 h. Figure 5.4 shows the different extents of 
complex activation (percentage of open-tether versus closed-tether ring) as determined 
by integration of the meta proton of the η6-bound arene in the NMR spectra of both 
species.  
 
Figure 5.4. (A) Activation (tether-ring opening) of the RuN(tether) bond in complexes 7·PF6, 
9·PF6 and 13·PF6 upon acidification. (B) Percentage of conversion of closed-tether to open-
tether species at 15 min and 24 h at 298 K in water at pH 0.  
 
The resultant activated species were characterised as protonated open-tether species, 
of formula [Ru(η6-arene:NH3)(en)Cl]
2+
.
4
 After 15 min of acidification, the extent of 
activated (protonated open-tether) species followed the trend 13·PF6 > 9·PF6 >> 7·PF6 
(79, 10, 0%, respectively). However, when the equilibrium was reached at 24 h both 
complexes had fully converted to their activated counterparts, [Ru{η6-
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C6H5(CH2)C5H4NH}(en)Cl]
2+
 and [Ru{η6-C6H5(C6H4)NH3}(en)Cl]
2+
, and  only 3% of 
the activated complex, [Ru{η6-C6H5(CH2)2NH3}(en)Cl]
2+
, was observed for 7·PF6. The 
total conversion of closed tethered species into the protonated open tether Ru
II
 for 
complexes 9·PF6 and 13·PF6 led to determine the half-life time for the ring opening 
reaction by monitoring 0.2 mM solutions of the Ru
II
 complexes over 24 h by UV-visible 
spectroscopy (Figure 5.5). Data were fitted to a pseudo-first-order kinetic equation 
which yielded a half-life value of 208 min for 9·PF6 (44 min for complex 13 as 
determined in Chapter 3). The data revealed that activation (ring opening) of the Ru
II
 
complex 13·PF6 is much faster at acidic pH.  
 
 
Figure 5.5. (A) UV-visible spectra showing that the largest change in absorbance occurs at 263 
nm. (B) Change in absorbance at 263 nm over 20 h during the opening of complex 9·PF6, from 
which the kinetic data (t1/2 = 208 min) was determined. 
 
According to the results we can highlight the importance of two features affecting the 
ring-opening process: i) the nature of the donor tether atom, and ii) the ring structural 
constrain, including flexibility along the tethering arm. Total activation of complexes 
13·PF6 and 9·PF6 (aromatic amine) versus poor activation of 7·PF6 (aliphatic amine) 
may be indicative of the importance of the hybridization on the tethering nitrogen (sp
3
 
in 7·PF6, sp
2
 in 9·PF6,  and between sp
2
 and sp
3
, in 13·PF6),
14
 which subsequently 
affects the basicity of the resulting amine derivative (7·PF6 being the most basic of the 
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series). Additionally, the tether arm in 9·PF6 and 13·PF6 is less flexible than that of 
complex 7·PF6, supporting that rigidity of the tether chain plays an important role in 
promoting the activation of the Ru–Z bond. Consistently, the significant difference on 
the activation rate in 9·PF6 and 13·PF6 (10 vs 79% after 15 min, respectively) and the 
half-lives values (208 vs 44 min, respectively) correlate with a higher ring constrain 
imposed by a sp
2
-hybridization on the C7 atom in complex 13·PF6 versus a more 
flexible tether ring by the sp
3
-hybridization on C7 in complex 9·PF6.  
 
5.2.5 Aqueous Solution Chemistry of Light Irradiated 
RuII Complexes 
 
5.2.5.1 Activation at Neutral pH 
Given the extraordinary stability of the Ru–Z bond at neutral pH, we explored the 
possibility of using light to photo-trigger Ru–Z bond activation for complexes 7·PF6, 
9·PF6 and 13·PF6. Additionally, we compared such activation to complexes 39·PF6 and 
40·PF6 (un-tethered analogues of 9·PF6 and 13·PF6, respectively), in order to identify 
the importance of the tether chelate in the light-mediated process. Solutions of 0.4 mM 
of freshly dissolved complexes in D2O at 298 K were prepared. The pH of the solutions 
varied within the range 6.5–7.1. The activation dynamics under light irradiation were 
explored by means of UV-visible and 
1
H NMR spectroscopy.  
Before irradiation all complexes displayed transitions in the visible region assignable 
to MLCT (metal-ligand charge transfer) from the filled 4d orbitals of Ru
II
 to the empty 
π* ligand orbitals (4d6 Ru→ π*). TD-DFT calculations of singlet-singlet transitions are 
in qualitative agreement with this assignment although they fail to predict the lowest-
energy transitions responsible for the absorption bands at > 425 nm (Figure 5.6 and 
Appendix III, Section B). 
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Figure 5.6. Comparison between DFT functionals for the TD-DFT calculation of the singlet-
singlet transitions of complexes 7·PF6, 9·PF6 and 13·PF6 (A–C) and their theoretical UV-
visible absorption spectra. Calculated singlet-singlet electronic transitions are shown as vertical 
bars with heights equal to their oscillator strength. Normalized experimental spectra for the 
complexes are depicted with a black line. 
 
Upon irradiation changes appeared in the electronic absorption spectra for all 
complexes. When complex 7·PF6 was irradiated for 53 min overall (see irradiation 
protocol in the Experimental Section), the spectra showed an increase of the absorption 
features at 200–230 nm and 292 nm, Figure 5.7A. The free ligand 2-phenylethylamine 
shows a strong absorption bands at 258 nm (Figure 5.7B), which is not observed upon 
irradiation of 7·PF6. When the effects of irradiation on the solution were checked by 
1
H 
NMR, no changes were observed in the spectrum. 
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Figure 5.7. (A) Corresponding UV-visible difference spectra showing increase of the bands at < 
240 and 292 nm of a solution of complex 7·PF6 (0.4 mM) in D2O upon irradiation at 365 nm at 
pH 7. (B) UV-visible spectra of the hemilabile ligand 2-phenylethylamine recorded at different 
concentrations. It presents a strong absorption band at 258 nm. 
 
The electronic absorption spectrum in aqueous solution of 9·PF6 exhibited an increase 
in intensity of the bands at 210–240 nm and 333 nm, and a decrease at 270 nm, as 
indicated in Figure 5.8A, when the solution was irradiated at 365 nm (36 min overall 
light exposure). The free ligand 2-benzylpyridine shows a strong absorption bands at 
263 nm. This is not observed upon irradiation of 9·PF6. The changes were also followed 
by 
1
H NMR (Figure 5.8B). The spectra showed a number of new peaks of small 
intensity, which we could not assign to any known species. Some of the signals seem to 
appear in the π-bound ligand-to-metal arene region. We could not assign any of these 
signals to free 2-benzylpyridine. When a new 
1
H NMR spectrum was acquired after 
leaving the sample in the dark overnight, total disappearance of these peaks was 
observed. Additionally, peaks corresponding to the free tether ligand (2-benzylpyridine) 
appeared accounting for about a ca. 30% of hemilabile ligand loss. 
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Figure 5.8. (A) UV-visible difference spectra showing increase of the bands at 210–240 and 
333 nm, and a decrease at 270 nm, of a solution of complex 9·PF6 (0.4 mM) in D2O upon 
irradiation at 365 nm at pH 7. (B) 
1
H NMR spectra recorded at different stages of 
photoirradiation at 365 nm of the aqueous solution of 9·PF6 at 298 K. After irradiation (2160 
sec), appearance of (a) new species () could be observed. 
 
When the aqueous solution of 13·PF6 was photo-irradiated at different time intervals 
(40 min overall) at 365 nm, the electronic absorption spectra presented some changes 
(Figure 5.9A). Bands at 220–230 nm and 283 nm showed a high increase with time-
irradiation evolution. The UV-visible spectra of the free ligand 2-aminobiphenyl 
presented similar bands at 224 and 283 nm (Figure 5.9B). The release of the hemilabile 
ligand (2-aminobiphenyl) was confirmed following different stages of photo-irradiation 
at 365 nm by 
1
H NMR (Figure 5.10). Upon 27 min of irradiation 35% of initial complex 
13·PF6 had lost its tether ligand.  
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Figure 5.9. (A) Corresponding UV-visible difference spectra of a solution of complex 13·PF6 
(0.4 mM) in D2O upon irradiation at 365 nm at pH 7 showing increase of the bands at 220–230 
and 283 nm. (B) UV-visible spectra of the hemilabile ligand 2-aminobiphenyl recorded at 
different concentrations. It presents bands at 224 and 283 nm. 
 
 
Figure 5.10. 
1
H NMR spectra recorded during the photoirradiation protocol at 365 nm of an 
aqueous solution of 13·PF6 at 298 K: () [Ru{η
6
:1-C6H5(C6H4)NH2}(en)]
2+
, (▲) free 
hemilabile tether ligand (2-aminobiphenyl).
 
 
Results obtained from irradiation of complex 7·PF6 are in accordance with the acidic 
activation experiments concluding that this type of tethered Ru–arene complex bearing 
an aliphatic amine is the most stable of this series of compounds. Irradiation 
experiments performed for complex 9·PF6 suggest formation of new ruthenium(II) 
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meta-stable -bonded arene species which appear to reverse to 9·PF6 with time and/or 
afford the free ligand, once the irradiation has stopped. On the other hand, complex 
13·PF6 appears to not only activate the Ru–Z ligand but also the Ru–arene bonding, 
resulting in the loss the hemilabile ligand, perhaps affording in situ the corresponding 
aqua adduct [Ru(en)(OH2)4]
2+
.
15
 As observed for (non-irradiated) acidic activation at pH 
0, complex 13·PF6 seems more reactive than 9·PF6 upon irradiation.  
Next, we also compared the photochemistry of complex 9·PF6 with its analogous un-
tethered complex 39·PF6. A solution of 39·PF6 was irradiated for 52 min at 365 nm. 
The UV-visible spectra revealed an increase of the band at 298 nm and a decrease in 
bands at 210–220 and 269 nm (Figure 5.11A). 1H NMR spectra was recorded after 
irradiation (Figure 5.11B), showing three sets of benzene signals corresponding to 
complex 39·PF6 (80%), the aqua complex [Ru(η
6
-benzene)(en)(H2O)]
2+
 (17%; 
identified by the singlet at ca. 5.9 ppm), and free benzene (arene loss identified by the 
appearance of a singlet at 7.4 ppm; 3%). In comparison to its non-irradiated analogue 
experiment, the aquation process occurred only upon irradiation (it did not aquate in the 
dark). This finding shows that irradiation of complex 39·PF6 results in a Ru–Z bond 
activation. 
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Figure 5.11. (A) Corresponding UV-visible difference spectra of complex 39·PF6 (0.4 mM) in 
D2O upon irradiation at 365 nm at pH 7 showing increase of the band at 298 nm and a decrease 
in bands at 210–220 and 269 nm. (B) 1H NMR spectra of solution for complex 39·PF6 before 
and after irradiation: () intact complex 39·PF6, () aqua adduct [Ru(η
6
-
benzene)(en)(H2O)]
2+
, (♦) free benzene. 
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We also compared the photochemistry of complex 13·PF6 with its analogous un-
tethered complex 40·PF6. The UV-visible spectra of complex 40·PF6 showed an 
increase of bands at 229 and 286 nm, and decrease at 254 and 309 nm (Figure 5.12A) 
when the solution was irradiated at 365 nm (total of 57 min). As determined by the 
1
H 
NMR analysis, when 40·PF6 was photo-irradiated, it aquated within 57 min up to 37% 
(Figure 5.12B). Arene loss was observed but not accounting for more than 1%. In 
comparison to its non-irradiated analogue experiment, the aquation process was more 
efficient upon irradiation (it aquated only 13% in 3 h in the dark). These results show 
that while in complex 13·PF6 light-mediated activation occurs in two positions of the 
Ru
II
 coordination sphere (the arene and the monodentate ligand, i.e. hemilabile ligand 
loss), for its non-tethered analogue 40·PF6 virtually all activation occurred in the Ru–Z 
bond. This fact shows how tethering (or un-tethering) can influence on the selectivity 
towards activation sites on organometallic complexes. 
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Figure 5.12. (A) Corresponding UV-visible difference spectra of complex 40·PF6 (0.4 mM) in 
heavy water upon irradiation at 365 nm at pH 7 showing increase in bands at 229 and 286 nm, 
and decrease at 254 and 309 nm. (B) 
1
H NMR spectra of solution for complex 40·PF6 before 
and after irradiation: () intact complex 40·PF6, () aqua adduct [Ru(η
6
-
benzene)(en)(H2O)]
2+
, (▲) free phenylamine, (♦) free benzene. 
 
5.2.5.2 Activation of Complex 9·PF6 at pH 2 
In order to investigate the phenomena observed when complex 9·PF6 was irradiated 
at pH 7.0, i.e. the increase of bands at 210–240 nm and 333 nm in the electronic 
absorption spectra and the appearance of unknown photo-products by 
1
H NMR, we 
proceeded to photo-irradiate complex 9·PF6 at pH 2.0. Given that the pKa of the 
hemilabile ligand is 4.9 we thought that following photo-activation of the Ru–Z bond of 
complex 9·PF6 at pH < pKa (i.e., pH 2.0), could perhaps block the reversible 
coordination of Z toward the metal centre. 
An aqueous solution of complex 9·PF6 (0.4 mM) at pH 2.0 was photo-irradiated for 
34 min at 365 nm at 298 K. The UV-visible absorption spectrum indicated an increase 
in intensity of the band 333 nm (Figure 5.13A). The 
1
H NMR spectra showed no 
significant changes, while the UV-visible absorption spectrum recorded after the NMR 
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showed some regression of the band at 333 nm. These results are in accordance with 
those observed after irradiation at pH 7.0. 
Further irradiation (additional 70 min) resulted in a great increase of the band at 265 
nm, which matches that of free 2-benzylpyridine. The 
1
H NMR data recorded 
afterwards showed clear presence of the free ligand (Figure 5.13B). Strikingly, the UV-
visible absorption spectrum recorded after the NMR, again shows a slight decrease of 
the bands at 234 and 333 nm, yet the strong band at 265 nm, attributed to the free 
ligand, remains unaffected. 
Activation by light of 9·PF6 in acidic conditions confirms that a two-step process 
occurs, the reversible formation of non-characterised photoproducts, followed by 
hemilabile ligand loss if irradiation persists. 
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Figure 5.13. (A) Time evolution of the electronic absorption spectra of a solution of complex 
9·PF6 (0.4 mM) upon irradiation at 365 nm at pH 2.0. (B) 
1
H NMR spectra of complex 9·PF6 
() at different stages of irradiation indicating the appearance of free hemilabile ligand 2-
benzylpyridine (). 
 
5.2.6 Computational Studies 
Light irradiation experiments show that tether complexes 7·PF6, 9·PF6 and 13·PF6 
have different photochemical features with respect to their un-tethered analogues. 
Complexes 39·PF6 and 40·PF6 undergo preferential photo-dissociation of the 
monodentate ligand and minimal arene loss over prolonged irradiation. Conversely, 
complexes 7·PF6, 9·PF6 and 13·PF6 are subject to a more intricate photochemical 
process, which appear to involve a multistep dissociation of the hemilabile tether 
ligands. Nevertheless, the photo-stability of these tether derivatives is ultimately 
remarkable, considering that their decomposition into photoproducts upon prolonged 
irradiation at 365 nm is overall moderate. 
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We have employed DFT to gain insights in the excited state chemistry of complexes 
7, 9 and 13 with the aim of guiding future ultrafast spectroscopy studies and the design 
of new tether complexes. For this reason, we determined the two lowest-lying triplet 
excited states for these complexes and compared their geometries with their ground-
state structures (LC-WPBE/SDD/6-31G**). The interplay between these low energy 
excited states generally determines the photochemical behaviour of transition metal 
complexes.
16
 Table 5.3 reports selected bond distances for the excited states of 7, 9 and 
13, while Figure 5.14 shows the geometries of the complexes and spin density surfaces 
in the case of triplets. For 7, 9 and 13, both triplet states (LL1 and LL2) are of metal-
centred nature. LL1 has the lowest energy and corresponds to a distorted structure in 
which the -bonded region of the arene ligand displays strongly elongated Ru–C 
distances compared to the ground state (GS) geometry, which may suggest a hapticity 
interconversion.
17
 Ru–N1(Z) distances in LL1 are shorter than 2.15 Å, indicating a 
strong interaction between the metal centre and the tether arm. Although the distorted 
coordination of the arene may hint that LL1 is dissociative, the tight coordination of N1 
rather suggests that this is not the case. The second optimized triplet geometry, LL2, 
shows elongated Ru–N1(Z) distances for 7, 9 and 13 (> 2.57 Å). This finding is 
consistent with a dissociative excited state capable of promoting the tether ring-opening. 
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Table 5.3. Selected bond lengths (Å) for the DFT-optimized structures of 7, 9 and 13 in the 
ground state (GS) and the two lowest-lying triplet states (LL1 and LL2). 
 
  Bond 
Complex Ru–centroid Ru–N1 Ru–N2 Ru–N3 
7 
GS 1.654 2.145 2.131 2.128 
LL1 2.759 2.137 2.145 2.117 
LL2 1.842 2.571 2.121 2.123 
 
9 
GS 1.653 2.133 2.114 2.143 
LL1 2.734 2.112 2.141 2.141 
LL2 1.837 2.607 2.112 2.131 
 
13 
GS 1.650 2.157 2.132 2.128 
LL1 2.745 2.147 2.130 2.124 
LL2 1.831 2.622 2.117 2.125 
 
 
 
Figure 5.14. DFT-optimized structures for the ground state and the two lowest-lying triplet 
states of 7, 9 and 13· (LC-WPBE/SDD/6-31G**). 
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5.3 Conclusions 
 
Three different hemilabile ligands were used to prepare closed tethered complexes 
7·PF6, 9·PF6 and 13·PF6, aiming to fine-tune the activation of the Ru–Z bond of these 
types of promising switchable organoruthenium compounds. Also, we synthesised the 
un-tethered complexes 39·PF6 and 40·PF6, analogues to 9·PF6 and 13·PF6, 
respectively. The crystal structures of 7 and 9·PF6 have been elucidated by X-ray 
diffraction. Subsequent crystallographic analysis has provided critical information about 
geometrical parameters which are closely related with their activation capability. The 
activation studies have shown that tethered complexes 7·PF6, 9·PF6 and 13·PF6 can 
only be activated in acid environments, i.e.; they are stable at neutral pH but they afford 
the corresponding open chlorido protonated species in 1 M HCl solutions. The observed 
differences between the percentage of the activated forms (13·PF6 > 9·PF6 >> 7·PF6) 
has been attributed to the structural variation concerning the hemilabile ligands, 
demonstrating that aromatic amines (9·PF6 and 13·PF6) are more prone to trigger the 
dissociation from the ruthenium(II) centre than aliphatic amines (7·PF6). We have also 
shown that the rigidity of the tether arm provides an important feature for the ring 
opening process, making the process faster.  
Photo-irradiation of complexes 7·PF6, 9·PF6 and 13·PF6 was performed to attempt 
the activation of these tethered complexes at pH 7.0. Complex 7·PF6 was too stable to 
be activated by light as determined by 
1
H NMR. Irradiation for 9·PF6 showed the 
appearance of unidentified photoproducts which maintained the Ru–arene bond, and 
which reversed to the original complex after irradiation stopped, and/or triggered 
hemilabile ligand loss over time in the dark. Irradiation of complex 9·PF6 at pH 2.0 was 
conclusive to suggest a two-step activation process whereby the hemilabile ligand is 
eventually lost upon persistan irradiation. Upon irradiation of complex 13·PF6, 
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hemilabile ligand loss (Ru–Z and Ru–arene cleavage) was observed by UV-visible and 
1
H NMR. 
Regarding the comparison between the reactivity observed for tethered versus un-
tethered complexes a summary follows (Figure 5.15). In the dark, complexes 9·PF6 and 
39·PF6 showed that none of them was activated at pH 7.0. However, after irradiation 
the un-tethered complex 39·PF6 showed cleavage of the Ru–Z bond, while 9·PF6 
showed formation of uncharacterised species in a little extent (only extensive irradiation 
ultimately triggered loss of the hemilabile ligand). On other hand, closed tethered 
complex 13·PF6 was not activated while its un-tethered analogue 40·PF6 hydrolysed at 
neutral pH in the dark. Upon irradiation, complex 13·PF6 lost the hemilabile ligand 
(cleavage of Ru–Z and Ru–arene bonds) and 40·PF6 also hydrolysed (Ru–Z bond) yet 
much faster than without light.  
 
Figure 5.15. (A) Hemilabile ligand loss percentages for complexes 9·PF6 and 13·PF6 under 
photoactivation at 365 nm and in the dark at 298 K. (B) Activation of the Ru–Z bond of 
complexes 39·PF6 and 40·PF6 in dark and under light irradiation after ca. 30 min followed by 
1
H NMR 
 
The preliminary DFT work reported here highlights that the photochemistry of 7, 9 
and 13 is likely driven by two metal-centred excited states, which are (i) capable of 
inducing a change in the arene coordination mode of the Ru centre (LL1) and (ii) cause 
ring opening of the tether (LL2). Additional computational studies and ultrafast 
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spectroscopy are required to have a full understanding of the interplay between these 
two states, and ultimately control the photochemistry of these complexes.  
 
.   
Chapter 5 
207 
5.4 Experimental Section 
 
5.4.2  Instrumentation 
 
NMR Spectroscopy, Mass Spectrometry, Elemental Analysis and pH 
Measurements have been described in Chapter 2. 
 
X-Ray Crystallography. Suitable crystals of compounds 7 and 9·PF6, were coated 
with mineral oil and mounted on Mitegen MicroMounts. The samples were measured in 
a Bruker D8 KAPPA APEX II diffractometer with CCD area-detector, equipped with 
graphite-monochromated Mo Kα radiation (λ = 0.71073 Å). The substantial redundancy 
in data allowed empirical absorption corrections (SADABS)
18
 to be applied using 
multiple measurements of symmetry-equivalent reflections. Raw intensity data frames 
were integrated with the SAINT program, which also applied corrections for Lorentz 
and polarization effects. The Bruker SHELXTL Software Package was used for space 
group determination, structure solution, and refinement.
19
 The space group 
determination was based on a check of the Laue symmetry, and systematic absences 
were confirmed using the structure solution. The structures were solved by direct 
methods (SHELXL-2014/7),
20, 21
 completed with different Fourier syntheses, and 
refined with full-matrix least-squares using SHELXS minimizing ω(Fo
2
 – Fc
2
)
2
. 
Weighted R factors (Rw) and goodness of fit (S) are based on F
2
; conventional R factors 
(R) are based on F. All non-hydrogen atoms were refined with anisotropic displacement 
parameters. Hydrogen atom positions were geometrically calculated and allowed to ride 
on their parent carbon or nitrogen atoms with fixed isotropic U. All scattering factors 
and anomalous dispersion factors are contained in the SHELXTL 6.10 program library. 
The data were processed by the modelling program Mercury version 3.9 (CSD System). 
The crystal structures of compounds 7, and 9·PF6, have been deposited at the 
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Cambridge Crystallographic Data Centre with deposition numbers CCDC 1534181 and 
1579152, respectively. 
 
UV-visible Spectroscopy. UV-visible absorption spectra were recorded on a Cary 5000 
UV-Vis-NIR spectrophotometer (Agilent Technologies, CA) using 1 cm path length 
quartz cuvettes (800 L) provided with a Temperature Controller. Spectra were 
recorded at 298 K in heavy water from 800 to 200 nm. The data were processed using 
OriginPro version 9.0 (OriginLab, Northampton, MA). 
 
5.4.3 Methods 
 
Acidic Activation of Ru
II
 Complexes. The ring-opening process (via the Ru–Z bond) 
of tethered complexes 7·PF6, 9·PF6,  and 13·PF6 was monitored by 
1
H NMR in 
aqueous solutions at 298 K. After dissolving complexes (6–7 mM) in D2O at pH 7.1, 
DCl was used to adjust the pH close to 0. The relative percentages of closed- versus 
open-tether species were quantified by integration of peaks in the 
1
H NMR spectra. 
 
Photoirradiation of Ru
II
 Complexes. Aqueous solutions of Ru
II
 complexes (0.4 mM) 
were photo-irradiated at 298 K using a UVA lamp (λirr = 365 nm providing an average 
light power of 3 J cm
-2
 h
-1
) placed 20 cm from the cuvette or NMR tube. Light-
irradiated solutions were stored in the dark between measurements to minimize 
unwanted photoreactions.  
 
Computational Methods. Calculations were performed with the Gaussian 09 (G09) 
program package,
22
 employing the DFT and TD-DFT methods.
23, 24
Solvent effects were 
included using the polarizable continuum model (PCM method),
25, 26
 with water as 
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solvent. The LC-WPBE
27 
functional together with the SDD
 
pseudopotential (Ru)
28
 and 
6-31G** basis set (C H N)
29
 were selected after benchmarking their performance as 
reported in the Appendix III, Section A. 
Geometry optimizations were carried out without any symmetry constraints, the nature 
of all stationary points was confirmed by normal-mode analysis and no imaginary 
frequencies were found. 
The UV-Visible electronic absorption spectra were simulated by TD-DFT computing a 
total of 32 singlet excited states. The electronic distribution and the localization of the 
singlet and triplet excited states were visualized using electron density difference maps 
(EDDMs). GaussSum 2.2.5
30
 was used to simulate the theoretical UV-Visible spectra 
and for EDDMs calculations (Appendix III, Section B). Molecular graphics images 
were produced using the UCSF Chimera package from the Resource for Biocomputing, 
Visualization, and Informatics at the University of California, San Francisco (supported 
by NIH P41 RR001081).
31
  
 
5.4.4 Synthesis 
 
MATERIALS 
RuCl33H2O was acquired from Precious Metals Online. Benzoic acid, ethylenediamine, 
2-phenylethylamine, 2-benzylpydirine, phenylamine, 2-picoline and 1,4-cyclohexadiene 
were purchased from Sigma-Aldrich. Dichloroethane and magnesium were acquired 
from Acros Organics, and 2-aminobiphenyl, iodine, molecular sieves of 3 Å and silver 
hexafluorophosphate from Fisher. Ethanol, dry methanol, diethyl ether, tetrahydrofuran, 
sodium metal, hydrochloric acid 37% and sodium chloride were purchased from 
Sharlau. For NMR spectroscopy, the solvents used were MeOD-d4, dimethyl-d6 
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sulfoxide, deuterium oxide (D2O), deuterium chloride (DCl) and 1, 4-dioxane obtained 
from VWR International.  
 
PREPARATION OF COMPLEXES 
Complexes  [Ru(6-bz)Cl2]2
6
 and [Ru(6-bz)(en)Cl]Cl32 were prepared according to 
previously reported procedures. Complexes [Ru(6-etb)Cl2]2,
33
 [Ru{η6:κ1-
C6H5(C2H4)NH2}Cl2], [Ru{η
6:κ1-C6H5(C6H4)NH2}Cl2]
5, [Ru{η6:κ1-
C6H5(CH2)C5H4N}Cl2] and [Ru{η
6:κ1-C6H5(C6H4)NH2}(en)]Cl2
4
 (13) have been 
described in Chapter 2. 
 
[Ru{η6:κ1-C6H5(CH2)2NH2}(en)](PF6)2 (7·PF6). Ethylenediamine (17 L, 0.260 
mmol) was added to a suspension of [Ru(η6:κ1-C6H5(C2H4)NH2)Cl2] (64 mg, 0.220 
mmol) in dry methanol (2 mL). The reaction mixture was stirred at ambient temperature 
for 2 h. The solvent was removed in the rotary evaporator to give a yellow solid, which 
was redissolved in the minimum volume of ethanol. A small amount of suitable crystals 
of X-ray diffraction appeared (complex 7). Addition of an excess of NH4PF6 to the 
remaining ethanolic solution led precipitation of a yellow solid. Yield: 65 mg (52%). 
Elemental analysis: Cald for C10H19F12N3P2Ru (572,28): C, 20.99; H, 3.35; N, 7.34. 
Found: C, 20.35; H, 3.59; N, 7.12. 
1
H NMR (400 MHz, D2O, δ): 6.31 (br s, NH2, 2H), 
6.07 (t, J = 6.0 Hz, Ar H, 2H), 5.60 (d, J = 6.1 Hz, Ar H, 2H), 5.32 (t, J = 6.0 Hz, Ar H, 
1H), 3.84-3.70 (m, 2H), 2.73 (t, J = 6.7 Hz, Ar H, 2H), 2.65-2.55 (m, 2H), 2.44-2.33 (m, 
2H). ESI-MS (m/z): [M–H]+ calcd. for C10H18N3Ru, 282.0; found, 282.1. 
 
[Ru{η6:κ1-C6H5(CH2)C5H4N}(en)](PF6)2 (9·PF6). AgPF6 (51 mg, 0.201 mmol) was 
added to a solution of [Ru{η6:κ1-C6H5(CH2)C4H4N}Cl2] (33 mg, 0.096 mmol) in 
Chapter 5 
211 
anhydrous methanol. The reaction mixture was stirred for 2 h. Then, the precipitated 
AgCl was removed by filtration, and ethylenediamine (7 L, 0.106 mmol) was added to 
the remaining solution. The solvent was removed in the rotary evaporator after 2 h of 
reaction to give a yellow solid, which was re-dissolved in the minimum volume of 
ethanol, which was washed with ethanol and diethyl ether, and dried in vacuum. Yield: 
55 mg (83%). Elemental analysis: Cald for C14H19F12N3P2Ru (620.33): C, 27.11; H, 
3.09; N, 6.77. Found: C, 27.32; H, 3.09; N, 7.03. 
1
H NMR (400 MHz, D2O, δ): 8.00 (td, 
J = 7.8, 1.6 Hz, Ar H, 1H), 7.56 (d, J = 8.0 Hz, Ar H, 1H), 7.46 (d, J = 4.8 Hz, Ar H, 
1H), 7.41 (t, J = 7.0 Hz, Ar H, 1H),  6.27 (t, J = 6.0 Hz, Ar H, 2H), 5.95 (d, J = 6.2 Hz, 
Ar H, 2H), 5.45 (t, J = 5.7 Hz, Ar H, 1H), 4.44 (s, 2H), 2.90-2.81 (m, 4H). ESI-MS 
(m/z): [M–H]+ calcd. for C14H19N3Ru, 330.0; found, 330.1. 
 
[Ru{η6:κ1-C6H5(C6H4)NH2}(en)](PF6)2 (13·PF6). Complex 13, containing PF6 as 
counter anions, was obtained by dissolving [Ru{η6:κ1-C6H5(C6H4)NH2}(en)]Cl2
4
 with 
an excess of NH4PF6 in water. Precipitation of a yellow solid afforded the desire 
product. Its 
1
H NMR spectrum was indistinguishable from that of the starting complex, 
confirming that the cation [Ru{η6:κ1-C6H5(C6H4)NH2}(en)]
2+
 remained unaltered.  
 
Ru(η6-bz)(en)(C6H7N)](PF6)2 (39·PF6). Using an aluminium foil-covered flask, 
complex [Ru(6-bz)(en)Cl]Cl (37 mg, 0.118 mmol) and AgPF6 (61 mg,  0.236 mmol) in 
2 mL of methanol were stirred for 2 h at room temperature. Precipitated AgCl was then 
removed by filtration. A large excess of 2-picoline (119 L, 1.2 mmol) was added, and 
the mixture was left stirring at reflux for 16 h. The volume was reduced by rotary 
evaporation to ca. 5% of its original volume. Addition of diethyl ether (1 mL) afforded a 
precipitate that was collected by filtration and washed with portions of ethanol and 
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diethyl ether, and dried overnight in vacuum. Yield: 42 mg (57%). Elemental analysis: 
Cald for C14H21F12N3P2Ru (622,34): C, 27.02; H, 3.40; N, 6.75. Found: C, 26.70; H, 
3.72; N, 6.80. 
1
H NMR (400 MHz, D2O, δ): 8.64 (d, J = 5.9 Hz, Ar H, 1H), 7.91 (t, J = 
7.6 Hz, Ar H, 1H), 7.58 (d, J = 8.2 Hz, Ar H, 1H), 7.35 (t, J = 6.4 Hz, Ar H, 1H), 5.99 
(s, 6H), 2.80 (s, 3H), 2.76-2.47 (m, 4H). [M–L–H]+ calcd. for C8H14N2Ru, 239.0; found, 
239.0. 
 
[Ru(η6-bz)(en)(C6H5NH2)](PF6)2 (40·PF6). Using an aluminium foil-covered flask, a 
mixture containing complex [Ru(6-bz)(en)Cl]Cl (37 mg, 0.118 mmol) and AgPF6 (61 
mg,  0.236 mmol) in 2 mL of methanol was stirred for 2 h at room temperature. 
Precipitated AgCl was then removed by filtration. A large excess of phenylamine (109 
L, 1.200 mmol) was added, and the mixture was left stirring at reflux for 16 h. The 
volume was reduced by rotary evaporation to ca. 5% of its original volume. Addition of 
diethyl ether (1 mL) afforded a precipitate that was collected by filtration and washed 
with ethanol and diethyl ether, and dried overnight in vacuum. Yield: 34 mg (46%). 
Elemental analysis: Cald for C14H21F12N3P2Ru (622,34): C, 27.02; H, 3.40; N, 6.75. 
Found: C, 26.26; H, 3.62; N, 6.56. 
1
H NMR (400 MHz, D2O, δ): 7.47 (t, J = 8.2 Hz, Ar 
H, 2H), 7.31 (t, J = 7.4 Hz, Ar H, 1H), 7.46 (d, J = 8.7 Hz, Ar H, 2H), 5.67 (s, 6H), 
2.64-2.57 (m, 2H), 2.46-2.38 (m, 2H). [M–L–H]+ calcd. for C8H14N2Ru, 238.9; found, 
239.0. 
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6.1 Introduction  
 
There is a continuous interest in crystalline materials able to reversibly incorporate 
small molecules into the crystal lattice due to the potential impact they can have on 
several applications, such as gas storage/separation, heterogeneous catalysis, and 
development of sensors.
1
 Solid state reactions with vapours, a different type of solvent-
free reactions where there has been much effort toward the design of materials capable 
of interacting with a range of gases, including O2, N2, H2, NO, and CO, are uncommon 
in the field of organometallic chemistry.  
A very early example of solid state organometallic synthesis using solid-gas 
techniques was reported in the 1960s when the oxidative addition of various HX gases 
(HF, HCl, HBr, HI and H2S) to Vaska-type complexes IrX‘(CO)(PPh3)2 (X‘ = Cl, Br, I, 
SCN) was reported to form trans-Ir(PPh3)2(X‘)(CO)(H)(X).
2
 Similarly, addition of I2 to 
Pt(acac)2 (acac = acetylacetonate) formed the oxidative addition product trans-
PtI2(acac)2.
3
 More recently, an interesting example was reported in this area by van 
Koten for the uptake and release of SO2 by an organoplatinum complex involving the 
corresponding formation and cleavage of a coordination bond (Pt–S).4 Also, Brammer 
and co-workers
5-7
 have shown that the conversion of trans-[CuCl2(n-X-C5H4N)2] (n = 3, 
4; X = Cl, Br) with HCl gas to form [n-X-C5H4NH]2[CuCl4] can take place under solid-
state conditions. These reactions have been monitored by powder diffraction, including 
in situ powder synchrotron diffraction.  
Solid-state reactions reported for ruthenium(II) complexes have been scarce. Werner 
and co-workers published that addition of CO to a Ru
II
 complex that contains a 
hemilabile phosphine ether ligand
8, 9
 (P,O) results in the dissociation of the oxygen atom 
from the Ru
II
 centre,
10
 while McGee et al. have investigated crystalline solid reactions 
of ruthenium(II) complexes as potential benzene and oxygen sensors.
 11, 12 
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Nowadays, the detection of volatile organic compounds (VOCs) by simple means 
requiring only a low-cost technology is an attractive research target.
13
 In this context 
platinum(II)- and gold(I)-containing compounds are the two largest families of 
vapochromic substances, i.e. substances which change colour upon exposure to certain 
vapors,
14
 and whose transformation can be often detect even by the naked eye.  
With these findings in mind, in this Chapter, we describe the solid state reaction of the 
crystalline closed complexes of formula [Ru(η6:κ1-arene:N)Cl2], bearing as hemilabile 
ligands 2-aminobiphenyl and 2-benzylpyridine, with hydrated HCl vapour, which led to 
the dissociation of the nitrogen atom from the ruthenium(II) centre to afford the 
corresponding open tether complexes, [Ru(η6:κ1-arene:NH)Cl3], as characterized by 
powder X-ray diffraction. We examined the reversibility of the solid-vapour reaction in 
presence of a HCl capture agent such as AgPF6. Finally, we further investigated the 
possibility of closing the open species upon heat-mediated loss of HCl gas at different 
temperatures. The reversibility of the tether-ring opening and closure in the solid state 
of ruthenium(II) complexes of formula [Ru(η6:κ1-arene:N)Cl2] (where arene:N is 2-
aminobiphenyl and 2-benzylpyridine) was examined in detail using powder X-ray 
diffraction and thermogravimetric analysis, and the kinetic parameters of the tether ring 
closure were also determined. 
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6.2 Results and Discussion 
  
6.2.1 Synthesis of the RuII Complexes 
 
Dichlorido closed-tether complexes 41 and 42 of general formula [Ru(η6:κ1-
arene:N)Cl2] and their corresponding open-tether complexes, 41HCl and 42HCl, with 
formula [Ru(η6-arene:NH)Cl3] (Figure 6.1), were prepared by previously reported 
procedures.
15, 16
  
 
Figure 6.1. Structures of complexes synthesized in this Chapter. Complexes 41 and 42 were 
synthesised as closed-tether complexes while 41HCl and 42HCl are the related protonated 
open-tether complexes. 
 
Typically, dimer [RuCl2(η
6
-etb)]2 and the corresponding hemilabile ligand (2-
aminobiphenyl or 2-benzylpyridine, respectively) were suspended in 1,2-
dichloroethane. The mixture was stirred for 45 min at ambient temperature giving a dark 
red solution. THF was added, and the mixture degassed with argon for 30 min. The 
vessel was closed, and the reaction mixture heated under pressure at 393 K (5–16 h). 
The air-stable microcrystalline material was collected by filtration, washed with 
chloroform and diethyl ether, and dried in air yielding complexes 41 and 42. The 
counterparts open-tether complexes 41HCl and 42HCl were obtained when the 
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corresponding closed complex was suspended in concentrated HCl (37%) and let stir 
overnight at room temperature. Details of the amounts of reactants, volume of solvents, 
stirring times, and the nature of the product are described in the Experimental Section 
for the individual reactions, as well as any variation in the synthetic procedure.  
All complexes were insoluble in most common solvents, whereas related complexes, 
such as [Ru(6-biphenyl)(NH3)Cl2], [Ru{
6:κ1P-(S)-(2-biphenyl)P(OMe)Ph}Cl2] are 
reported to be soluble in water, dichloromethane and/or in chloroform.
17,18
 After 
prolonged sonication, dichlorido closed-tether complexes 41 and 42 appeared to 
dissolve in DMSO-d6 but detailed examination of the 
1
H NMR spectra showed a 
chemical shift pattern consistent with the dmso-adduct [Ru{η6-
C6H5(C6H4)NH2}(DMSO)Cl2],
15
 where the N(tether) has been displaced by a DMSO 
molecule. In fact, strongly coordinating solvents such as acetonitrile or DMSO are 
known to be capable to exchange N-ligands from Ru
II
 complexes such as [Ru (6-p-
cym)(MBZ)Cl2] where MBZ = non-symmetrical nitrogen-binding benzimidazole 
ligands or [Ru(6:κ1-PheOH)Cl2] where PheOH = phenylalanine.
19,20 
Because of the 
ability of some solvents to coordinate to the ruthenium(II) centre and the intrinsic lack 
of solubility of 41 and 42 in others, all complexes were further characterized by solid 
state techniques as elemental analysis, powder X-ray diffraction, thermogravimetric 
analysis and/or single crystal X-ray diffraction to confirm their structures.  
 
6.2.2 Single Crystal X-Ray Diffraction 
 
X-ray diffraction data of suitable crystals corresponding to closed-tether complexes 
were collected for [Ru{η6:κ1-C6H5(C6H4)NH2}Cl2] (41) and [Ru{η
6:κ1-
C6H5(CH2)C5H4N}Cl2] (42). The crystallographic analyses revealed that both 
complexes crystallized in the monoclinic P 21/n space group with four molecules in the 
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unit cell. ORTEP diagrams and atom numbering of 41 and 42 are shown in Figure 6.2. 
In these complexes, the coordination environment of the Ru
II 
atom retains the half-
sandwich geometry in which the η6-arene ligand occupies half of the coordination 
sphere (Ru–centroid distances of 1.631 Å for 41 and 42) using the typical hexahapto 
coordination mode. Two chlorides and a nitrogen atom from the pendant arm occupy 
the three remaining coordination sites. Selected bond lengths and angles are shown in 
Table 6.1, and detailed crystallographic data in Appendix II. Data of 41HCl,
15
 already 
reported, has been included for comparison purposes. 
 
Figure 6.2. Molecular structures and atom numbering of closed tether complexes (A) 
[Ru{η6:κ1-C6H5(C6H4)NH2}Cl2] (41) and (B) [Ru{η
6:κ1-C6H5(CH2)C5H4N}Cl2] (42). The 
hydrogen atoms have been ommited for clarity (except on Ntether in 41). 
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Table 6.1. Crystallographic selected bond lengths (Å) and angles (deg) for complexes 
[Ru{η6:κ1-C6H5(C6H4)NH2}Cl2] (41), [Ru{η
6:κ1-C6H5(C6H4)NH3}Cl3] (41HCl)
15
  and 
[Ru{η6:κ1-C6H5(CH2)C5H4N}Cl2] (42).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Ru–Cl bonds in complexes 41 [2.4193(7), 2.4126(7) Å] and 42 [2.4056(9), 
2.4224(8)] are within the range found for other ruthenium(II) arene complexes.
21
 The 
Ru–N bond in complex 41 is longer than that found in complex 42 where de N atom 
belongs to an aromatic pyridine ring [2.140(2) vs 2.127(3) Å, respectively]. This 
observation has been reported in related Ru
II
 structures.
22, 23
 The Ru–C(arene) bond 
lengths are in the range 2.090(3)–2.211(3) Å. A tilt in the η6-bound arene carbon is 
evidenced by the differences in the RuC3 versus RuC6 bond lengths [2.211(3) vs 
2.090(3) Å, and 2.189(3) vs 2.093(3) Å, for complexes 41 and 42, respectively]. A 
strong offset of C7 toward the Ru
II
 atom with regard to the plane that contains the η6-
bound arene, ca. 0.498 Å was observed for both complexes. A similar C7-offset in the 
range 0.4600.488 Å was found for closed complexes of general structure [Ru(η6:κ1-
arene:NH2)(XY)]
2+
.
16
 The Ru-C6-C7 angle, where C7 is the first carbon atom of the 
tether arm, is 113.43 and 115.18º for complexes 41 and 42, respectively. These 
Bond / angle 41 42 41HCl
15
 
Ru–C6 2.090(3) 2.093(3) 2.1970(18) 
Ru–C5 2.142(3) 2.146(4) 2.1798(18) 
Ru–C4 2.169(3) 2.165(3) 2.1799(18) 
Ru–C3 2.211(3) 2.189(3) 2.1591(18) 
Ru–C2 2.180(3) 2.174(4) 2.1707(18) 
Ru–C1 2.158(3) 2.164(4) 2.1721(19) 
Ru–centroid 1.631 1.631 1.647 
Ru–Cl1 2.4193(7) 2.4056(9) 2.4053(5) 
Ru–Cl2 2.4126(7) 2.4224(8) 2.4367(4) 
Ru–N1 2.140(2) 2.127(3) 2.4175(5) 
Cl1-Ru-Cl2 88.20(3) 88.32(3) 87.049(16) 
Cl1-Ru-N1 88.20(6) 86.08(8) 87.532(17) 
Cl2-Ru-N1 84.77(6) 91.00(8) 86.288(17) 
C7–offset[a] 0.497 (+) 0.498 (+) 0.014 (-) 
Ru-C6-C7 113.43 115.18 132.05 
[a] Offset of C7 with respect to the plane formed by the bound arene (carbons 
C1C6); (+) toward ruthenium, (-) away from ruthenium 
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observations are in agreement with others Ru
II
 η6:κ1-arene:N closed tether 
complexes where the same angle for a five-member tether ring has been found to range 
within 113115º.16, 20, 21, 24 The structural analysis comparison between the closed 
tethered complex 41 and the crystal structure of its related open complex 41HCl
15
 
shows a significant difference in the Ru-C6-C7 angle (ca. 114º for 41 and 132.05º for 
41HCl). This angle is an important geometrical parameter which correlates with the 
strain imposed on the arene by the tether arm. This suggests that the higher the Ru-C6-
C7 angle, less strain is imposed, as indicated by the similarity between this angle in 
41HCl and the angle observed for non-strained complexes (ca. 130º).  
 
6.1.1 Solid-state Reaction to Open Closed-Tethered 
Complexes 
Processes in the crystalline phase that involve substrate binding and release, and thus 
a change in the overall atom content within the unit cell are not very common in the 
organometallic field. Closed-tether complexes 41 and 42 were chosen to explore the 
possibility of activating ruthenium(II) organometallic compounds through a solid-state 
reaction consisting in tether-ring opening. This choice was based on the aqueous 
chemistry of their derivatives of formula [Ru(η6:κ1-arene:NH2)(XY)]
2+
 (where XY is a 
variety of bidentate ligands), since they showed tuneable reversible pH- and pCl-
dependent activation of the Ru–N(tether) bond.16 We believed they were good 
candidates as activatable molecules due to the lability of the Ru–N(tether) bond and the 
relative readiness to form single crystals. Since we had already observed this reaction in 
the solution state, HCl vapours were thought to be useful in order to promote inclusion 
of HCl and cleavage of the Ru–N bond to ultimately transform the complexes in their 
related open-tether species 41HCl and 42HCl (Figure 6.3).  
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Figure 6.3. Structural re-arrangement of closed complexes 41 or 42 after exposure to HCl 
vapours to afford open tether complexes (41HCl or 42HCl, respectively). Ru–N bond is cleaved 
while Ru–Cl and N–H bonds are formed. 
 
For this purpose, crystals of 41 and 42 were exposed to an atmosphere of concentrated 
aqueous HCl vapours in a sealed vessel at 298 K. The reaction was monitored by 
powder X-ray diffraction after 2 and 6 days of exposure to the acidic vapours. A colour 
change of the material (from yellow to red in both cases) seemed to indicate re-
arrangement of the ligands around the ruthenium(II) sphere (Figure 6.4). Analogous 
experiments using H2SO4 or HBr as inorganic acids did not result in a change in colour, 
so they were not used for further investigation. 
 
 
Figure 6.4. Solid-state reactions 41→ 41HCl and 42→ 42HCl led to a change in colour from 
yellow (closed-tether complex) to red (open-tether complex) after 6 days of exposure to HCl 
vapours. 
 
The powder X-ray diffraction analysis of the product obtained by the solid-gas 
reaction of 41 with HCl vapours is depicted in Figure 6.5. The patterns showed peaks 
Chapter 6 
226 
belonging to the starting complex which decreased significantly, while new signals 
corresponding to another crystalline phase appeared. The reaction had not reached 
completion within 2 days (ca. 30%), and 100% conversion could not be obtained by 
extending the period of reaction with the HCl vapours for 6 days (ca. 60% of 
conversion). Exposure of HCl vapours even during 27 days for complex 1 did still not 
show the full conversion (ca. 70%).  
 
Figure 6.5. Powder X-ray diffraction patterns monitoring  the solid-gas reaction of 41 with HCl 
vapours over time, to afford a mixture that contains remaining 41 and a product identified as 
41HCl (dotted lines). Powder X-ray diffraction patterns for 41 (bottom) and 41HCl (top) 
correspond to the complexes synthesised in bulk (and are in accordance with the patterns 
calculated from their single crystal X-ray structures). 
 
The identity of the new products was attributed to the open-tether species 41HCl. The 
powder diffraction pattern calculated on the basis of the crystal structure of 41HCl
15
 
was compared with that obtained by the solid-gas reaction and both corresponded to the 
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same crystalline structure, confirming that partial conversion of 41 to 41HCl under 
exposure of HCl vapours took place, as shown in Figure 6.5. The structural features of 
41 and 41HCl are known from single crystal X-ray analyses (Figure 6.6A–B). The 
powder diffraction diagram of the mixture could be used to determine the ratio of open 
and closed complexes because their patterns are very different. The precise composition 
of these mixtures was strongly dependent on the exposure time. 
 
Figure 6.6. Comparison between the powder pattern calculated on the basis of the single crystal 
structure of 41 (A), 41HCl (B) and 42 (C) and those determined experimentally on the powder 
of the complexes synthesized in bulk showing 10–25º 2θ intervals, where the signals of the two 
involved phases are well distinguishable.  
 
Figure 6.7 shows the powder X-ray diffraction patterns obtained by solid-gas reaction 
of complex 42 with HCl vapours. Contrary to complex 41, total consumption of 42 
occurred after 6 days of exposure to HCl vapours. The structural feature of 42 is also 
known from single crystal X-ray analyses (Figure 6.6C), yet not for 42HCl. A number 
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of attempts to grow X-ray quality single crystals of 42HCl were performed 
unsuccessfully. The pattern resulting for exposure of 42 for 6 days matched to that 
obtained for 42HCl synthesised in bulk, as shown in Figure 6.7, although traces of an 
additional phase was suggested by the appearance of some diffraction peaks of little 
intensity which are not present in the pattern of 42HCl. It is worth mentioning that these 
extra peaks disappeared when the tether-ring opening was reversed to the original 
closed-tether complex 42 (vide infra). 
 
Figure 6.7. Powder X-ray diffraction patterns monitoring of the solid-gas reaction of 42 with 
HCl vapours overtime. The patterns of 42 (bottom) and 42HCl (top) correspond to the 
complexes synthesised in bulk (pattern of 42 is in accordance with the patterns calculated from 
their single crystal X-ray structures). Dotted lines highlight the prsence of the major product in 
the mixture, 42HCl, at 2 and 6 days.  
 
Once the single crystals of 41 and 42 were exposed to acid vapours, transformation to 
41HCl and 42HCl implied formation of red crystalline powders that were no longer 
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suitable for a full single crystal X-ray analysis. The geometrical modification around 
ruthenium(II) was expected to affect the crystallinity. In fact, the loss of crystallinity is a 
typical event in solid state reactions because most chemical reactions cause considerable 
stress and intermolecular re-organization.
4
 The processes here explained involve 
multiple changes in covalent and coordinative bonding. Specifically, a HCl molecule is 
inserted into Ru–N bond requiring rupture of that coordinative bond and formation of 
coordination Ru–Cl and covalent N–H bonds. The crystalline products, 41HCl and 
42HCl, now contain three Ru–Cl bonds in an open-ring arrangement rather than two 
Ru–Cl and one Ru–N bonds in the closed tether-ring geometry of 41 and 42, consistent 
with the change in colour. Dissociation of the nitrogen atom from the ruthenium(II) 
centre is faster for complex 42. This finding is contrary to our previous results obtained 
in solution state for analogues complexes described in Chapter 5, where the Ru–
N(tether) bond cleavage was faster for the complex containing 2-aminobiphenyl as 
hemilabile ligand. This is consistent with previous reports that claim that solid-state 
reactions can promote different reactivity than that observed in the solution phase.
10
 
 
6.1.2 Solid-State Reaction to Close Open-Tether Complexes 
In order to explore the possibility of our system to undergo the reversed process, vials 
containing the red crystalline products obtained after treatment of 41 and 42 with HCl 
vapours for 6 days were exposed to a mixture 1:1 methanol/water solution of AgPF6 at 
298 K for 24 h. A significant colour change back to yellow was observed under 
microscope examination (Figure 6.8), suggesting the reversible formation of 41 and 42.  
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Figure 6.8. Microscopic images obtained for the solid-state reaction of single crystals of 41 and 
42 (yellow) with hydrated HCl vapours to afford complexes 41HCl and 42HCl (red), and 
reversible formation to 41 and 42 after exposure with hydrated AgPF6 (yellow; loss of 
crystallinity). 
 
Remarkably, structural determination of powder X-ray diffraction confirmed 
unequivocally the total reversibility of the process, reverting back to the original closed 
complexes 41 and 42, as depicted in Figure 6.9 and 6.10 for complex 41 and 42, 
respectively. Therefore, sequestration of proton and Cl
–
 ions by the AgPF6 vapours had 
promoted the extrusion of HCl from the open-tether complexes 41HCl and 42HCl. 
Elemental analysis also confirmed this finding. In the absence of a HCl capturing agent, 
no apparent reaction occurs in a sealed vessel.  
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Figure 6.9. Powder X-ray diffraction patterns demonstrating the capture and release of a 
chlorido ligand by complex 41. Complex 41 was exposed to HCl vapours for 6 days and new 
peaks corresponding to 41HCl appeared, affording a mixture containing both 41 and 41HCl. 
When this mixture was exposed to AgPF6 as a HCl capturing agent, peaks corresponding to 
41HCl disappeared completely, demonstrating reversibility of the solid-vapour reaction. 
 
 
Figure 6.10. Powder X-ray diffraction patterns demonstrating the capture and release of a 
chlorido ligand by complex 42. Complex 42 was totally consumed after exposure to HCl 
vapours for 6 days and new peaks corresponding to 42HCl appeared (traces of an intermediate 
phase were also observed). When this mixture was exposed to AgPF6 as a HCl capturing agent, 
all peaks disappeared completely to afford only peaks corresponding to complex 42, 
demonstrating reversibility of the solid-vapour reaction. 
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We were also interested in verifying the possibility of transforming open complexes 
41HCl and 42HCl into their counterparts closed complexes 41 and 42 by HCl extrusion 
by other means than using a HCl scavenger, but vacuum alone was not sufficient even if 
applied overnight. However, complete de-hydrochlorination could be achieved by 
heating the complexes for 16 h (at 373 and 423 K, for 41HCl and 42HCl, respectively) 
as suggested by a change in colour (Figure 6.11) and confirmed by the elemental 
analysis of the resulting crystalline powder. Powder X-ray diffraction patterns 
unequivocally demonstrated that the heating process led to complete regeneration of the 
original complexes 41 and 42. 
 
 
Figure 6.11. Colour changes observed after heating the open complexes 41HCl and 42HCl 
(red) at 373 K and 423 K, respectively, to afford closed tether complexes 41 and 42 (yellow).  
 
 Interestingly, when complex 41HCl was introduced in a sealed vessel close to a pH 
strip and then heated, the paper indicator changed to red, illustrating the loss of HCl 
molecules (Figure 6.12). These observations led us to investigate the reversibility of the 
reaction in depth, to examine the elimination of HCl more closely. In order to do that, 
the reversibility and kinetics of these crystalline-state reactions were further investigated 
by thermogravimetric analysis (TGA). 
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Figure 6.12. Images show complex 41HCl in a closed vial with a pH strip at 423 K. HCl 
elimination is indicated by coloration of the pH strip overtime. 
 
The loss of the corresponding HCl molecules to promote the conversion to the closed 
complexes and the kinetic parameters of the process were investigated by means of 
TGA for complexes 41HCl and 42HCl at different temperatures under a nitrogen 
atmosphere. The isothermal extrusion of HCl was carried out at 373, 378, 383 and 398 
K for 41HCl, and at 423, 433, 443 and 453 K for complex 42HCl over 400 min. The 
temperature dependency of the complete removal of HCl (and hence the re-generation 
of Ru–N(tether) bonds) for 41HCl and 42HCl is shown in Figure 6.13 and 6.14, 
respectively. Within all temperatures, a weight loss of 9.3% and 9.9% was recorded for 
41HCl and 42HCl, respectively, corresponding to the elimination of one molecule of 
HCl per formula unit. At temperatures lower than 348 K for 41HCl and 398 K for 
42HCl, almost no mass loss occurred.  
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Figure 6.13. Isothermal extrusion of HCl in complex 41HCl carried out at 373, 378, 383 and 
398 K. The graphic shows the weight loss with time, corresponding to one HCl molecule per 
formula unit. 
 
Figure 6.14. Isothermal extrusion of HCl in complex 42HCl carried out at 423, 433, 443 and 
453 K. The graphic shows the weight loss with time, corresponding to one HCl molecule per 
formula unit. 
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In each case the temperature dependency of the HCl loss followed first-order kinetics, 
corresponding to the rate constant k-HCl and half-lives listed in Table 6.2. The rate of 
conversion toward closed-tether complexes was found to be markedly temperature-
dependent, increasing with an increase in temperature. The rate constants varied one 
order of magnitude with increasing temperature from 373 K to 398 K for 41HCl 
(1.84·10
-4
 vs 3.34·10
-3
 s
-1
, respectively), and from 423 K to 453 K for 42HCl (2.66·10
-4
 
and 2.30·10
-3
 s
-1
, respectively). Moreover, these results show that the closure of the 
complex by extruding HCl molecules by heating is faster for 41HCl than for 42HCl.  
Table 6.2. Rate constants and half-lives obtained for the heat-mediated HCl elimination 
reaction for complexes 41HCl and 42HCl. 
41HCl 398 K 383 K 378 K 373 K 
k(s
-1
) 3.34E-03 5.61E-04 4.75E-04 1.84E-04 
t1/2(s) 207.31 1235.91 1457.75 3769.08 
r
2
 0.9944 0.9906 0.9813 0.9886 
 
42HCl 453 K 443 K 433 K 423 K 
k(s
-1
) 0.0023 0.0012 5.161E-4 2.661E-4 
t1/2(s) 301.87 579.58 1342.99 2604.83 
r
2
 0.99211 0.99309 0.99508 0.99265 
 
Contrary to 42, which was fully converted to its corresponding open complex 42HCl 
in 6 days, complex 41 could not be fully converted to 41HCl even after exposure of 27 
days. This is in accordance with the high rate constant obtained for the closure reaction 
to afford complex 41, showing a preference of complex 41 to be maintained in its 
closed form.  
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Determination of the rate constants at different temperatures allowed for 
determination of the activation energy (Ea), activation enthalpy (ΔH
†
) and activation 
entropy (ΔS†). The activation parameters resulting from the Arrhenius and Eyring plots 
for the de-hydrochlorination are listed in Table 6.3. The ΔS† term is very informative, 
since the activation entropies for 41HCl and 42HCl (41.76 and -49.72 J K
-1
 mol
-1
, 
respectively) can help determine whether the reaction occurs through an associative or 
dissociative mechanism.
25, 26
 The positive value obtained for 41HCl indicates that the 
closure reaction to afford closed complex 41 takes places via a dissociative mechanism, 
which shows an increase in the randomness when the complex reaches its transition 
state. Conversely, complex 42HCl appears to eliminate its HCl molecule via an 
associative mechanism due to the negative value obtained for the activated entropy, 
implicating that there are less molecules/ions present in the transition state than in the 
reactants, where the metal increases its coordination number in the activated complex.  
 
Table 6.3. Kinetics parameters obtained from the Arrhenius and Eyring plots for the HCl 
elimination reaction for complexes 41HCl and 42HCl. 
 
 
Ea (KJ mol
-1
) ΔH†(KJ mol-1) ΔS† (J K-1 mol-1) 
41HCl 137.18 133.95 41.76 
42HCl 116.49 112.86 -49.72 
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6.3 Conclusions  
 
We have described the synthesis of closed-tether complexes 41 and 42, and their 
counterparts open-tether complexes 41HCl and 42HCl. The crystallographic structures 
for 41 and 42 have been elucidated and discussed. The solid-state reaction of 41 and 42 
with vaporous HCl triggered the activation of the Ru–N(tether) bond to afford 41HCl 
and 42HCl, accompanied by a change in colour from yellow to red. Total activation for 
complex 41 was not achieved after 27 days (ca. 70%), contrary to 42 which after 6 days 
of exposure to HCl underwent total conversion. This suggests that complex 42 promotes 
the ring opening process more efficient than 41, contrary to studies in solution-state for 
investigated analogues previously inthis dissertation. Interestingly, the reaction in the 
solid state of open-tether complexes 41HCl and 42HCl with vaporous AgPF6 as a HCl-
capture agent promoted the completely reversible reaction toward the closed-tether 
analogues 41 and 42. Similar results were obtained through a heat-mediated reaction at 
373 K for 41HCl and 423 K for 42HCl, where the expected change in colour red to 
yellow also occurred. The loss of the corresponding HCl molecules to promote the 
conversion to the closed complexes and the kinetic parameters of the process showed 
that complex 42HCl requires a higher range of temperatures than that for 41HCl, to 
carried out the closure of the complex. In other words, 42HCl needed more energy to 
convert into 42, than 41HCl to convert into 41.The activation entropies for 41HCl and 
42HCl (41.76 and -49.72 J K
-1
 mol
-1
, respectively) seem to indicate that a dissociative 
mechanism occurs for the closure reaction of 41HCl, but an associative mechanism 
occurs for the elimination of the HCl molecule in 42HCl. This highlights how 
isostructural hemilabile ligands (but with different rigidity in the tether arm and 
different functional group coordinated to the metal centre, i.e. NH2 vs Npyr) can afford 
complexes with different mechanism for ring-closure reactions. These results describe 
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unprecedented HCl capturing and realising behaviour for ruthenium(II) complexes, 
phenomena that can be tuned via hemilabile ligand variation. Extensive investigations 
are planned in our laboratory to extend this study and clarify our understanding of the 
reaction mechanisms for the bond-breaking and bond-making steps in the described 
solid-state reactions. 
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6.4 Experimental Section 
 
6.4.1  Instrumentation 
 
NMR Spectroscopy and Elemental Analysis have been described in Chapter 2. 
 
Single Crystal X-ray Diffraction. Suitable crystals of compounds 41 and 42 were 
coated with mineral oil and mounted on Mitegen MicroMounts. The samples were 
measured in a Bruker D8 KAPPA APEX II diffractometer with CCD area-detector, 
equipped with graphite-monochromated Mo Kα radiation (λ = 0.71073 Å). The 
substantial redundancy in data allowed empirical absorption corrections (SADABS)
27
 to 
be applied using multiple measurements of symmetry-equivalent reflections. Raw 
intensity data frames were integrated with the SAINT program, which also applied 
corrections for Lorentz and polarization effects. The Bruker SHELXTL Software 
Package was used for space group determination, structure solution, and refinement.
28
 
The space group determination was based on a check of the Laue symmetry, and 
systematic absences were confirmed using the structure solution. The structures were 
solved by direct methods (SHELXL-2014/7),
29, 30
 completed with different Fourier 
syntheses, and refined with full-matrix least-squares using SHELXS minimizing ω(Fo
2–
Fc
2
)
2
. Weighted R factors (Rw) and goodness of fit (S) are based on F
2
; conventional R 
factors (R) are based on F. All non-hydrogen atoms were refined with anisotropic 
displacement parameters. Hydrogen atom positions were geometrically calculated and 
allowed to ride on their parent carbon or nitrogen atoms with fixed isotropic U. All 
scattering factors and anomalous dispersion factors are contained in the SHELXTL 6.10 
program library.  
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CCDC identifiers are 1812917 and 1523006 for 41 and 42, respectively. These data are 
provided free of charge by The Cambridge Crystallographic Data Centre. 
 
Powder X-ray diffraction. All of the samples were lightly ground in an agate mortar. 
Powder X-ray diffractograms were collected at ambient temperature on a Panalytical 
X‘Pert PRO diffractometer (Cu-Kα1 X-radiation, λ1 = 1.5406 Å) equipped with a 
X‘Celerator detector and a flat-plate sample holder Bragg-Brentano para-focusing 
optics configuration (45 kV, 40 mA). Intensity data were collected by the step-counting 
method (step 0.0167º), in continuous mode, in the 10 ≤ 2θ ≤ 60º range. The program 
Mercury was used for calculation of powder X-ray patterns. 
 
Thermogravimetric analysis. TGA studies were carried out using a TA Instruments 
TGAQ500 system under nitrogen atmosphere with a flow rate of 10 mL/min. The 
sample size used for each isothermal TG run was kept small and relatively constant 
(0.5–1.1 mg) for each experiment. The material was evenly spread at the bottom of the 
pan before being placed in the TG instrument to ensure consistent and reproducible 
results.  
 
Solid-state reactions. Exposure to the hydrated HCl vapours was carried out by placing 
a small vial, containing the powder sample of complexes 41 or 42, in a cylindrical bottle 
containing 5 mL of the acid aqueous solution (HCl, 37%) at room temperature for the 
days described for each particular experiment. The powder and the solution were not in 
contact. The reaction took place in a closed system. A change of colour of the powder 
from yellow to orange occurred within hours, yet the samples were allowed to react for 
6 days, time during which the powder became red in colour.  
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Solid-state reactions with AgPF6 were carried out as follows. A vial containing powder 
Ru
II
 complex 41HCl or 42HCl was introduced in a cylindrical bottle with 130 mg of 
AgPF6 dissolved in a 1:1 mixture water/methanol solution (5 mL). The powder and the 
solution were not in contact. The reaction took place over 24 h inside a closed system, 
showing a change in colour over time. 
Heat-mediated reactions of complex 41HCl at 373 K and 42HCl at 423 K in the solid 
state were carried out as follows. The crystalline powder was spread over a glass holder 
which was placed on a heating plate at the desire temperature overnight. The reaction 
took place in an open system and the solids changed colour from red to yellow. 
 
6.4.2 Synthesis 
 
MATERIALS 
 
RuCl33H2O was acquired from Precious Metals Online and Johnson Matthey Fine 
Chemicals. Ethyl benzoate was adquired from Sigma Aldrich. Dichloroethane, 2-
aminobiphenyl, 2-benzylpyridine, silver hexafluorophosphate and hydrochloride acid 
37% were purchased from Acros Organics, and iodine from Fisher. Ethanol, dry 
methanol, diethyl ether, tetrahydrofuran and sodium metal were purchased from 
Sharlau. For NMR spectroscopy, the solvent used was DMSO-d6 from VWR 
International.  
 
PREPARATION OF COMPLEXES 
The Ru
II
 dimer [Ru(6-etb)Cl2]2 where etb is ethyl benzoate was synthesized following 
the reported synthesis by Habtemariam et al..
31
 and is described in Chapter 2. The 
dichlorido complexes [Ru{η6:κ1-C6H5(C6H4)NH2}Cl2] (41) and [Ru{η
6:κ1-
C6H5(CH2)C5H4N}Cl2] (42) were synthesized via thermal displacement of ethyl 
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benzoate in the Ru
II
 dimer [Ru(6-etb)Cl2]2 by the hemilabile ligand (2-aminobiphenyl 
or 2-benzylpyridine) in 1,2-dichloroethane under pressure overnight as reported by 
Pizarro et al.
16, 32
 Subsequent reaction of the corresponding dichlorido complex with 
HCl aqueous solution overnight, afforded the open-tether complexes [Ru{η6-
C6H5(C6H4)NH3}Cl3] (41HCl) and [Ru{η
6
-C6H5(CH2)C5H4NH}Cl3] (42HCl). 
 
[Ru{η6:κ1-C6H5(C6H4)NH2}Cl2] (41). [RuCl2(η
6
-etb)]2 (200 mg, 0.310 mmol) and 2-
aminobiphenyl (105 mg, 0.620 mmol) were suspended in 1,2-dichloroethane (25 mL). 
The reaction mixture was heated under pressure at 393 K for 5 h. The red crystals were 
collected by filtration, washed with acetone and diethyl ether, and dried in air. Yield: 
202 mg (95%). Elemental analysis: Cald for C12H11Cl2NRu (341.20): C, 42.24; H, 3.25; 
N, 4.11. Found: C, 42.11; H, 3.22; N, 3.97. TGA (isotherm at 150 ºC for 300 min): 
observed loss <1%. Suitable crystals for X-ray diffraction were obtained from the 
reaction mixture.  Formation of 41A and phase purity were confirmed by powder X-ray 
diffraction. 
 
[Ru{η6:κ1-C6H5(C6H4)NH2}Cl2] (41HCl). Complex [Ru{η
6:κ1-C6H5(C6H4)NH2}Cl2] 
(1) (71 mg, 0.211 mmol) was suspended in 37% HCl and left stirring at ambient 
temperature for 18 h. The solvent was removed and the red powder was collected by 
filtration, washed with ethanol and diethyl ether, and dried in vacuum. Yield: 62 mg 
(78%). Elemental analysis: Cald for C12H12Cl3NRu (377.66): C, 38.16; H, 3.20; N, 3.71. 
Found: C, 38.82; H, 3.45; N, 3.57. 
1
H NMR (400 MHz, DMSO-d6, δ): 7.38 (d, J = 7.7 
Hz, Ar H, 1H), 7.16 (t, J = 7.4 Hz, Ar H, 1H), 6.80 (d, J = 8.0 Hz, Ar H, 1H), 6.67 (t, J 
= 7.4 Hz, Ar H, 1H), 6.22 (d, J = 6.0 Hz, Ar H, 2H), 6.13 (t, J = 5.5 Hz, Ar H, 1H), 5.95 
(t, J = 5.9 Hz, Ar H, 2H). TGA (isotherm at 150 ºC for 300 min): observed loss: 9.3%; 
Chapter 6 
243 
calculated loss for 1 molecule of HCl: 9.7%. The crystal structure of this complex has 
been previously reported.
15
  Formation of 41HCl and phase purity were confirmed by 
powder X-ray diffraction. 
 
[Ru{η6:κ1-C6H5(CH2)C5H4N}Cl2] (42). [RuCl2(η
6
-etb)]2 (117 mg, 0.182 mmol) and 2-
benzylpyridine (58 L, 0.364 mmol) were suspended in 1,2-dichloroethane (12 mL). 
The reaction mixture was heated under pressure at 393 K for 16 h. A pale yellow 
powder was collected by filtration, washed with acetone and diethyl ether, and dried in 
air. Yield: 92 mg (75%). Elemental analysis: Cald for C12H11Cl2NRu (341.20): C, 
42.24; H, 3.25; N, 4.11. Found: C, 42.45; H, 3.26; N, 3.95. TGA (isotherm at 150 ºC for 
300 min): observed loss <1%. Single crystals suitable for X-ray diffraction were 
obtained from the reaction mixture. Formation of 2 and phase purity were confirmed by 
powder X-ray diffraction. 
 
[Ru{η6:κ1-C6H5(CH2)C5H4N}Cl2] (42HCl). Complex [Ru{η
6:κ1-
C6H5(CH2)C5H4N}Cl2] (42) (59 mg, 0.175 mmol) was suspended in aqueous 37% HCl 
and left stirring at ambient temperature for 18 h. Solvent was removed until dryness. 
The red powder was collected by filtration, washed with ethanol and diethyl ether, and 
dried in vacuum. Yield: 46 mg (70%). Elemental analysis: Cald for C12H12Cl3NRu 
(377.66): C, 38.16; H, 3.20; N, 3.71. Found: C, 38.07; H, 3.35; N, 3.61. 
1
H NMR (400 
MHz, DMSO-d6, δ): 7.95 (td, J = 7.7, 1.7 Hz, Ar H, 1H), 7.76 (dd, J = 5.8, 1.4 Hz, Ar 
H, 1H), 7.50 (d, J = 7.9 Hz, Ar H, 1H), 7.36 (t, J = 6.7 Hz, Ar H, 1H), 5.99 (t, J = 5.8 
Hz, Ar H, 2H), 5.79 (d, J = 5.8 Hz, Ar H, 2H), 5.56 (t, J = 5.6 Hz, Ar H, 1H), 4.43 (s, –
CH2–, 2H). TGA (isotherm at 150 ºC for 300 min): observed loss: 9.9%; calculated loss 
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for 1 molecule of HCl: 9.7%. The phase purity was established by X-ray powder 
diffraction.  
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General Conclusions 
 
In this dissertation a family of ruthenium-based metallodrugs, which are design to 
target the disrupted metabolism in the cancer cell, has been developed. For this purpose, 
a tethered ruthenium(II) arene scaffold was selected and the activation of the Ru–Z 
bond was extensively explored by following different strategies. Structural 
modifications have been performed both on the hemilabile ligand and on the chelating 
ligand with the aim of finely tuning the activation of the κ1Z bond under different 
conditions. 
The results obtained in this Thesis allows us to conclude that: 
 
The novel structure-activation relationship established between the new tethered 
complexes of formula [Ru(η6:κ1-arene:Z)(en)]n+ in which only a building block is varied 
(tether hemilabile ligand), is a useful method to gain information about the hemilabile 
ligand structural features and how they affect the susceptibility of Ru–Z activation. Both 
length and rigidity of the spacer, and the nature of the donor atom that closes the tether 
appear to play a key role in the activation of the Ru–Z bond. We demonstrate that 
complexes with κ1N-coordination bearing aromatic amines are more prone to activation 
than those containing aliphatic amines as donor group. Also, we determine that κ1O-
coordination is weaker than κ1N-coordination.  
 
Complexes containing 2-aminobiphenyl as hemilabile ligand, [Ru(η6:κ1-
C6H5(C6H4)NH2)(XY)]Cln, were excellent scaffolds to understand the ring-opening and 
ring-closing processes in view of the development of new pH-activatable metallodrugs. 
Our complexes showed activation, to different extents and at different rates, of the Ru–
Z bond in different solvents. We determine that the activation under acidic conditions is 
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fully reversible and it can be modulated by the electronic and steric effects provided by 
varying the chelating ligand (XY). Moreover, only open-tether complexes were 
susceptible to interact with nucleobases, validating the pro-drug approach in this new 
family of complexes. 
 
The complexes containing phenylacetic acid as hemilabile ligand (κ1O-coordination) 
are promising structures to build reversible pH-dependent systems. The activation of the 
Ru–Z bond was finely tuned by changing the chelating ligand. The extensive study 
about their speciation in aqueous solution demonstrates how these species can be pH 
controlled. Also, we determine that these complexes can undergo selective hydrogen-
transfer reactions, proving that ring-opening is involved in the catalytic cycle. More 
importantly, we demonstrate that these complexes can reduce NAD
+
 to NADH and this 
might have an effect inside the cell in presence of formate, decreasing the IC50 value 
compared to that in absence of formate. 
 
We demonstrate that the rigidity of the tether arm provides an important feature for 
the ring-opening process, making the process faster. Preliminary photo-irradiation 
experiments helped us to start to understand the behaviour of these complexes under 
light excitation. However, we determine that irradiation of these tether complexes does 
not provide a useful methodology to activate the Ru–Z bond, demonstrating that the 
tethering feature in the structure of the Ru-arene (i) provides the complex with 
extraordinary structural stability, (ii) affords complexes with different reactivity when 
compared with their un-tether counterparts under light irradiation, and (iii) the photo-
reactivity of the tether complexes within a series differs from that in the dark. 
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The solid-state reaction of closed tether complexes with vaporous HCl triggers the 
activation of the Ru–N(tether) bond accompanied by a change in colour. The novelty in 
this area lies on (i) the selectivity of dissociating the donor atom from the ruthenium 
centre only when the vapour is HCl (but not when it comes from HBr or H2SO4 
solutions), (ii) different activation rates depending on the hemilabile ligand (influenced 
by the rigidity and the donor atom), and (iii) the reversibility to the original complex 
using a HCl scavenger and upon heating. Therefore, these complexes could serve as gas 
sensors. 
 
In summary, the results reported in this dissertation describe a novel family of 
tethered ruthenium(II) arene complexes as a unique scaffold in cancer drug discovery. 
They can serve as new pharmacological tools to exploit the particular pericellular 
environment of the cancer cell.  
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Crystallographic data for closed tethered complexes included in Chapter 2. 
 
Complex 5 6 7 
Formula C15H33Cl2N3O2Ru C12H23Cl2N3ORu C10H23Cl2N3ORu 
MW 459.41 397.30 373.28 
Crystal description yellow prismatic yellow prismatic yellow-orange plate 
Crystal size (mm) 0.08 x 0.14 x 0.16 0.02 x 0.04 x 0.08 0.12  x 0.47  x 0.56 
λ (Å) 0.71073 0.71073 0.71073 
T (K) 200(2) 296(2) 296(2) 
Crystal system monoclinic monoclinic orthorhombic 
Space group P 1 21/c 1 P 1 21/n 1 P 21 21 21 
a (Å) 13.8329(5) 8.8098(4) 8.2419(6) 
b (Å) 8.7529(3) 14.4814(5) 11.6210(5) 
c (Å) 16.8436(5) 13.4656(5) 16.3156(13) 
α (deg) 90 90 90 
β (deg) 94.273(2) 104.596(2) 90 
γ (deg) 90 90 90 
Vol (Å
3
) 2033.72(12) 1662.47(11) 1562.69(18) 
Z 4 4 4 
R [F > 4α(F)] (%) 2.02 4.81 1.68 
Rw (%) 5.58 14.93 4.09 
GOF 1.167 1.079 1.052 
Δρ max and min (e Å-3) 0.370 and -0.489 2.060 and -1.349 0.301 and -0.406 
RMS (e Å
-3
) 0.085 0.187 0.045 
Complex 9 12 13 
Formula C14H19F12N3P2Ru C14H11F6NNaO6PRu C14H13Cl2N3O2Ru 
MW 620.33 558.27 427.24 
Crystal 
description 
yellow prismatic yellow prismatic colourless prismatic 
Crystal size (mm) 0.114 x 0.168 x 0.170 0.05 x 0.09 x 0.10 0.02 x 0.04 x 0.06 
λ (Å) 0.71073 0.71073 0.71073 
T (K) 200(2) 200(2) 200(2) 
Crystal system orthorhombic monoclinic monoclinic 
Space group P n a 21 C 1 2/c 1 I 1 2/m 1 
a (Å) 12.8394(6) 26.2903(12) 7.800(4) 
b (Å) 14.8390(8) 14.6155(6) 9.812(4) 
c (Å) 10.7448(6) 10.0480(4) 23.048(14) 
α (deg) 90 90 90 
β (deg) 90 107.757(2) 92.57(5) 
γ (deg) 90 90 90 
Vol (Å
3
) 2047.14(19) 3677.0(3) 1762.2(15) 
Z 4 8 4 
R [F > 4α(F)] (%) 2.16 3.51 7.78 
Rw (%) 4.84 9.77 23.10 
GOF 1.009 1.093 1.094 
Δρ max and min 
(e Å
-3
) 
0.299 and -0.243 0.630 and -0.740 0.956 and -1.118 
RMS (e Å
-3
) 0.047 0.115 0.239 
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Crystallographic data for open tether complexes included in Chapter 2. 
 
Complex 15Cl 16Cl 17Cl 
Formula C10H18Cl2N2ORu C14H25Cl2N2ORu C21H25Cl2N4O2.25Ru 
MW 354.23 409.33 541.42 
Crystal description brown-green plate clear yellow plate dark purple prismatic 
Crystal size (mm) 0.03 x 0.22 x 0.38 0.01 x 0.08 x 0.14 0.12 x 0.20 x 0.20 
λ (Å) 0.71073 0.71073 0.71073 
T (K) 296(2) 296(2) 200(2) 
Crystal system orthorhombic monoclinic orthorhombic 
Space group P n m a P 1 21 1 P b c a 
a (Å) 9.0990(2) 8.2545(3) 13.5363(15) 
b (Å) 7.2049(2) 10.8769(4) 16.5216(17) 
c (Å) 20.2635(6) 9.5166(4) 21.902(3) 
α (deg) 90 90 90 
β (deg) 90 90.276(3) 90 
γ (deg) 90 90 90 
Vol (Å
3
) 1328.42(6) 854.42(6) 4898.2(10) 
Z 4 2 8 
R [F > 4α(F)] (%) 2.26 6.61 6.93 
Rw (%) 9.07 16.97 28.48 
GOF 1.025 1.087 1.028 
Δρ max and min (e Å-3) 0.509 and -0.249 1.137 and -0.818 2.695 and -0.999 
RMS (e Å
-3
) 0.086 0.134 0.320 
Complex 18Cl 20Cl 
Formula C39H48Cl4N4O5Ru2 C10H16Cl2N2O2Ru 
MW 996.75 368.22 
Crystal description light orange prismatic yellow prismatic 
Crystal size (mm) 0.06 x 0.06 x 0.38 0.080 x 0.180 x 0.200 
λ (Å) 0.71073 0.71073 
T (K) 296(2) 296(2) 
Crystal system Monoclinic monoclinic 
Space group C 1 c 1 P 1 21/c 1 
a (Å) 7.0923(16) 7.51280(10) 
b (Å) 20.307(5) 13.6076(3) 
c (Å) 29.055(5) 13.1434(3) 
α (deg) 90 90 
β (deg) 91.815(11) 92.3830(10) 
γ (deg) 90 90 
Vol (Å
3
) 4182.5(15) 1342.50(5) 
Z 4 4 
R [F > 4α(F)] (%) 8.27 1.74 
Rw (%) 24.29 4.46 
GOF 1.002 1.011 
Δρ max and min (e Å-3) 1.315 and -1.945 0.485 and -0.420 
RMS (e Å
-3
) 0.180 0.053 
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Crystallographic data for closed tethered complexes included in Chapter 3. 
 
 Complex 26Cl 28Cl 28HCl 
Formula C23H39Cl2N3ORu C18H29Cl2N3ORu C18H28Cl3N3O0.50Ru 
MW 545.54 475.41 501.85 
Crystal description orange prismatic yellow prismatic orange prismatic 
Crystal size (mm) 0.09 x 0.12 x 0.14 0.06 x 0.08 x 0.10 0.08 x 0.14 x 0.20 
λ (Å) 0.71073 0.71073 0.71073 
T (K) 200(2) 296(2) 296(2) 
Crystal system monoclinic triclinic monoclinic 
Space group P 1 21/c 1 P -1 P 1 21/n 1 
a (Å) 12.675(4) 7.6786(2) 9.1375(2) 
b (Å) 19.0058(5) 9.7149(3) 24.7797(7) 
c (Å) 11.0177(3) 14.7107(5) 9.8170(2) 
α (deg) 90 108.527(2) 90 
β (deg) 106.2210(10) 100.957(2) 103.0430(10) 
γ (deg) 90 96.9360(10) 90 
Vol (Å
3
) 2548.49(13) 1002.00(5) 2165.46(9) 
Z 4 2 4 
R [F > 4α(F)] (%) 3.37 2.44 2.68 
Rw (%) 11.8 5.1 9.74 
GOF 1.165 1.001 1.163 
Δρ max and min (e Å-3) 1.081 and -0.572 0.450 and -0.442 0.572 and -0.469 
RMS (e Å
-3
) 0.171 0.074 0.102 
 
 Complex 23 27 29 
Formula C18H25Cl2N3O1.16Ru C23H35Cl2N3ORu C19H19Cl2N3ORu 
MW 473.94 541.51 477.34 
Crystal description yellow prismatic  yellow prismatic yellow prismatic 
Crystal size (mm) 0.18 x 0.35 x 0.42 0.19 x 0.38 x 0.41 0.03 x 0.05 x 0.21 
λ (Å) 0.71073 0.71073 0.71073 
T (K) 200(2) 200(2) 200(2) 
Crystal system Monoclinic triclinic orthorhombic 
Space group C 1 2/c 1 P -1 P 21 21 2 
a (Å) 25.0917(14) 9.3207(3) 12.6688(16) 
b (Å) 8.9754(4) 10.1655(4) 14.2715(14) 
c (Å) 19.1582(10) 13.1494(5) 11.4437(15) 
α (deg) 90 106.958(2) 90 
β (deg) 96.994(2) 101.054(2) 90 
γ (deg) 90 90.749(2) 90 
Vol (Å
3
) 4282.5(4) 1166.45(7) 2069.1(4) 
Z 8 2 4 
R [F > 4α(F)] (%) 4.8 4.15 4.21 
Rw (%) 17.24 12.95 13.55 
GOF 1.103 1.084 1.187 
Δρ max and min (e Å-3) 1.870 and -0.598 3.144 and -0.987 1.558 and -0.657 
RMS (e Å
-3
) 0.219 0.129 0.217 
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Crystallographic data for complexes included in Chapter 4. 
 
Complex 34dimer 35Cl 
Formula C16H16Cl4O4Ru2 C21H20Cl2N2O3Ru 
MW 616.23 520.36 
Crystal description orange plate orange prismatic 
Crystal size (mm) 0.020 x 0.070 x 0.080 0.040 x 0.050 x 0.050 
λ (Å) 071073 0.71073 
T (K) 296(2) 296(2) 
Crystal system Triclinic orthorhombic 
Space group P -1 P b c a 
a (Å) 7.1124(3) 13.6426(5) 
b (Å) 10.0188(4) 15.1243(5) 
c (Å) 14.6863(6) 19.7624(5) 
α (deg) 70.587(2) 90 
β (deg) 77.652(2) 90 
γ (deg) 71.649(2) 90 
Vol (Å
3
) 929.82(7) 4077.7(2) 
Z 2 8 
R [F > 4α(F)] (%) 4.01 4.21 
Rw (%) 10.03 15.50 
GOF 1.070 1.122 
Δρ max and min (e Å-3) 0.726 and -0.788 0.717 and -0.937 
RMS (e Å
-3
) 0.176 0.267 
Complex 37Cl 38·PF6 
Formula C10H8ClNaO7.75Ru C14H23F6N2O2PRu 
MW 411.67 513.38 
Crystal description yellow plate yellow prismatic 
Crystal size (mm) 0.040 x 0.122 x 0.134 0.120 x 0.120 x 0.350 
λ (Å) 0.71073 0.71073 
T (K) 296(2) 293(2) 
Crystal system orthorhombic monoclinic 
Space group P n a 21 P 1 21/n 1 
a (Å) 15.5647(7) 9.1170(6) 
b (Å) 25.9037(15) 16.9924(10) 
c (Å) 7.3193(3) 12.3649(7) 
α (deg) 90 90 
β (deg) 90 95.196(3) 
γ (deg) 90 90 
Vol (Å
3
) 2951.0(2) 1907.7(2) 
Z 8 4 
R [F > 4α(F)] (%) 6.23 4.38 
Rw (%) 17.99 12.44 
GOF 1.070 1.027 
Δρ max and min (e Å-3) 1.514 and -1.220 1.128 and  -0.578 
RMS (e Å
-3
) 0.188 0.102 
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Crystallographic data for complexes included in Chapter 5 and Chapter 6. 
 
Complex 7 9·PF6 
Formula C10H23Cl2N3ORu C14H19F12N3P2Ru 
MW 373.28 620.33 
Crystal description yellow-orange plate brown-yellow prismatic 
Crystal size (mm) 0.12 x 0.47 x 0.56 0.114 x 0.168 x 0.170 
λ (Å) 0.71073 0.71073 
T (K) 296(2) 200(2) 
Crystal system orthorhombic orthorhombic 
Space group P 21 21 21 P n a 21 
a (Å) 8.2419(6) 12.8394(6) 
b (Å) 11.6210(5) 14.8390(8) 
c (Å) 16.3156(13) 10.7448(6) 
α (deg) 90 90 
β (deg) 90 90 
γ (deg) 90 90 
Vol (Å
3
) 1562.69(18) 2047.14(19) 
Z 4 4 
R [F > 4α(F)] (%) 1.68 2.16 
Rw (%) 4.09 4.84 
GOF 1.052 1.009 
Δρ max and min (e Å-3) 0.301 and -0.406 0.299 and -0.243 
RMS (e Å
-3
) 0.045 0.047 
Complex 41 42 
Formula C18H19Cl2N3Ru C12H11Cl2NRu 
MW 449.34 341.19 
Crystal description clear orange plate orange prismatic 
Crystal size (mm) 0.03 x 0.08 x 0.26 0.08 x 0.08 x 0.19 
λ (Å) 0.71073 0.71073 
T (K) 296(2) 296(2) 
Crystal system monoclinic Monoclinic 
Space group P 21/n P 21/n 
a (Å) 9.4741(2) 6.8305(2) 
b (Å) 7.7849(2) 13.5339(3) 
c (Å) 15.9151(4) 12.3545(2) 
α (deg) 90 90 
β (deg) 100.2770(10) 92.8240(10) 
γ (deg) 90 90 
Vol (Å
3
) 1154.99(5) 1140.70(5) 
Z 4 4 
R [F > 4α(F)] (%) 2.05 2.17 
Rw (%) 5.73 8.27 
GOF 1.052 1.216 
Δρ max and min (e Å-3) 0.387 and -0.331 0.592 and -0.693 
RMS (e Å
-3
) 0.095 0.259 
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Section A 
 
Benchmarking of the computational methods. Calculated bond lengths (Å) and angles 
(deg) for complex 9 using different DFT functional and basis sets. 
 
  
Bond / angle 
X-ray 
Structure 
PBE1PBE/ 
CEP-31G 
B3LYP/ 
CEP-31G 
LC-
WPBE/ 
CEP-31G 
M062X/ 
CEP-31G 
WB97XD/ 
CEP-31G 
Ru-centroid 1.651 1.741 1.805 1.724 1.839 1.753 
Ru-N1 2.157 2.124 2.151 2.128 2.139 2.142 
Ru-N2 2.138 2.121 2.147 2.115 2.138 2.135 
Ru-N3 2.130 2.150 2.177 2.142 2.176 2.163 
N2-Ru-N3 79.26 79.84 79.73 80.04 79.78 79.76 
N2-Ru-N1 88.40 89.66 89.99 89.95 89.64 89.95 
N3-Ru-N1 90.39 94.2 94.78 93.93 94.68 94.05 
N2-Ru-Centroid 133.36 130.9 131.12 130.78 131.32 130.85 
N3-Ru-Centroid 130.11 110.02 130.18 130.01 130.93 130.08 
N1-Ru-Centroid 121.00 119.62 118.79 119.64 118.13 119.62 
ΔTd* 21.80 18.57 20.27 20.28 20.44 20.36 
Bond / angle 
LC-WPBE/ 
CEP-31G 
LC-
WPBE/ 
LANL08/ 
6-31G** 
LC-
WPBE/ 
SDD/ 
6-31G** 
LC-
WPBE/ 
SDD/ 
6-311G** 
LC-
WPBE/ 
SDD/ 
6-
31G**+ 
 
Ru-centroid 1.724 1.672 1.653 1.649 1.653  
Ru-N1 2.128 2.123 2.133 2.136 2.133  
Ru-N2 2.115 2.151 2.114 2.118 2.114  
Ru-N3 2.142 2.140 2.143 2.146 2.143  
N2-Ru-N3 80.04 78.81 78.91 78.74 78.91  
N2-Ru-N1 89.95 89.61 89.31 89.37 89.31  
N3-Ru-N1 93.93 94.03 93.82 93.63 93.82  
N2-Ru-Centroid 130.78 131.46 131.49 131.57 131.49  
N3-Ru-Centroid 130.01 130.6 130.48 130.67 130.48  
N1-Ru-Centroid 119.64 119.44 119.8 119.75 119.8  
ΔTd* 20.28 20.83 20.89 20.99 20.89  
The LC-WPBE/SDD/6-31G** level was selected for all geometry calculations. Together with the LC-
WPBE/SDD/6-311G**, this method provided the best agreement between computed geometry and X-
ray structure of 3. However, the 6-31G** basis set required half the computational cost of the 6-
311G** analogue. 
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Section B 
 
Selected singlet-singlet transition and corresponding Electron density difference maps 
(EDDMs) for complex 7 calculated at the LC-WPBE/SDD/6-31G** level. In the 
EDDMs electron density migrates from grey to green areas. 
 
Transition Energy / eV (nm) f* Major Contributions 
1 3.55 (349) 0.0020 
H-1L+1 (42%) 
HOMOLUMO (35%) 
2 3.70 (335) 0.0056 
H-2L+1 (32%) 
HOMOL+1 (36%) 
3 3.78 (328) 0.0017 H-2LUMO (61%) 
4 3.81 (325) 0.0021 
H-1LUMO (43%) 
HOMOL+1 (20%) 
5 4.20 (295) 0.0027 
H-2LUMO (10%) 
H-1L+1 (33%) 
HOMOLUMO (38%) 
6 4.35 (285) 0.0051 
H-2L+1 (46%) 
H-1LUMO (18%) 
HOMOL+1 (18%) 
 
Transition 1 
 
Transition 2 
 
Transition 3 
 
Transition 4 
 
Transition 5 
 
Transition 6 
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Selected singlet-singlet transition and corresponding Electron density difference maps 
(EDDMs) for complex 9 calculated at the LC-WPBE/SDD/6-31G** level. In the 
EDDMs electron density migrates from grey to green areas. 
  
Transition Energy / eV (nm) f* Major Contributions 
1 3.50 (352) 0.0008 
H-1LUMO (11%) 
H-1L+2 (11%) 
HOMOL+1 (49%) 
2 3.60 (337) 0.0099 
H-3L+1 (27%), H-1->L+1(10%) 
HOMOLUMO (14%) 
HOMOL+2 (14%) 
3 3.64 (330) 0.0027 
H-1L+1 (45%) 
HOMOLUMO (11%) 
HOMOL+2 (11%) 
4 3.69 (329) 0.0017 
H-3LUMO (28%) 
H-3L+2 (31%) 
5 4.14 (297) 0.0028 
H-1LUMO (21%) 
H-1L+2 (20%) 
HOMOL+1 (23%) 
6 4.20 (288) 0.0102 
H-3L+1 (44%) 
H-1L+1 (18%) 
7 5.39 (231) 0.0013 
H-1L+6 (11%) 
HOMOL+1 (13%) 
HOMOL+5 (53%) 
 
Transition 1 
 
Transition 2 
 
Transition 3 
 
Transition 4 
 
Transition 5 
 
Transition 6 
 
Transition 7 
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Selected singlet-singlet transition and corresponding Electron density difference maps 
(EDDMs) for complex 13 calculated at the LC-WPBE/SDD/6-31G** level. In the 
EDDMs electron density migrates from grey to green areas. 
 
 
Transition Energy / eV (nm) f* Major Contributions 
1 3.54 (350) 0.0004 
H-3L+1 (22%) 
H-1LUMO (24%) 
HOMO->L+1 (24%) 
2 3.70 (335) 0.0066 
H-4L+1 (37%) 
H-2L+1 (10%) 
H-1L+1 (20%) 
3 3.78 (328) 0.0019 
H-4LUMO (35%) 
H-3LUMO (12%) 
H-1L+1 (11%) 
HOMOLUMO (13%) 
4 3.79 (327) 0.0022 
H-4LUMO (35%) 
H-1L+1 (12%) 
5 4.20 (295) 0.0028 
H-4LUMO (11%) 
H-3L+1 (13%) 
H-2LUMO (12%) 
H-1LUMO (30%) 
HOMOL+1 (15%) 
6 4.32 (287) 0.0067 
H-4L+1 (46%) 
H-1L+1 (16%) 
 
Transition 1 
 
Transition 2 
 
Transition 3 
 
Transition 4 
 
Transition 5 
 
Transition 6 
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The following table shows the numbering assigned to most of the complexes 
compiled in this Thesis taking into account its building blocks, i.e. both the hemilabile 
ligand and the chelating ligand. 
In red are represented the complexes which were synthesised in the closed form, 
while in green are indicated the complexes which were synthesised in the open form. 
  
 
 
